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Local supplementation of brain-derived neurotrophic factor for 
the treatment of neuronal damage 
 
Tao SU 
Tutor: Prof. Michele Simonato 
Department of Clinical and Experimental Medicine, Section of Pharmacology, Neuroscience Center, 
University of Ferrara, Ferrara 44100, Italy; National Institute of Neuroscience, Italy 
Abstract 
The importance of nerve growth factors, especially brain-derived neurotrophic 
factor (BDNF) in the regulation of neuronal survival and plastic changes in 
morphology and function has been increasingly studied during the recent years. It 
has been proposed that the pathogenesis of some neurological diseases may be due 
to an alteration in neurotrophic factor and/or Trk receptor levels. The use of 
neurotrophic factors as therapeutic agents is a promising approach aimed at 
restoring and maintaining neuronal function in the central nervous system (CNS). 
This study is undertaken to develop a novel stem cell-based gene therapy to deliver 
neurotrophic factors to vulnerable regions of the CNS. Stem cell-based gene 
therapy is a potential delivery option by which cells are engineered to produce 
neurotrophic factors in vitro and then transplanted to the target area where 
neurotrophic factors are secreted to exert protective and/or restorative effects on the 
host tissue. A recently isolated mesodermal stem cell, mesoangioblast (MAB), has a 
high adhesin-dependent migratory capacity and may selectively cross the 
blood-brain barrier and home in the lesioned areas. Therefore, MABs provide an 
ideal cellular source for BDNF delivery. In this study, we generated a genetically 
modified mesoangioblast producing BDNF (MABs-BDNF). These engineered 
MABs maintained transgene expression and secretion of bioactive BDNF in time. 
We investigated the protective effects of MABs-BDNF in vitro using primary 
cultures and organotypic cultures of hippocampal slices. The viability of the 
cultured slices was assessed in several ways: fluorescein diacetate (FDA) 
hydrolysis assay, lactate dehydrogenase (LDH) release assay, 
immunohistochemistry for MAP2, immunoblot for neurofilament 68, and field 
potential recordings. Direct exposure of recombinant BDNF to primary cultured 
neurons and adult slices resulted in a concentration-dependant protective effect. 
The conditioned medium from MABs-BDNF highly promoted cell survival, while 
the conditioned medium from control cells (MABs) or an equivalent amount of 
rBDNF showed beneficial effects on cell survival to a lesser extent. The protective 
effects of MABs-BDNF were attenuated by adding either with the TrkB receptor 
blocker K252a or the BDNF scavenger TrkB-IgG.. This indicates that the 
conditioned medium from MABs-BDNF can foster the adult slice culture through 
secreting the engineered BDNF and unknown pro-survival factors produced 
intrinsically by MABs. The MABs-BDNF conditioned medium was optimal for 
retention of morphologic characteristics and viability in organotypic cultures from 
adult hippocampal slices. Moreover, MABs-BDNF were found to promote 
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neurogenesis and glia proliferation. Treatment with the MABs-BDNF conditioned 
medium was found to increase the number of BrdU-labeled and BrdU/NeuN double 
labeled cells in the dentate gyrus of cultured slices. These in vitro findings 
demonstrate the beneficial effects of MABs-BDNF on neurons and provide a 
rationale for transplanting MABs-BDNF in the damaged brain as a therapeutic 
approach. Thus, we tested the transplantation of MABs-BDNF in an animal model 
of neuronal loss, the hippocampal sclerosis induced by status epilepticus. So far, we 
have not detected a deposition of MABs-BDNF in the epileptic brain after their 
systemic administration. Future experiments will aim at optimizing the 
transplanting conditions, changing the delivering routes, and assessing their 
therapeutic value in other neurological diseases associated with cell death. In terms 
of their prominent beneficial by-stander effects on neurons, MABs-BDNF hold 
substantial promise as therapeutic agents in the treatment of neurological diseases. 
 
Keywords: BDNF, mesoangioblasts, gene therapy, delivery, brain damage 
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trattamento del danno neuronale 
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Abstract 
 
L’importanza dei fattori neurotrofici, in particolare del brain-derived neurotrophic 
factor (BDNF), nel controllo della sopravvivenza neuronale e nelle modificazioni 
plastiche morfo-funzionali del sistema nervoso è diventata sempre più rilevante 
negli ultimi anni. Si è infatti ipotizzato che un’alterazione di questo fattore 
neurotrofico e/o dei livelli del suo recettore Trk possano rappresentare tappe 
patogenetiche importanti nello sviluppo di alcune patologie neurologiche. Da ciò 
deriva che l’utilizzo dei fattori neurotrofici come agenti terapeutici sia un approccio 
farmacologico promettente per il recupero ed il mantenimento delle funzioni 
neurali del sistema nervoso centrale (SNC). Scopo dello studio intrapreso è stato 
quello di cercare di sviluppare una nuova terapia genica basata sulle cellule 
staminali per ottenere il rilascio di fattori neurotrofici in aree vulnerabili del SNC. 
La terapia genica basata sull’impiego di cellule staminali è una delle possibili 
tecniche di bio-delivery per mezzo della quale le cellule, ingegnerizzate per 
produrre fattori neurotrofici in vitro, vengono trapiantate nell’area bersaglio dove 
rilasciano i fattori neurotrofici con effetti protettivi e/o rigenerativi sul tessuto 
ospite. Il mesoangioblasto (MAB) è una cellula staminale, recentemente isolata, 
che possiede un’alta capacità migratoria adesina-dipendente, può attraversare 
selettivamente la barriera emato-encefalica e raggiungere l’area neurale lesionata. I 
MAB, perciò, offrono una sorgente cellulare ideale per il rilascio di BDNF. Nella 
nostra ricerca sono stati generati mesoangioblasti geneticamente modificati per la 
produzione di BDNF (MABs-BDNF). I mesoangioblasti in questione mantengono 
nel tempo l’espressione del transgene e le proprietà secretorie di BDNF 
biologicamente attivo. Successivamente abbiamo studiato i loro effetti 
neuroprotettivi in vitro, su colture primarie e su colture organotipiche ippocampali. 
Si è valutata la vitalità delle fettine tissutali ippocampali mantenute in coltura 
mediante diverse metodiche: test di idrolisi della Fluoresceina DiAcetato (FDA), 
saggio di rilascio della LattatoDeidrogenasi (LDH), immunoistochimica per MAP2 
(Microtubule Associated Protein 2, proteina associata ai microtubuli di tipo 2), 
immunoblot per il neurofilamento 68, registrazione dei potenziali di campo. Si è 
visto che l’esposizione diretta delle colture primarie neuronali e delle colture 
d’ippocampo adulto al BDNF ricombinante (rBDNF) produce effetti protettivi 
dose-dipendente. Il medium condizionato dai MABs-BDNF promuove in maniera 
rilevante la sopravvivenza cellulare, mentre sono assai minori gli effetti benefici 
sulla sopravvivenza cellulare indotti dal medium condizionato ottenuto dalle cellule 
di controllo (MABs) o da un equivalente quantità di rBDNF. Gli effetti protettivi 
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dei MABs-BDNF vengono attenuati dall’aggiunta sia di K252a, bloccante 
recettoriale di TrkB, sia da TrkB-IgG, sottrattore anticorpale di BDNF. Questo sta 
ad indicare che il medium condizionato dai MABs-BDNF può proteggere le colture 
organotipiche di adulto non solo mediante la liberazione di BDNF ma anche tramite 
il rilascio di non ancora noti fattori neuroprotettivi prodotti intrinsecamente dai 
MABs. Il medium condizionato MABs-BDNF è risultato ottimale per il 
mantenimento delle caratteristiche morfologiche e di vitalità delle colture 
organotipiche ippocampali di adulto. I MABs-BDNF, inoltre, sono risultati 
promuovere la neuronogenesi e la proliferazione gliale. Il medium condizionato dai 
MABs-BDNF ha incrementato, infatti, il numero di cellule marcate con la 
BromoDeossiUridina (BrdU) e delle cellule doppiamente marcate, BrdU/NeuN 
(BromoDeossiUridina/Neuronal Nuclear protein, proteina nucleare neuronale) nel 
giro dentato delle fettine in coltura. Queste scoperte ottenute in vitro dimostrano gli 
effetti positivi dei MABs-BDNF sui neuroni e forniscono un razionale per l’utilizzo 
terapeutico del trapianto di MABs-BDNF nelle aree cerebrali danneggiate. In modo 
preliminare abbiamo testato il trapianto di MABs-BDNF in un modello animale di 
perdita neuronale, la sclerosi ippocampale indotta dallo stato epilettico, non avendo 
purtroppo riscontrato una localizzazione di MABs-BDNF nel cervello epilettico, in 
seguito alla loro somministrazione sistemica. Successivi esperimenti saranno 
necessari per ottimizzare le condizioni del trapianto, modificando le vie di delivery 
e valutando il loro valore terapeutico in altre patologie neurologiche associate alla 
morte cellulare. I MABs-BDNF, per il loro preminente effetto benefico, seppur 
indiretto, a tipo “spettatore innocente” sui neuroni, risultano promettenti agenti 
terapeutici per il trattamento delle malattie neurologiche. 
 
Parole chiave: BDNF, mesoangioblasti, terapia genica, delivery, danno cerebrale 
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Preface 
Back in the early 1950s, a group of embryologists discovered that a series of 
signalling molecules secreted by the target tissues in the developing nervous system, 
which were called neurotrophic factors (NTFs). NTFs were defined as 
target-derived, antiapoptotic molecules that maintain embryonic or adult neuronal 
cells. The word ‘trophic’ is derived from Greek ‘trophé’ meaning nourishment or 
taking up of nutrients. Various families of neurotrophic factors exist, e.g., the 
neurotrophin (NT) family, the fibroblast growth factor (FGF) family, the epidermal 
growth factor (EGF) family, the insulin-like growth factor (IGF) family, the 
vascular-endothilial growth factor (VEGF) faimily, the glial cell-derived 
neurotrophic factor (GDNF) family, and the ciliary neurotrophic factor (CNTF). 
Currently, six neurotrophins have been isolated: NGF, BDNF, NT-3, NT-4 (also 
known as NT-5), NT-6, and NT-7. The NT-6 and NT-7 genes have been identified 
only in fish and probably do not have mammalian or avian orthologues (Gotz et al., 
1994; Nilsson et al., 1998). The FGF family includes 22 known members in human, 
which initially were found to influence the growth of fibroblasts and later their 
ability in many other cell types were demonstrated (Burgess and Maciag, 1989). 
For example, basic FGF (bFGF, also called FGF-2, EDGF, or HBGF-2) can 
influence the differentiation and migration of neurons and glia (Walicke et al., 
1986). All these NTFs signal via factor specific multicomponent receptor 
complexes. The NGF-superfamily of receptors includes p75 and the receptor 
protein tyrosine kinases (Trk): TrkA, TrkB and TrkC. The mammalian FGF 
receptor family has 4 members, FGFR1, FGFR2, FGFR3, and FGFR4. The GDNF 
family of receptors includes a receptor complex of Ret and growth factor receptor 
α1-4. The neurokine superfamily ligands act via the receptors gp130 and leukemia 
inhibitory factor receptor-β (LIFR-β).  
Since their discovery, research in the field of NTFs has provided a vast amount 
of data not only on their biochemical properties but also on how they function 
during development and how they maintain neuronal activity in the adult nervous 
system. It has been evidenced that NTFs regulate almost all aspects of neuronal 
development and function, including precursor proliferation and commitment, cell 
survival, axon and dendrite growth, membrane trafficking, synapse formation and 
function, neurotransmitter release, synaptic plasticity, as well as glia differentiation 
and interaction with neurons. It is well accepted that NTFs are critical to the 
development and maintenance of the mammalian CNS. Alterations in NTF levels 
have profound effects on a wide variety of phenomena, including myelination, 
regeneration, pain, aggression, depression and substance abuse. The influence of 
neurotrophic factors spans from developmental neurobiology to neurodegenerative 
and psychiatric disorders. Recently, NTFs have received considerable interest as 
possible means for the treatment of neurodegenerative diseases, psychiatric 
disorders and CNS trauma. There are many successful paradigms with respect to 
pre-clinical and clinical applications of NTFs, especially neurotrophin family 
member (e.g. NGF, BDNF) to prevent, slow the progression of, or even reverse the 
effects of a number of neurodegenerative diseases and other types of insults in both 
the central and peripheral nervous system, since the idea that degenerative diseases 
of the nervous system may result from insufficient supply of these neurotrophins 
has generated great interest in these NTFs as potential therapeutic agents.  
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Besides the neurotrophin family, many other NTFs show significant 
therapeutic potential in a variety of diseases states, from neurological diseases, 
Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis 
(ALS), stroke, schizophrenia, and depression to diabetic neuropathies, neuropathic 
pain, macular degeneration, and obesity. These factors include members of the 
fibroblast growth factor (FGF) family, GDNF family, CNTF family, and 
insulin-like growth factors I and II (IGF-I and -II). Here, we will focus primarily on 
the neurotrophin family and their cognate receptors. 
In this chapter, we will summarize the knowledge acquired on the gene and 
protein structure of neurotrophins and their molecular and cellular biology during 
the last decade. Because of the importance of BDNF on neuronal survival and 
regeneration, we will review particularly the distribution and alteration of BDNF 
and its therapeutic potential in the neurological diseases. In addition, the various 
therapeutic strategies against neurodegenerative diseases are introduced. Among 
these strategies, a novel cell source (mesoangioblast) for cell based therapy 
attracted our interest. 
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1 Neurotrophins 
The neurotrophins are a family of structurally related secretory proteins that 
are widely expressed in neurons and their target cells (Alderson et al., 1990). These 
secreted proteins play a crucial role in the control of neuronal numbers and of 
dendritic growth. To date five members have been identified. They are called nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin 
(NT) 3, 4/5, and 6. The first neurotrophin identified was the NGF (Levi-Montalcini, 
1966). It was found, however, that only a few CNS neurons were responsive to 
NGF. The second neurotrophin, BDNF, initially purified from the pig brain as a 
trophic factor for dorsal root ganglion cells, helped to establish the concept that the 
diffusible growth factors could regulate the fate and the shape of most vertebrate 
neurons (Hofer and Barde, 1988). Molecular cloning of BDNF revealed that its 
amino acid sequence had a strong homology to that of NGF. By using the 
contiguous regions between NGF and BDNF to design oligonucleotides for 
polymerase chain reaction cloning, a third related protein called neurotrophin 3 
(NT-3) was cloned (Maisonpierre et al., 1991; Hallbook et al., 1993; Dawson et al., 
1995). This is located on human chromosome 12 (12p13) (Maisonpierre et al., 
1991). Finally, the last member of the neurotrophin family (NT-4) was identified 
and cloned in Xenopus (Hallbook et al., 1991). The equivalent human cDNA is 
different from Xenopus NT-4 and is thought to be a separate gene and called 
NT-5(Berkemeier et al., 1991; Berkemeier et al., 1992). Subsequently it was 
realized that they are homologueous genes and this neurotrophin is often termed 
NT-4/5. NT-4/5 is present on human chromosome 19 (19q13.3) (Berkemeier et al., 
1992; Ip et al., 1992). NT-6 has only been found in fish (Gotz et al., 1994).  
To better exploit the NTFs therapeutic potential, we need to understand the 
details of the molecular biology of the neurotrophin system and integrate them with 
the physiology of neurotrophins. In the following sections, we review their gene 
and protein structure, biosynthesis and secretion, receptors, signaling pathways, and 
regulation of neuronal activity. The data on the molecular mechanisms of gene 
regulation from other fields of biomedical science, together with the physiological 
data on neurotrophic factor action and known intracellular signal transduction 
pathways help us to get insight into the function and modulation of these NTFs, 
thereby contributing to the exploitation of potential therapies for neurological 
disorders. 
 
1.1 Gene and protein structure 
The recent explosion in genomics research has given us dozens of amino acid 
sequences of NTFs from dozens of species. In addition, the crystal structures of 
many NTFs are now available after a decade of intense research. Comparing the 
amino acid sequences and structural features of the NTFs can give insight into the 
evolutionary history of these families and can help reveal functionally important 
regions of the molecules.  
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Sequence alignments  
All genes encoding neurotrophins have a basically similar structure. A single 
discontinuous exon contains all the information for encoding the prepropeptide. 
The coding exon is preceded by several noncoding exons that are subject to 
alternative splicing and give rise to alternative 5’- untranslated regions (UTRs) of 
mRNA. Multiple promoters have been demonstrated for all neurotrophins.  
The BDNF gene (bdnf), mapped to chromosome 11p in humans, has four 
upstream exons (exons I-IV) that are associated with distinct promoters, and one 3’ 
exon (exon V) that encodes the mature BDNF protein (Metsis et al., 1993; 
Timmusk et al., 1993). Recently, some novel exons had been identified in the 
upstream noncoding exons (Aid et al., 2007). According to the new nomenclature, 
BDNF transcripts contain 9 exons (I-IXA) in the upstream unstranslated region, 
while the common coding region previously called exon V is now named as exon 
IX. The usage of different promoters gives rise to mRNAs that contain only one of 
the upstream noncoding exons spliced to the coding exon. Upstream exons of the 
BDNF gene do not contain a splicing acceptor site thus preventing the splicing of 
the more upstream exons to those located proximally to the coding exon. As many 
as 11 different BDNF transcripts can be generated in both humans and rodents by 
alternative splicing. They differ only in their upstreanm untranslated region but 
share a common exon IX (Aid et al., 2007). All these BDNF mRNAs are expressed 
in the brain at very different levels and generating a spatial diversity of expression. 
Moreover, different promoters in the BDNF gene have specific developmental 
patterns of expression and differential activation capacities. For instance, a 5-kb 
region of promoter Ⅲ is involved in BDNF gene induction after sciatic nerve 
transaction (Timmusk et al., 1995).  
Following the detailed description of BDNF gene structure, many attempts 
have been made to localize structural elements of the gene governing mRNA 
regulation in vivo or in vitro. For instance, the first intron of the BDNF gene 
contains a neuron-restrictive silencer element (NRSE)-type regulatory sequence 
(Timmusk et al., 1999). Alterations in the NRSE affected expression levels of 
promoters II and I that are located nearby. In the brain, mutation of the NRSE 
modulated the responsiveness of BDNF promoters I and II to activation of the 
glutamatergic system (Timmusk et al., 1999). Short regions flanking promoters I, II, 
and III in the BDNF gene have been localized as putative calcium responsive 
regions (Bishop et al., 1997). Two different regulatory sequences involved in the 
activation of transcription were localized in the proximal promoter region. One is a 
novel calcium response element required for calcium-dependent BDNF expression 
in both embryonic and postnatal cortical neurons. The second element matches the 
consensus sequence of a cAMP response element (CRE) and is required for 
transactivation of the promoter in postnatal but not in embryonic neurons (Tabuchi 
et al., 2002). Differential cell-specific activation of different BDNF promoters via 
activation of the glutamatergic system most likely reflects involvement of specific 
kinase pathways in the cells (Marmigere et al., 2001).  
The human NGF gene is located on the short arm of chromosome 1 (1p22) 
(Francke et al., 1983) and codes for a polypeptide of 307 amino acids. It contains 
three upstream exons and the promoter activity has been linked to the first and the 
third exon. The NGF gene has the most complex splicing pattern. The majorities of 
transcripts are transcribed from the distal promoter and contain exon I, while the 
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other noncoding exons are combined by alternative splicing and give rise to a 
variety of mRNAs with different 5’-UTRs. In addition to ngf and bdnf, two other 
neurotrophin genes, neurotrophin-3 (nt3) and neurotrophin-4/5 (nt4/5), have been 
identified in mammals (Sekimoto et al., 1998). The NT-3 gene contains two 
upstream exons flanked by promoters.  
 
Molecular evolution 
The evolution of the NTFs has been studied using phylogenetic trees that 
organize the relationships between their amino acid sequences (Kullander et al., 
1997). The works have divided neurotrophin residues into two categories: 
conserved and variable, based on early sequence alignments (Thoenen, 1991). With 
the exception of NT4/5, neurotrophin sequences are highly conserved. For instance, 
BDNF shares about 50% amino acid identity with NGF, NT-3. Based on sequence 
comparisons and on the isolation of neurotrophin genes in various vertebrates, it is 
thought that ngf / nt3 and bdnf / nt4/5 evolved from separate duplication events 
(Hallbook, 1999). The most primitive neurotrophin genes have been isolated from 
jawless fishes, a river lamprey and the Atlantic hagfish. In bony fishes, more 
neurotrophin and receptor genes have been isolated than in mammals (Hallbook, 
1999).The neurotrophin receptors of the trk family seem to have coevolved with the 
neurotrophin genes (Hallbook, 1999). So far, no neurotrophin-like sequences have 
been detected in invertebrates (Bargmann, 1998). No ortholog of the NT-4 gene has 
been found in teleost fishes, and no ortholog of the NT-6 or NT-7 genes has been 
found in tetrapods (although the names are similar, the human NT-6 genes are 
closer to NGF). 
 
Proteins structure 
All the neurotrophins are synthesized as precursor proteins a little over 200 
amino acids long (approximately 30 kDa in size), containing a signal sequence for 
secretion. Following proteolytic cleavage, a mature C-terminal active peptide 
slightly shorter than 120 amino acids long (approximately 13 kDa) is released 
containing six cysteine residues at identically spaced positions in all mammalian 
neurotrophins (Chao and Bothwell, 2002). The mature part is very well conserved 
and approximately 50% of the amino acids are common to all neurotrophins. The 
neurotrophins are secreted as noncovalent-linked dimers, containing a signal 
peptide following the initiation codon and a pro-region containing an N-linked 
glycosylation site. They are all basic proteins with isoelectric points above 9.0, a 
somewhat unusual property for secreted proteins, which may serve the purpose of 
limiting their range of action (Chao and Bothwell, 2002). 
Three-dimensional structures of most of the human neurotrophins have been 
determined. These structures can be aligned to reveal that the regions of similarity 
are much larger than was suggested from sequence alignments. Most of the residues 
that participate in secondary structure are strongly conserved both within and 
between sub-families, but there are numerous exceptions.  
The core structure consists of two pairs of intertwined two-strand beta sheets, 
joined by three disulfide bonds. There are also three shorter beta strands leading to 
beta turns and loops (Fig. 1). The four core beta strands are virtually 
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superimposable across all the structures. The characteristic formation of a double 
loop formed by two disulphide bonds, penetrated by a third disulphide bond, is 
named cysteine ‘knot’ (McDonald and Hendrickson, 1993). The neurotrophins and 
GDNF family members are members of a large superfamily of growth factors that 
contain a cysteine knot motif (Holland et al., 1994; Saarma and Sariola, 1999). This 
reveals strong conservation, especially within secondary-structure elements. This 
family includes transforming growth factor (TGF)- β , human chorionic 
gonadotropin, platelet-derived growth factor, vascular endothelial growth factor, 
and many others (McDonald and Hendrickson, 1993). The cysteine knot consists of 
three cysteine disulphide bonds. The crystal structures of the neurotrophins show 
the classic cysteine knot growth factor structure with head-to-head sub-units 
forming a noncovalently linked dimer. These residues implicated in binding that are 
conserved across families are thought to represent a common interface to the Trk 
receptors, while the unique ones may represent elements of specificity (Robinson et 
al., 1995). 
The only significant differences 
between neurotrophins are found in the 
loops and turns between beta strands 
(McDonald and Hendrickson, 1993), 
especially loop 3. Loop 3 is the most 
different among the four neurotrophin 
structures. NT-3 has a single loose 
helical turn in this region. NT-4 and 
NT-6 sub-families have a large 
insertion in this portion, including a 
small eight-residue beta turn. 
Interestingly, two cysteines that make 
up the knot are missing from the 
human NT-6 molecules (Lai et al., 
1998). The N- and C-termini are 
highly variable in both sequence and 
structure among the neurotrophins, and 
the temperature factors of these loosely 
structured residues are comparatively 
high. The N-terminus assumes a 
helical structure upon binding the Trk 
receptor. The role of the C-terminal 
residues is not known, although they 
may participate in p75 binding in NT-3 
(Carraway and Mitra, 1987) and NGF 
(Bax et al., 1997). 
 
Fig. 1. Schematic of the neurotrophin 
molecule. Dashed blue lines represent 
the three disulfide bonds of the 
cysteine knot. The N terminus is 
disordered in the unbound structures 
and is shown by a dashed line. (Butte 
et al., Cell. Mol. Life Sci. 58 (2001) 
1003–1013) 
 
By comparing the residues involved in the interface between TrkA-d5 and 
NGF with the corresponding sequence alignments for the neurotrophins and the Trk 
receptors, they can be seen to form two groups of conserved and non-conserved 
residues (Wiesmann et al., 1999). One set of residues making up a large patch and 
centered on Arg 103 form a common set across all the neurotrophins and receptors. 
As these residues are highly homologous and consist mainly of hydrophobic and 
aromatic side chains, they probably mediate the bulk of common binding affinity 
between neurotrophin and receptor. The other portion of the TrkA interface centers 
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on the N-terminal residues of the neurotrophin. These residues show little 
conservation, either on the neurotrophin or the receptor side (Hallbook et al., 1991). 
The N-terminus, which was disordered in all the unbound neurotrophin structures, 
forms a one-and-a-half-turn helical arrangement in the complex between TrkA and 
NGF (Wiesmann et al., 1999). NGF binding buries two helical hydrophobic 
residues and creates a salt bridge across the interface. BNDF, NT-3, and NT-4 do 
not share the same pattern of residue types at the N-terminus, and TrkB and TrkC 
also differ in their corresponding interacting residues (Robinson et al., 1995). 
Together, these results suggest that the N-terminal residues help determine receptor 
binding specificity and that each neurotrophin probably uses a different specific 
interface with its cognate receptor in this region (Kullander et al., 1997). Other 
specificity-determining residues appear to lie scattered within the common binding 
site.  
The neurotrophins are initially synthesized as precursors or pro-neurotrophins, 
which are cleaved to produce the mature proteins. Pro-neurotrophins are cleaved 
intracellularly by FURIN or pro-convertases at a highly conserved dibasic 
amino-acid cleavage site to release carboxy-terminal mature proteins (Mouri et al., 
2007). The mature proteins exist exclusively as dimers, though a variety of 
arrangements are seen, including heterodimers and homodimers, covalent and 
non-covalent association of the promoters, and different spatial configurations 
(head-to-toe, head-to-head, and skew). They are normally expressed at very low 
levels during development. The amino-terminal half of the pro-neurotrophin is 
believed to be important for the proper folding and intracellular sorting of 
neurotrophins (Mouri et al., 2007; Nomoto et al., 2007). It is worthy to note that the 
discovery that pro-neurotrophins are biologically active has revolutionized the field 
of neurotrophin research, necessitating the re-evaluation of much published data 
(Nomoto et al., 2007). Biological activity has also been attributed to two other 
peptides produced as a result of proNGF cleavage, LIP1 and LIP2 (Dicou et al., 
1997), which have been shown to protect against excitotoxin-induced cell death 
(Dicou, 2006).  
 
1.2 Neurotrophin receptors: identification and structure 
Neurotrophins bind to two different classes of transmembrane receptor 
proteins: the Trk (tropomyosin receptor kinase) family of RTKs (receptor tyrosine 
kinases) and p75NTR (p75 neurotrophin receptor). This dual system allows the 
transduction of very different signals following ligand binding, which can be as 
contrasting as signaling cell death through p75NTR or cell survival through the Trk 
receptors. These two classes of receptors also directly interact, allowing fine tuning 
and cross talk (Chao and Hempstead, 1995). Different neurotrophins show binding 
specificity for particular receptors: TrkA preferentially binds NGF; TrkB 
preferentially binds BDNF and NT4, while TrkC displays preference for NT3. 
These interactions have generally been considered to be of high affinity. However, 
in reality, the binding of NGF to TrkA, and of BDNF to TrkB is of low affinity 
(Kaplan and Miller, 1997), but it can be regulated by receptor dimerization, 
structural modifications or association with the p75 receptor (Heumann, 1994). The 
p75NTR binds all mature neurotrophins with approximately equal low affinity and 
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has, in recent years, been demonstrated to bind the proneurotrophins with high 
affinity (Massa et al., 2006). The ability of Trk and p75 receptors to present 
different binding sites and affinities to particular neurotrophins determines both 
their responsiveness and specificity. The ratio of receptors is important in dictating 
the number of surviving cells, and interactions between p75 and Trk receptors 
provide greater discrimination between different neurotrophins (Chao and 
Hempstead, 1995). Upon ligand binding, Trk receptors dimerize and become 
catalytically active, resulting in receptor autophosphorylation (Jing et al., 1992) and 
subsequent activation of a number of signalling cascades, including the Ras/ 
Raf/MAPK (mitogen-activated protein kinase) (Thomas et al., 1992), PI3K 
(phosphoinositide 3-kinase) (Soltoff et al., 1992), and phospholipase C-γ  1 
pathways (Widmer et al., 1993). Independent of Trk, the binding of neurotrophins 
to the p75NTR receptor results in activation of NF-κb, a transcription factor (Carter 
et al., 1996), and c-Jun N-terminal kinase (Harrington et al., 2002). 
 
P75 NTR receptor  
 The receptors for NGF were first identified on chick sensory ganglia and 
dorsal root ganglia (DRG) using receptor binding techniques (Sutter et al., 1979). 
For many years this was believed to be a low-affinity receptor specific for NGF. It 
was eventually established that P75NTR binds to all of the neurotrophins with a very 
similar affinity (Rodriguez-Tebar et al., 1991). The gene is present on the human 
chromosome 17 (17q21–22) (Huebner et al., 1986). P75NTR is a transmembrane 
glycoprotein receptor of ∼75 kD. There are four cysteine repeats (CR1-CR4) in the 
extracellular domain. It contains a 28 amino acid signal peptide, a single 
transmembrane domain and a 155 amino acid cytoplasmic domain. The 
cytoplasmic domain of this receptor contains a “death” domain, known to be 
involved in apoptosis (Liepinsh et al., 1997). Signaling of P75 occurs through 
cytoplasmic interactors. P75NTR is a distant member of the tumor necrosis factor 
receptor family (Chao, 1994; von Bartheld et al., 1995). The defining motifs of this 
receptor family are cysteine repeats in the extracellular domain, which form the 
ligand-binding domain. With the exception of the neurotrophins, all other known 
ligands of this receptor family are trimeric proteins that lead to the trimerization of 
the receptor following ligand binding. Neurotrophin binding to p75NTR has been 
shown to affect cell survival (Barrett and Bartlett, 1994) and axonal outgrowth 
(Walsh et al., 1999; Bentley and Lee, 2000). Signaling by this receptor is discussed 
at length below. 
 
Trk receptors  
In 1986 a human oncogene was isolated from colon carcinoma and was called 
trk (tyrosine receptor kinase) (Martin-Zanca et al., 1986). The protooncogene TrkA 
was first identified as an NGF receptor (Kaplan et al., 1991; Klein et al., 1991a), 
followed by TrkB and TrkC through screening of cDNA libraries (Barbacid, 1994). 
TrkB protein was shown to be a receptor for BDNF (Klein et al., 1991b) and 
NT-4/5 (Klein et al., 1992) and TrkC was found to be a receptor for NT-3 (Lamballe 
et al., 1991). These specificities are not absolute, and NT3 is also a ligand for TrkA 
and TrkB. Members of other neurotrophic factor families have also been shown to 
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activate Trk. These include GDNF, CNTF and other neuropoietic cytokines (Neet 
and Campenot, 2001). These Trk activate many of the same intracellular signaling 
pathways regulated by the receptors for mitogens. The protein Trk domains are 
highly homologueous (∼80% amino acid identity), whereas the extracellular 
domains are more divergent (∼30%). The TrkA gene is located on chromosome 1 
(1q21– 22) near ngf; TrkB is on chromsome 9 (9p22.1) and TrkC is on 
chromosome 15 (15q25). The Trk receptors are transmembrane glycoproteins of ∼
140 kD, comprising about 800 amino acids with half of the residues at the amino 
terminus forming the extracellular portion of the receptor. Examination of sequence 
motifs in the extracellular region of the Trk receptors showed that there are five 
distinct domains. They are tyrosine kinases with an extracellular ligand-binding 
domain containing multiple repeats of leucine-rich motifs (LRR1-3), two cysteine 
clusters (C1, C2), two immunoglobulin-like domains (Ig1, Ig2), and a single 
transmembrane domain (Schneider and Schweiger, 1991). The most important site 
at which Trk receptors interact with neurotrophins has been localized to the most 
proximal immunoglobulin (Ig) domain of each receptor (Urfer et al., 1995; Urfer et 
al., 1998). The three-dimensional structures of each of these Ig domains has been 
solved (Ultsch et al., 1999), and the structure of NGF bound to the TrkA membrane 
proximal Ig domain has also been determined (Wiesmann and de Vos, 1999). This 
exciting structural information has provided detailed information about interactions 
that regulate the strength and specificity of binding between neurotrophins and Trk 
receptors. 
 
1.3 Signaling pathway 
Binding of neurotrophins to the Trk receptors causes signaling events that 
promote neuron survival, whereas activation of the p75NTR pathway triggers 
apoptosis and cell death (Kaplan and Miller, 2000). Through Trk receptors, 
neurotrophins activate Ras, phosphatidyl inositol-3 (PI3)-kinase, phospholipase 
C-g1 and signalling pathways controlled through these proteins, such as the MAP 
kinases. Activation of p75NTR results in activation of the nuclear factor-κB (NF-κ
B) and Jun kinase as well as other signalling pathways. Neurotrophins can bind 
both Trk and p75NTR and activate the different singalling pathways simultaneously, 
and the signaling pathways through Trk receptors and p75NTR may interact with 
each other (Gargano et al., 1997).  
 
Signaling through the P75NTR receptor 
The mechanisms of transduction mediating the biological effects of p75NTR in 
neurons are poorly understood. On the one hand, p75NTR can modulate cellular 
responses to neurotrophins, by interacting with Trk. Modulation of Trk interaction 
with neurotrophins has been considered as the main p75NTR mechanisms of action 
since the discovery of Trk receptors (Barbacid, 1994; Chao, 1994; Chao and 
Hempstead, 1995). On the other hand, ligand engagement of p75NTR has been 
shown to promote survival of some cells and apoptosis of others (Barrett and 
Bartlett, 1994) and affects axonal outgrowth (Yamashita et al., 1999; Bentley and 
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Lee, 2000) through interacting with the intracellular binding proteins. To date, 
several proteins had been identified that directly interact with p75NTR, such as 
RhoA, a member of the Ras superfamily of GTP-binding proteins (Yamashita et al., 
1999), tumor necrosis factor receptor-associated factor-6 (TRAF6) (Khursigara et 
al., 1999), and a zinc finger protein named NT receptor interacting factor (NRIF) 
(Casademunt et al., 1999). RhoA has been shown to control the organisation of the 
actin cytoskeleton in many cell types (Ridley, 2006). Like other members of the 
Ras superfamily, RhoA cycles between active, GTP-bound and inactive, 
GDP-bound states. These proteins are presumptively the mediators of p75NTR 
-induced changes in NF-κB and c-Jun kinase activities, and activation of the 
sphingomyelin cycle, which result in the biological effects of p75NTR activation 
(Chao, 1994). An important pathway promoting cell survival of many cell 
populations involves activation of NF-κB (Barrett and Bartlett, 1994). As is the 
case with TNF receptor 1 signaling, it appears that activation of NF-κB prevents 
cell death (Liu et al., 1996; Hamanoue et al., 1999). Beyond the activation of NF-
κB, there are also clear indications that p75NTR activation by neurotrophins causes 
programmed cell death. Cell death signaling involves caspase activation, as well as 
Bax/Bad, Bcl-2, and Bcl-xL (Coulson et al., 1999; Soilu-Hanninen et al., 1999), but 
the details of the pathway linking p75NTR with cell death execution are far from 
clear. Inhibition of Jun kinase (JNK) activity blocks apoptosis through p75NTR, 
suggesting that JNK plays a significant role in p75-mediated apoptosis (Yoon et al., 
1998; Bhakar et al., 2003). It is assumed that the different use of cytoplasmic 
interactors for signal transduction causes the considerably various consequences of 
p75NTR activation associated with the cellular context (Barker, 1998). 
 
Signaling through the Trk receptors 
Binding of the neurotrophins activates the Trk receptors by a two-step process: 
ligand-induced receptor dimerization, and autophosphorylation of tyrosine residues 
in its autoregulatory loop (Schlessinger and Ullrich, 1992). The activated receptors 
become able to interact and phosphorilate several intracellular targets (Segal and 
Greenberg, 1996). Among the proteins that can be activated by autophosphorilated 
Trk receptors are phospholipase C-1g (Obermeier et al., 1994; Stephens et al., 
1994); the adapter proteins Shc, rAPS and SH2-B (Obermeier et al., 1994; Stephens 
et al., 1994; Qian et al., 1998); phosphatidylinositol-3’ kinase (PI3K) (Stephens et 
al., 1994); Fyn, a protein tyrosine kinase involved in regulation of cell adhesion and 
synaptic plasticity (Iwasaki et al., 1998); the brain immunoglobulin-like molecule 
with tyrosine-based activation motifs (BIT), also known as SHPS-1 and SIRPa 
(Ohnishi et al., 1999); and fibroblast growth factor receptor substrate 2 (FRS2) 
(Easton et al., 1999). In turn, these activated proteins lead to activation of the 
Ras/mitogen-activated protein kinase (MAPK) signaling pathway and 
phosphorylation of extracellular signal-regulated kinases (ERKs) (Kaplan and 
Stephens, 1994), to an increase in intracellular calcium concentration and 
subsequent activation of calcium/ calmodulin-dependent kinases and casein kinase 
2 (Finkbeiner et al., 1997; Blanquet, 1998), CREB phosphorylation (Finkbeiner et 
al., 1997), and further activation of phosphatidylinositol-3 ‘ kinase (Baxter et al., 
1995). Three main signaling cascades are activated by the Trk receptors and their 
substrates. First, the activation of the Ras/Raf/MEK/MAPK pathway results from 
the formation of a variety of complexes of adapter molecules. Phosphorylated Shc 
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leads to the activation of the Ras/Raf/MEK/MAPK pathway (Kaplan and Miller, 
2000). Phospho-Shc binds to the Grb2–SOS complex, which activates Ras, and 
MAP kinase is activated through Raf and MEK. Similarly, phosphorylated FRS2 
recruits a complex of the tyrosine phosphatase SHP-2/Grb2/SOS and activates 
Ras/Raf/MEK/MAPK (Kouhara et al., 1997; Hadari et al., 1998). Also, SNT seems 
to activate this pathway, which mediates neuritogenesis (Stephens et al., 1994). 
Other docking molecules seem to form complexes with Grb2/SOS, such as rAPS 
and SH2-B (Qian et al., 1998). They were identified in developing neurons and 
may be involved in neuronal differentiation. This complexity of activation allows a 
sustained activation of the MAPK pathway in response to neurotrophins, ultimately 
leading to activation of gene expression, neuronal survival and neurite outgrowth 
(Kaplan and Stephens, 1994).  
 
 
Fig. 2. Multicomponent receptor systems of neurotrophic factors. The neurotrophins family of 
NGF, BDNF, NT-3 and NT-4 bind to specific Trk receptors. Cross-talk is also apparent in these 
interactions as more than one neurotrophin may bind to the same Trk receptor, and more than 
one Trk may bind to the same neurotrophin with less efficiency (e.g. NT3 activate TrkA and 
TrkB) in some cellular contexts. All members of the neurotrophin family interact with p75NTR. 
Each proneurotrophin also binds p75NTR, but not the Trk receptors. Each Trk receptor activates 
several signal transduction pathways. Neurotrophin binding to the Trk receptors mediates 
survival, cell migration and myelination through several signalling pathways. The Trk receptor 
extracellular domain consists of two cysteine rich domains (C1,C2), three leucine-rich motifs 
(LRR 1-3), and two IgG-like (Ig 1-2) domains; the intracellular domain is a protein tyrosine 
kinase. The extracellular portion of p75NTR contains four cysteine-rich repeats, and the 
intracellular part contains one or two death domains. Additional details are provided in the text. 
(Modified from Chao, Nature, 2003) 
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2 BDNF 
As reviewed above, neurotrophins are critical molecules that support the 
development, differentiation, maintenance and plasticity of brain function 
throughout life. Among these molecules, BDNF is the most abundantly expressed 
and widely distributed in the central nervous system (CNS), and has survival 
promoting actions on a variety of CNS neurons including hippocampal and cortical 
neurons (Ghosh et al., 1994; Lindholm et al., 1996; Lowenstein and Arsenault, 
1996), cholinergic neurons (Alderson et al., 1990; Nonomura and Hatanaka, 1992), 
and nigral dopaminergic neurons (Hyman et al., 1991; Ostergaard et al., 1996). 
Moreover, BDNF regulates almost all aspects of neuronal development and 
function including precursor proliferation and commitment (Davies, 1994), axon 
and dendrite growth (Davies, 2000), membrane trafficking, synapse formation and 
function (Li et al., 1998), as well as glial differentiation and interactions with 
neurons (Lykissas et al., 2007). Recent research suggests that alterations in the 
levels of BDNF or its main receptor TrkB can lead to neuronal death and contribute 
to the pathogenesis of many CNS disorders such as Parkinson disease, Alzheimer 
disease, Huntington disease, amyotrophic lateral sclerosis, and also aging (Dawbarn 
and Allen, 2003). There is widespread interest in the use of BDNF to treat these 
CNS disorders. To better exploit its potential application in the therapy of CNS 
disorders, here we describe in detail BDNF distribution, regulation, secretion and 
function. 
 
2.1 Distribution and cellular localization 
BDNF mRNA and protein levels have been detected in the hippocampus, 
amygdala, thalamus, projection areas of the olfactory system, inner and outer 
pyramidal layers of the neocortex, claustrum, septum, cerebellum and the superior 
colliculus (Murer et al., 2001), indicating that BDNF has a more widespread 
distribution than NGF. In the rat (Nishio et al., 1994; Yan et al., 1997) and human 
(Quartu et al., 1999) hippocampus, BDNF mRNA and protein levels have been 
visualized in both the pyramidal and granule cell layers. BDNF-immunoreactivity 
has also been observed in the hilar region of the dentate gyrus as well as the 
pyramidal and apical dendritic processes of the CA3, CA2, CA1 and subiculum 
regions (Goutan et al., 1998). There are only few brain areas like the striatum that 
completely lack BDNF mRNA (Yan et al., 1997). BDNF expression is low in 
developing regions of the CNS and increases as these regions mature (Maisonpierre 
et al., 1990). TrkB, receptor for BDNF, is also found in neuronal perikarya in 
neocortex and striatum and in reactive astrocytes (Soontornniyomkij et al., 1998). 
The presence of both receptor and factor in the neocortical perikarya suggests an 
autocrine function in those neurons while the presence of factor in neurites of 
striatum suggests that the factor is not synthesized locally in striatum but is in the 
process of being taken up by retrograde transport (Canals et al., 2001). It is 
important to keep in mind that BDNF-IR can result either from targeting of the 
newly synthesized NT in BDNF producing cells or from BDNF uptake and 
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redistribution of endocytosed BDNF, which was originally released from 
neighboring cells.  
In the cortex, BDNF-immunostained cell bodies with a pyramidal morphology 
were present in all regions, including the primary visual cortex and other occipital 
areas, the motor and somatosensory cortex, the insular cortex, and cortex of the 
temporal pole (Murer et al., 1999). Non-pyramidal neurons were rarely stained. 
Pyramidal BDNF-immunoreactive neurons were preferentially located in layers V 
and III. The distribution is more abundant in the insular and temporal cortices than 
primary motor and sensory cortices. Scattered pyramidal neurons show intense 
labeling in the cells of deeper pyramidal layers. BDNF-immunoreactive neurons 
were also noticeable in the white matter immediately adjacent to the cortex (see 
(Conner et al., 1997) and(Yan et al., 1997), for a detailed description in the rat 
brain).  
In the hippocampal formation of the adult human brain, a minority of neurons 
displayed a strong cell body BDNF-immunoreactivity (Goutan et al., 1998). The 
density of perikaryal staining seemed higher in the granule cell layer of the dentate 
gyrus than in the Ammon’s horn (Nishio et al., 1994). Within the latter, the density 
of immunoreactive pyramidal cell bodies was lowest in CA1. Intensely labeled 
axon-like fibers were present in the polymorph layer and hilar region of the dentate 
gyrus, and in the pyramidal layer of fields CA3 and CA4. In fields CA3 and CA4, 
the intensity of neuropile staining revealed the location of non-labeled pyramidal 
neuronal cell bodies. The disposition of BDNF-immunoreactive axon-like fibers in 
the CA3 and CA4 fields strongly suggested that they were in close contact with the 
proximal dendrites of pyramidal neurons (Dawson et al., 2001). In conjunction, the 
anatomical distribution of BDNF in the hippocampal formation supports that a 
large part of hippocampal BDNF is contained in the mossy fiber system, that is, in 
the axons of dentate gyrus granule cells which make synaptic contacts on the 
proximal dendrites of pyramidal neurons in the Ammon’s horn after traversing the 
polymorph layer and hilar region of the dentate gyrus (Wetmore et al., 1994). 
Moderately intense neuropile staining was also found in the inner molecular layer 
of the dentate gyrus. The two outer thirds of the molecular layer were almost 
devoid of labeling, however, suggesting scarce or no BDNF in afferent fibers 
arriving from the entorhinal cortex (the perforant path). In the molecular layer, 
labeled neuronal profiles were rarely found (Conner et al., 1997). 
With respect to the subcellular localization of endogenous BDNF, (Fawcett et 
al., 1997) showed BDNF-IR in the vesicular fraction of isolated synaptosomes from 
rat cortex homogenates, and Western blot analysis revealed colocalization with the 
synaptic marker synaptotagmin, which is associated with small synaptic vesicles as 
well as with dense core vesicles (DCV) (Berg et al., 2000). A postsynaptic 
localization of BDNF at glutamatergic synapses is directly evident in the 
postsynaptic density of rat cortical synapses (Aoki et al., 2000). Interestingly, Berg 
et al. (2000) reported about the ultrastructural localization of BDNF in DCV, which 
had been biochemically isolated by density gradient centrifugation from the axons 
of the optic nerve, from tissue of the superior colliculus and from the lateral 
geniculate nuclei of the thalamus, respectively. Taken together, the ultrastructural 
localization of endogenous BDNF in central neurons is not yet completely resolved, 
which might in part be due to the low abundance of BDNF protein in central 
neurons under basal conditions. The available data are consistent with a vesicular 
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storage in both axons and presynaptic structures as well as in dendrites and 
postsynaptic structures (Altar and DiStefano, 1998).  
Earlier efforts showed that BDNF is retrogradely transported by peripheral and 
CNS neurons (Altar and DiStefano, 1998; Mufson et al., 1999). Locally applied 
BDNF can be taken up by axons and retrogradely transported to neuronal cell 
bodies in the adult mammalian CNS (Mufson et al., 1999). Both p75NTR and TrkB 
seem to be able to mediate retrograde transport of BDNF (Curtis et al., 1995; Pease 
et al., 2000; Hibbert et al., 2006; Iwabe et al., 2007). The distribution of exogenous 
BDNF protein following localized brain injections, is compatible with BDNF 
anterograde transport from cell bodies to nerve endings. There are many studies 
that demonstrated the existence of anterograde axonal transport of BDNF (Spalding 
et al., 2002; Butowt and von Bartheld, 2005). Evidence regarding a functional role 
of anterogradely transported BDNF in the CNS, however, is scarce. There are 
studies showing a functional role of BDNF in the adult mossy fiber and CA3 
pyramidal neuron synapse, suggesting that anterogradely transported BDNF can be 
involved in normal synaptic function (Scharfman, 1997) and epileptogenesis 
(Binder et al., 1999b; Scharfman et al., 1999). A report by Fawcett et al. (1998) 
provided evidence supporting a trophic action of anterogradely transported BDNF 
in the developing rodent CNS (Fawcett et al., 1998). Another means of delivering 
BDNF would be via dendritic targeting of BDNF protein or mRNA. Such locally 
synthesized BDNF could regulate synaptic strength in a site-specific manner. 
Indeed, dendritic accumulation of BDNF mRNA and protein was found selectively 
in discrete dendritic lamnias during epileptogenesis (Tongiorgi et al., 2004). 
 
2.2 Expression regulation 
The expression of the neurotrophins in the mammalian brain is regulated 
during development and by neuronal electrical activity. BDNF expression levels are 
low at birth but increase dramatically during the first weeks of postnatal 
development (Dieni and Rees, 2002). BDNF expression shows distinct 
modifications during fetal and early postnatal development. Expression of the 
BDNF gene in the adult CNS can be regulated by a series of events, either 
physiological signals or insults, including an increased expression following 
hypoxia-ischemia and hypoglycemic coma (Lindvall et al., 1992; Merlio et al., 
1993; Korhonen et al., 1998; Hughes et al., 1999), an increased expression in 
interneurons located close to axotomized cortical projection neurons (Wang et al., 
1998), and a reduced expression after stress (Smith et al., 1995; Altar, 1999). Some 
spontaneous changes in bioelectrical activity, or changes in activity induced by 
pharmacological manipulations can modify BDNF mRNA expression in vitro 
(Rutherford et al., 1997; Rutherford et al., 1998; Gorba et al., 1999). The regulation 
of BDNF expression occurs in an activity dependent manner. Activity-induced 
changes in BDNF expression have a very short latency, suggesting that BDNF can 
function as an immediate-early gene. BDNF expression can also be regulated by 
neurotransmitters and hormones (Cosi et al., 1993; Vaidya et al., 2001). Other 
synaptic mediators and hormones involved in the regulation of BDNF expression in 
the CNS are acetylcholine (Lapchak et al., 1993; French et al., 1999), serotonin 
(Vaidya et al., 1999; Zetterstrom et al., 1999), nitric oxide (Xiong et al., 1999), 
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thyroxine (Luesse et al., 1998), glucocorticoids and mineralocorticoids (Schaaf et 
al., 1998), and sexual steroids (Gibbs, 1999). 
Zafra et al. showed that a balance between the glutamatergic and GABAergic 
systems controls the physiological levels of BDNF and NGF mRNA within 
hippocampal neurons both in vitro and in vivo (Zafra et al., 1990; Zafra et al., 
1991). Blockage of glutamatergic receptors and/or stimulation of the GABAergic 
system results in a reduction of BDNF and NGF mRNA levels in the hippocampus 
and NGF protein in the septum and hippocampus. The refined and rapid regulation 
of both BDNF and NGF mRNA by glutamate and GABA transmitter systems 
suggests that BDNF and NGF may be involved in activity-dependent synaptic 
plasticity. Hippocampal neurons receive glutamatergic afferents from the entorhinal 
cortex via the angular bundle perforant pathway. The maintenance of basal NGF 
and BDNF mRNA levels appears to be mediated by excitatory neurotransmitters 
acting via NMDA/nonNMDA receptors (Rocamora et al., 1994; Brandoli et al., 
1998). Supporting these findings, transynaptic stimulation of hippocampal afferents 
was observed to increase the level of BDNF mRNA within the hippocampus 
(Falkenberg et al., 1992).  
Recent molecular cloning of the BDNF gene also revealed how the BDNF 
promoters I, II and III regulate BDNF expression (Hayes et al., 1997; Dennis and 
Levitt, 2005). These promoters are predominantly detected in the brain. The 
alternative usage of these promoters and different splicing can result in four forms 
of BDNF mRNA with different 5’ untranslated exons and a common exon encoding 
the mature part of BDNF. The BDNF exons have been reported to be regionally and 
specifically induced by different forms of brain insult (Kokaia et al., 1994b). 
Falkenberg et al. reported that activation of entorhinal cortical afferents resulted in 
the regulation of different BDNF promoters within the hippocampus in a 
differential and dose-dependent manner (Falkenberg et al., 1993). Functionally, it is 
possible that the multipromoter system of the BDNF gene regulates BDNF 
synthesis in different cell types at both the transcriptional and translational levels. 
 
2.3 BDNF secretion 
The first two studies that addressed qualitatively the release of endogenous 
BDNF from central neurons were by Wetmore et al. (1994) and Ghosh et al. 
(1994)(Ghosh et al., 1994). The study by Wetmore et al. showed a shift of 
BDNF-IR from intracellular compartments to the extracellular neuropil of CA2 and 
CA3 pyramidal neurons, following kainate-induced depolarization of the 
hippocampus in vivo (Wetmore et al., 1994). Direct detection of released BDNF 
protein was accomplished by Goodman et al. (1996) who showed a 
depolarization-induced accumulation of BDNF in the extracellular medium using 
Western blot analysis of cultured hippocampal neurons overexpressing BDNF (i.e. 
bulk secretion) (Goodman et al., 1996). BDNF has been shown to be released both 
constitutively and in a regulated manner by different cells. Subsequently, BDNF 
was demonstrated to be present in a synaptosomal vesicular fraction obtained from 
rat cortical extracts (Fawcett et al., 1997). Localization of BDNF to vesicles was 
found in primary cultured rat cortical neurons (Haubensak et al., 1998) and further 
studies in hippocampal neurons addressed the mechanism of neuronal BDNF 
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secretion (Lessmann et al., 2003).  
Release of endogenous BDNF could be elicited by electrical field stimulation, 
50 mM K+ or glutamate-induced depolarization in a calcium-dependent manner 
(Canossa et al., 1997; Griesbeck et al., 1999). Extracellular BDNF protein generally 
peaked within 50–250 s after the start of the stimulation (Canossa et al., 1997; 
Griesbeck et al., 1999; Hartmann et al., 2001). Glutamate-induced secretion of 
BDNF from hippocampal neurons has been suggested to be mediated by AMPA 
receptors and/or metabotropic glutamate receptors (Canossa et al., 2001). 
Application of AMPA can trigger depolarization-induced Ca2+ influx via 
voltage-gated calcium channels (VGCCs). It is of note that electrically evoked (as 
high K+ induced) bulk secretion of BDNF is also dependent on intact intracellular 
Ca2+ stores (Balkowiec and Katz, 2002). Ca2+ release from internal stores could be 
an important amplification mechanism to reach an amplitude and a time course of 
intracellular Ca2+ at the plasma membrane that can trigger efficient peptide 
secretion (Gartner and Staiger, 2002).  
Interestingly, neurotrophin secretion can also be triggered by neurotrophins 
themselves: using NT-4/5- or NT-3-induced stimulation of neuronal TrkB and TrkC 
receptors, Canossa et al. (1997) showed secretion of endogenous and of 
overexpressed BDNF from acute hippocampal slices. This NT-induced secretion of 
neurotrophins is mediated by mobilization of Ca2+ from internal stores. This is a 
common signal cascade downstream of Trk receptor activation (Berninger et al., 
1993; Li et al., 1998; Patapoutian and Reichardt, 2001), and it is mediated by 
activation of PLC via a specific intracellular tyrosine in Trk receptors (Canossa et 
al., 2001). In CNS neurons, which are known to coexpress BDNF and TrkB 
receptors, the BDNF-induced release of BDNF could be important for prolonged 
BDNF release by this autocrine loop and could account for sustained NT secretion 
even when the triggering stimulus has ceased.  
The axonal localization and dendritic targeting of BDNF (Kohara et al., 2001) 
had been clearly observed. In line with the axonal and dendritic localization of 
endogenous BDNF in different brain regions, pre- and postsynaptic secretion of 
BDNF had both been proven. The mechanism of secretion, however, was not 
addressed. Hartmann et al. (2001) showed that synaptic secretion of BDNF is 
dependent on the presence of extracellular Ca2+ and can be either mediated via 
activation of VGCC upon high K+-induced depolarization or via activation of 
synaptic glutamate receptors following electrical stimulation (Hartmann et al., 
2001). Interestingly, axonal as well as dendritic release of BDNF has been shown to 
depend on action potential generation, whereas steady depolarization alone was 
inefficient (Kohara et al., 2001; Gartner et al., 2006; Taniguchi et al., 2006). The 
relief of Ca2+ channel inactivation by intermittent post-spike hyperpolarizations is 
an important prerequisite for BDNF secretion (Kolarow et al., 2007).  
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3 The role of BDNF in the pathogenesis of some 
neurological diseases 
As mentioned earlier, BDNF is vital for nervous system development, as 
indicated by the lethality of homozygous knockout mice for BDNF or severe 
developmental abnormalities in the nervous system and other organs of 
homozygous and heterozygous knockout animals (Pozzo-Miller et al., 1999; Hall et 
al., 2003; Zhu et al., 2009). Abnormal expression or signaling of BDNF can also 
have consequences on synaptic function, neuronal gene expression, and behavior, 
leading to neuronal dysfunction and neurological disorders such as 
neurodegenerative diseases, epilepsy, pain, hypoxia-ischemia, and hypoglycemia, 
depression etc (See review (Kuipers and Bramham, 2006). Recent studies suggest 
that changes in retrograde transport, decreased synthesis, altered processing of 
pro-neurotrophins or signaling through p75NTR may contribute as a secondary event 
to neuronal degeneration in some CNS disorders (Zhou et al., 2004; Iwabe et al., 
2007; Wang et al., 2008). Although loss of BDNF signaling during development 
and adulthood has clearly been shown to result in developmental deficits and 
neuronal degeneration, no direct evidence has been provided to link BDNF to the 
etiology of any specific neurological disease. The possible involvement of BDNF 
in neurodegenerative diseases, epilepsy, pain, depression will be reviewed blow. 
 
3.1 BDNF in neurodegenerative diseases 
There is growing evidence that reduced neurotrophic support is a significant 
factor in the pathogenesis of neurodegenerative diseases such as Alzheimer’s 
disease (AD), Huntington disease (HD), Parkinson’s disease (PD) and amyotrophic 
lateral sclerosis (ALS).  
Alzheimer’s disease 
Growing evidence suggests that a decrease in BDNF levels could be 
associated with AD pathogenesis. AD is characterized by a progressive decline in 
cognitive function that correlates with a number of pathological changes in several 
different brain regions. Selective reduction of BDNF mRNA in the hippocampus 
has been reported in Alzheimer’s disease specimens (Phillips et al., 1991; Ferrer et 
al., 1999). The BDNF transcript in AD patients was reduced to 50% relative to 
control individuals. Decreased BDNF protein has been demonstrated in individuals 
with Alzheimer’s disease by cell counting, optical density measurements (Connor et 
al., 1997) and western blot assay (Ferrer et al., 1999). Murer et al. (1999) 
demonstrated in AD brains that neurons showing neurofibrillary tangles are usually 
devoid of BDNF-immunoreactive material, whereas most intensely BDNF labeled 
neurons were devoid of tangles (Murer et al., 1999). Besides, in the hippocampus 
of AD patients, high amounts of truncated (95 kDa) TrkB receptors have been 
found in amyloid plaques (Connor et al., 1996). These data suggest a progression of 
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changes with loss of BDNF and conversion of full length to truncated TrkB during 
the amyloid plaque formation. It was also suggested that BDNF signaling might be 
impaired early in the course of AD (Murer et al., 1999). Connor et al. (1997) 
reported that immunoreactive TrkA and TrkB receptors were increased in astrocytes 
in the CA1 region in AD brains and to some degree were associated with amyloid 
plaques. In the basal forebrain, immunostaining showed a large reduction in TrkA, 
TrkB and TrkC expression in AD (Salehi et al., 1996). Allen et al. (1999) reported a 
profound decrease in catalytic TrkB protein expression in the frontal and temporal 
cortices of individuals with Alzheimer’s disease (Allen et al., 1999). CREB, a 
crucial BDNF signaling molecule, has been reported to be impaired in AD patients 
(Yamamoto-Sasaki et al., 1999). The precursor form of BDNF and mature BDNF 
(Michalski and Fahnestock, 2003; Peng et al., 2005) or its mRNA (Holsinger et al., 
2000) were also decreased in the parietal cortex and hippocampus, even in 
pre-clinical stages of AD. In summary, the available evidence suggests that AD 
patients have a reduced mRNA and protein content of BDNF, pro-BDNF or 
BDNF-containing molecules in the hippocampal formation, temporal cortex, and 
probably other cortical areas. These alterations vary in the course of the disease and 
are correlated with the severity of dementia (Tapia-Arancibia et al., 2008). 
 
Huntington’s disease 
Interestingly, recent work has implicated BDNF in Huntington’s disease as 
well. In Huntington’s disease the mutant protein huntingtin leads to a 
down-regulation of BDNF in the basal ganglia, and loss of huntingtin-mediated 
BDNF transcription leads to loss of trophic support to striatal neurons which 
subsequently degenerate in the hallmark pathology of the disorder (Zuccato et al., 
2001). These data demonstrated a role of huntingtin in influencing BDNF transport 
and BDNF expression (Wu et al., 2009b). A recent study has demonstrated that 
huntingtin normally inhibits the neuron restrictive silencer element (NRSE) 
involved in tonic repression of transcription from BDNF promoter II (Zuccato et al., 
2003; Rigamonti et al., 2007). BDNF protects the majority of striatal projection 
neurones from excitotoxin lesions. Reduced BDNF levels or TrkB receptors have 
been found in brain regions most affected in HD patients (caudate and putamen) 
(Gines et al., 2006; Ciammola et al., 2007) and in transgenic mice that express 
human mutant huntingtin (Zuccato et al., 2005). In animals treated with the 
excitotoxin quinolinic acid, cells genetically engineered to release BDNF, NT-3 or 
NT-4/5 were implanted into the striatum. All these neurotrophins were shown to 
promote the survival of striatal projection neurones, with BDNF being most 
effective as a survival agent (Perez-Navarro et al., 2000). BDNF has been proposed 
for the clinical treatment of HD patient (Roze et al., 2008). 
 
Parkinson’s disease 
Parkinson’s disease is characterized by the selective degeneration of nigral 
dopaminergic neurons and subsequent depletion of striatal dopamine which leads to 
motor dysfunction. One hypothesis of the cause of degeneration of the nigrostriatal 
dopaminergic neurons is that PD is caused by apoptosis due to decreased 
neurotrophins. Decreased BDNF protein has been demonstrated in the substantia 
nigra (SN) in Parkinson’s disease (Parain et al., 1999; Howells et al., 2000). In 
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substantia nigra pars compacta (SNc) of PD brains compared to age-matched 
controls, the number of pigmented neurons containing BDNF was reduced to 9.6% 
of the control value while the number of pigmented neurons non-immunoreactive 
for BDNF was reduced only to 23.9% of the control value, thus suggesting that 
SNc pigmented neurons not expressing BDNF have a greater probability of 
surviving than BDNF-positive pigmented neurons. All the dopaminergic neurons 
observed to have Lewy bodies were immunoreactive for BDNF (Parain et al., 1999). 
These data suggest that BDNF actually confers a greater sensitivity to degeneration 
in PD. In a quantitative assessment of NTFs content within individual neurons 
based on density of staining with either immunoperoxidase or immunofluorescent 
labeling (Nagatsu et al., 2000), small decreases in BDNF and CNTF (5 to 10%) 
were observed, but little or no significant changes in NGF, NT-3 or NT-4/5 in 
surviving neurons of SNc in PD. To date, supplementation of some specific NTFs 
(e.g. BDNF) has been used as potential therapy against PD in experimental animal 
and in vitro models (Jiang et al., 2006; Singh et al., 2006; Sadan et al., 2009). 
Further elucidation on the relationship between BDNF and PD will be need to 
reach a clinical application. 
 
Amyotrophic lateral sclerosis 
ALS is a neurodegenerative disease that usually attacks both upper and lower 
motor neurons and causes degeneration throughout the brain and spinal cord. A 
majority of spinal cord motor neurons in humans exhibit immunoreactive BDNF 
and their respective receptors, TrkB and TrkC, thus suggesting autocrine regulation 
by BDNF and NT-3 (Kawamoto et al., 1998). In the spinal cords of patients died of 
ALS, three-quarters of the motor neurons were lost and the remaining motor 
neurons demonstrated decreased BDNF/TrkB and increased NGF and TrkA 
(Koliatsos et al., 1993; Mutoh et al., 2000). Other studies showed that a number of 
NTF promote survival of spinal motor neurons, including BDNF (Kishino et al., 
1997), CNTF, IGF and glial-derived neurotrophic factor. However, only IGF-I 
slowed the efficiency in the progression of functional impairment in patients with 
ALS when administered with these NTFs (Turner et al., 2001). BDNF therapy 
produced no significant overall survival effect or benefit for the primary end points 
but did show statistically significant benefits in subgroups of patients with early 
respiratory impairment in a phase III trial (Kalra et al., 2003). A recent report 
showed that BDNF enhances branching and arborization but not axon outgrowth in 
corticospinal motor neurons (Ozdinler and Macklis, 2006).  
 
3.2 BDNF and epilepsy 
The discovery that limbic seizures increase NGF mRNA levels (Gall and 
Isackson, 1989) led to the idea that seizure-induced expression of NTFs may 
contribute to the lasting structural and functional changes underlying 
epileptogenesis (Gall et al., 1991; Simonato et al., 2006). It is well known that 
epileptogenic insults increase the synthesis of BDNF and the activation of trkB 
receptors (Binder et al., 1999b; Binder et al., 2001). Increases in BDNF mRNA 
expression were found not only after long-lasting or recurrent seizures, but also 
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after brief episodes of hippocampal epileptiform activity, and were not restricted to 
the hippocampal formation, but involved widespread regions of the cerebral cortex 
and the amygdaloid complex (See review Simonato et al. 2006). Remarkably, 
increased BDNF expression in the hippocampus is found in specimens from 
patients with temporal lobe epilepsy (Mathern et al., 1997; Takahashi et al., 1999). 
In temporal lobes resected for treatment of refractory epilepsy and showing 
hippocampal sclerosis, compared to autopsy material or resections for mass lesions, 
granule cells contain increased levels of mRNAs for BDNF, NGF and NT-3. 
Interestingly, BDNF is down-regulated under chronic epileptic conditions (Shetty et 
al., 2003). Nevertheless, it was suggested that there were functional associations 
among granule cell neurotrophins, mossy fiber synaptic plasticity and hippocampal 
neuron damage in hippocampal sclerosis and epilepsy. Many studies convincingly 
support the notion that BDNF have a proepileptogenic role. Infusion of anti-BDNF 
agents (Binder et al., 1999b) or use of BDNF knockout (Kokaia et al., 1995) or 
truncated trkB-overexpressing (Lahteinen et al., 2002) mice inhibits epileptogenesis 
in animal models. Direct application of BDNF induces hyperexcitability in vitro 
(Scharfman et al., 1999), overexpression of BDNF in transgenic mice leads to 
spontaneous seizures (Croll et al., 1999), and intrahippocampal infusion of BDNF 
into intact adult rats initiates mossy fiber sprouting and seizure activity (Scharfman 
et al., 2002a). However, BDNF also seems to have some beneficial effects during 
the course of TLE. For instance, it has been shown that the BDNF amplifies GABA 
currents in oocytes expressing GABAA receptors transplanted from surgically 
removed specimens of human epileptic brains (Palma et al., 2005). Furthermore, 
our previous studies shows that the BDNF favors survival and regeneration of 
hippocampal neurons damaged by the SE (Simonato et al., 2006; Paradiso et al., 
2009). Thus, the role of BDNF in epilepsy needs to be elucidated much more 
profoundly.  
 
3.3 BDNF and other neurological disorders 
Neurotrophins control survival, differentiation and synaptogenesis, and play 
important roles in activity-dependent forms of synaptic plasticity in the nervous 
system. It is well accepted that alterations in the levels of NTFs or their receptors 
contribute to the pathogenesis of neuropathy, pain and psychiatric disorders. 
Studies performed from human nerve biopsies in cases of neuropathy showed that 
the neurotrophin receptors were upregulated in p75NGR while downregulated in 
TrkB and TrkC in nerves with axonal pathology (Goettl et al., 2004). The mRNA 
levels for NGF, BDNF and NT-3 are increased in diseased nerves (Rodriguez-Pena 
et al., 1995; Anand, 2004). 
 BDNF signaling may also be involved in affective disorders (Altar, 1999). A 
recent series of studies has linked a polymorphism in the pro-domain of BDNF 
with depression, bipolar disorders and schizophrenia (Skibinska et al., 2004; Tsai, 
2004; Kolarow et al., 2007). This polymorphism, which was identified from a 
single nucleotide polymorphism screen, is caused by a single amino-acid change, in 
the pro-domain of the BDNF protein (Lu and Martinowich, 2008). However, a 
recent meta-analysis did not support BDNF genotype as a major influence on the 
development of depression (Chen et al., 2008). Several lines of evidence have 
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implicated neurotrophins in depression (Castren and Rantamaki, 2008). 
Environmental stresses such as immobilization induce depression and also decrease 
BDNF mRNA (Smith et al., 1995; Murakami et al., 2005). In animal models, 
restraint stress leads to decreased expression of BDNF in the hippocampus 
(Rasmusson et al., 2002; Chourbaji et al., 2004). The administration of BDNF to 
the midbrain or hippocampus results in antidepressant effects in animal models of 
depression (Shirayama et al., 2002). Existing pharmacological antidepressants are 
thought to act primarily by increasing endogenous monoaminergic (i.e. serotonergic 
and nor-adrenergic) synaptic transmission, and recent studies have shown that 
effective antidepressants increase BDNF mRNA (Dias et al., 2003) and protein 
(Chen et al., 2001a; Altar et al., 2003). BDNF has been shown to have trophic 
effects on 5-HT and noradrenergic neurons. Mutant mice with decreased levels of 
BDNF show a selective decrement in the function of 5-HT neurons and behavioural 
dysfunctions that are consistent with serotonergic abnormalities (Lyons et al., 1999). 
Interestingly, lithium, a major drug for the treatment of bipolar disorder, increases 
BDNF and trkB activation in cerebral cortical neurons (Hashimoto et al., 2002).  
BDNF also may play an important neuromodulatory role in pain transduction 
(Malcangio and Lessmann, 2003). BDNF is synthesized by dorsal horn neurons and 
markedly upregulated in inflammatory injury to peripheral nerves (along with NGF) 
(Fukuoka et al., 2001). BDNF acutely sensitizes nociceptive afferents and elicits 
hyperalgesia which is abrogated by BDNF inhibitors (Kerr et al., 1999; Pezet et al., 
2002). Spinal neurons show increased excitability to nociceptive inputs after 
treatment with exogenous BDNF (Thompson et al., 1999). Electrophysiological and 
behavioural data demonstrate that inhibition of BDNF signal transduction inhibits 
central pain sensitization (Kerr et al., 1999; Pezet et al., 2002).  
30                                                                Chapter I: BACKGROUND 
4 BDNF as a potential therapeutic agent for 
neurological diseases 
Substantial evidence indicates that NTFs can protect and even restore impaired 
functions resulting from trauma, aging, toxic agents, and genetically linked 
neurodegenerative disorders. The use of NTFs as therapeutic agents is becoming a 
promising approach in the treatment of CNS disorders. Clinical trials are now in 
progress to assess the therapeutic efficacy of NTFs in a variety of 
neurodegenerative diseases such as AD, PD, HD or ALS. Many studies were 
undertaken to determine whether members of the neurotrophic factor family have 
potential therapeutic roles in preventing and/or reducing the neuronal cell loss and 
atrophy. For example, NGF administration prevents cholinergic neuron atrophy 
caused by lesions of the septohippocampal and basal forebrain or cortical systems 
(Tuszynski et al., 2005).. The compiled evidence led to the suggestion that NGF 
administration might produce some benefit to individuals with Alzheimer’s disease 
(Tuszynski et al., 2005). Clinical trials with GDNF in PD patient showed a marked 
reduction of symptoms when GDNF was administered directly into the parenchyma 
of the dorsal putamen via a pump and a catheter (Salvatore et al., 2006). On the 
contrary, clinical trials with CNTF in amyotrophic lateral sclerosis have showed 
either no improvement in neurological outcome (Penn et al., 1997) or a worsening 
(Miller et al., 1996b), with deleterious side effects (Miller et al., 1996a). 
Systemically administered bFGF decreased brain injury resulting from 
experimental focal ischemia (Bethel et al., 1997). In peripheral neuropathies caused 
by chemotherapeutic agents, systemically given neurotrophins have been 
demonstrated to be of benefit in some instances (Apfel and Kessler, 1996).  
The important role of BDNF in the CNS, mentioned above, provides 
possibilities for predicting therapeutic approaches in the treatment of psychiatric 
and neurological disorders. BDNF have the potential to protect diseased and injured 
neurons from dying, to induce neuronal sprouting and to increase neuronal 
metabolism and function. The neurotrophic actions of BDNF can be used to reduce 
neuronal loss and mobilize the internal resources of an organism in the 
rearrangement of neural circuits to cure the diseases. BDNF has survival promoting 
actions on a variety of CNS neurons including hippocampal and cortical neurons, 
cholinergic neurons, and nigral dopaminergic neurons. These facts raised keen 
interest in BDNF as a potential therapeutic agent for many injury-related 
neurological diseases. This interest has been intensified by in vitro and in vivo 
studies demonstrating the essential role of BDNF and Trk receptors in the 
pathogenesis of neurological disorders. The idea that neuronal death in 
degenerative disorders can result from the lack of an endogenous trophic molecule 
highlights the therapeutic use of BDNF to prevent and/or reduce selective neuronal 
loss in the diseased human brain. Indeed, BDNF has been observed to increase the 
survival of ventral dopaminergic neurons and prevent the rotational asymmetry in 
an animal model of PD (Singh et al., 2006; Sadan et al., 2009). BDNF has also 
been shown to promote the survival of motorneurons both in culture and in 
neonatal rats as well as to rescue motorneurons from axotomy-induced 
degeneration (Canals et al., 2004). The effects of BDNF in treating motorneuron 
disorders has been investigated in the progressive wobbler mouse, a natural murine 
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model of motorneuron disease (Tsuzaka et al., 2001). The administration of 
exogenous BDNF can retard motor dysfunction and diminish denervation muscle 
atrophy and motor axon loss (Ikeda et al., 1995). It has also been proposed a 
potential benefit of BDNF in HD. The promising suggestion came from in vitro 
studies by Saudou et al. (1998), who reported that cultured mammalian neurons 
bearing the mutant huntingtin were prevented from dying when BDNF was 
administered (Saudou et al., 1998). Intrathecal administration of BDNF increased 
the survival of enkephalin-expressing striatal cells, the most affected cells in HD 
(Canals et al., 2004).Following the discovery that AD pathology may primarily be 
due to a deficit in neurotrophic factor protein and/or trk receptor expression, the 
protective effect of BDNF was demonstrated against toxicity induced by Aβ 
peptides on neuronal survival of primary cultures of cortical neurons (Yao et al., 
2005) and applied in an animal model of AD (Singh et al., 2006). In the clinical 
trials in treatment of ALS patients, BDNF appeared to increase survival rate and 
retard loss of pulmonary function (BDNF-study-group-Phase-III, 1999).  
Interestingly, BDNF has received considerable attention for being modulated 
in the brain by antidepressant treatments, such as drugs, electroconvulsive shocks, 
physical exercise, although there is still no direct evidence that endogenous BDNF 
plays a role in the mechanism of antidepressant drug action. The potential BDNF 
application in the treatment of neuropsychiatric disorders has been initiated. 
To date, however, clinical trials of BDNF have not been particularly successful. 
For better results, it will elementary to improve the delivery strategies. 
32                                                                Chapter I: BACKGROUND 
5 Strategies of NTFs therapy 
As stated above, evidence from preclinical and clinical studies indicates that it 
may be possible to use NTFs to prevent, slow the progression of, or even reverse 
the effects of a number of neurodegenerative diseases and other types of insults in 
both the central and peripheral nervous system. Despite the encouraging results 
from these studies, progress in adaptation of this treatment strategy to human 
disease has been slow and sometimes disappointing. The clinical failure of many 
candidate trophic factors is often ascribable to poor delivery methods (Thorne and 
Frey, 2001). NTFs need to be specifically targeted and regionally restricted to the 
area of interest to achieve significant results without widespread, unwanted adverse 
effects. The direct injection of NTFs such as BDNF to the brain is, however, 
problematic due to: (i) their inability to cross the blood–brain barrier; (ii) brain 
diffusion and pharmacodynamic issues; and (iii) side-effects associated with 
binding to extra-target receptors.  
In an attempt to overcome such problems, other therapeutic approaches have 
been developed to aim at searching drugs capable of increasing the synthesis of 
endogenous BDNF or simulating BDNF action to activate its signaling pathway. 
These options include: (i) activation of receptors by small, nonpeptidyl molecules 
amenable to chemical synthesis; (ii) rigid peptides interacting with the ligand 
binding domain (LeSauteur et al., 1995); (iii) Trk receptor antibodies to engage and 
dimerize Trk, thereby mimicking NTFs-like trophic effects (Lucidi-Phillipi et al., 
1996); (iv) neurotrophic factor–transferrin receptor antibody fusion proteins, to 
facilitate transferrin receptor-mediated cellular entry (Friden and Walus, 1993). 
Moreover, the improved methods in molecular biology allow a local and regulated 
supply of BDNF by either in vivo or ex vivo gene transfer. In this section, we will 
review the delivery strategies of NTFs. 
 
5.1 Direct infusion 
Since the discovery of the effects of BDNF on the survival of peripheral and 
CNS neurons, and the demonstration of its deficit in diseased brains, BDNF 
received considerable interest as possible means for the treatment of 
neurodegenerative diseases and CNS trauma. For example, infusion of the 
neurotrophin BDNF (10±30 μg/day) for 14 days proximal to the substantia nigra 
in PD patients is effective in partially rescuing axotomized dopaminergic neurons 
previously retrogradely labeled with dye (Hagg, 1998). Supranigral BDNF (7.2 
mg/day) for 21 days also rescues cresyl violet identified nigral neurons that have 
undergone transneuronal degeneration due to removal of their striatal target 
neurons (Volpe et al., 1998). BDNF (168 mg total beginning 6 days prior to lesion) 
was effective in attenuating turning behavior but not in restoring dopamine levels 
(Altar et al., 1994).  
Despite the promising results, BDNF supplementation raises a number of 
problems. The major problem is how to assess the amount of BDNF that reaches 
the affected neurons, and this is compounded by the fact that BDNF is relatively 
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unstable and only a small amount can cross the blood-brain barrier (Betz et al., 
1989; Knusel et al., 1992; Pardridge, 2002). If the supplyed amount of BDNF is too 
small, it may not be sufficient to produce the required effects; if it is too large, it 
may be dangerous because, besides regulating survival, differentiation and 
maintenance of neuron-specific characteristics, BDNF is also important in 
modulating activity-dependent neuronal plasticity, which is essential for the 
functional and structural refinement of neuronal circuits, as well as in learning and 
memory (Binder and Scharfman, 2004). Uncontrolled BDNF administration may 
interfere with these mechanisms and even give rise to serious side effects such as 
epileptic activity (Binder et al., 2001). It has also been reported that high BDNF 
levels may downregulate the expression of TrkB receptors, thus reducing the 
signalling activated by BDNF and therefore blocking any possible beneficial effect 
(Frank et al., 1996; Knusel et al., 1997; Sommerfeld et al., 2000). It is probably for 
these reasons that subcutaneous and intrathecal BDNF administrations had little 
clinical success (BDNF-study-group-Phase-III, 1999; Ochs et al., 2000).  
Intracerebroventricular (ICV) administration of BDNF has been explored as a 
possibility to bypass the blood–brain barrier. These studies suggest that infusion 
with i.c.v administration of neurotrophins (NGF/BDNF) will probably result in 
hyperplasia in man that, although probably reversible and nonmalignant, it may be 
partly responsible for pain (Cirulli et al., 2000). Intracranial infusion of NGF to a 
single Alzheimer’s disease patient had positive clinical effects (Seiger et al., 1993), 
but a subsequent study with three patients proved negative (Eriksdotter Jonhagen et 
al., 1998). There are the other routes of administration reports in which I125-NGF 
was injected into the olfactory bulb of rats, the radio labeled NGF was found to be 
retrogradely transported specifically to basal forebrain cholinergic nuclei (Altar and 
Bakhit, 1991). Similarly, it has been shown that radio labeled NGF can be 
transported into the brain following administration as nose drops (Chen et al., 1998). 
This may be a alternative mode of administration for BDNF delivery.  
Although the exogenous addition of BDNF can rescue neurons from death in 
vitro and in vivo, neurotrophin administration in the human brain induces side 
effects such as pain and weight loss (Schulte-Herbruggen et al., 2007), limiting its 
possible therapeutic utilization. The situation underscores the need for the 
development of BDNF mimetics. 
 
5.2 BDNF mimetics 
Neurotrophins have a number of suboptimal pharmacological properties, 
including poor stability with a serum half-life of minutes or less, poor oral 
bioavailability, and restricted CNS penetration (Poduslo and Curran, 1996; 
Pardridge, 2002). The pharmacokinetic properties of the neurotrophins are probably 
the key factor in the therapeutic success or failure of these proteins. The production 
of small molecule agonists acting via targeted neurotrophic receptors would help to 
circumvent this problem. The small-molecule neurotrophin mimetics possess 
favorable stability and tissue penetration profiles. With the mass screening of large 
libraries of synthetic chemicals, researchers have developed small-molecule BDNF 
analogues with improved pharmacokinetic properties and an ability to penetrate the 
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blood brain barrier to an appreciable extent. The discovery of the small-molecule 
BDNF analogues has been achieved largely through a detailed knowledge of the 
three-dimensional structures of BDNF and its receptors. Cyclic peptides were 
designed to mimic BDNF specific domains, which are required for binding to TrkB 
receptors (Fletcher et al., 2008). In combination with the X-ray crystal structure of 
the Trk-binding domains, it is possible to develop useful therapeutic compounds by 
screening the BDNF mimetics from very large virtual libraries of molecules with 
the aid of high performance computers. Preliminary studies have identified the 
peptides capable of interacting with erythropoietin receptors and mimicking the 
actions of the protein granulocyte colony stimulating factor (G-CSF). In the case of 
G-CSF, Tian et al. (1998) have now demonstrated that a small, nonpeptidyl 
molecule (SB 247464) is capable of triggering the activation of a large receptor 
protein that requires dimerization for activation, through a domain not involved in 
binding the natural ligand (Tian et al., 1998). Application of this strategy to Trk 
receptors should be particularly interesting.  
Also, there is also the possibility of developing small molecules that activate 
Trk receptors in the absence of neurotrophins, acting through G protein-coupled 
receptors (GPCRs) to activate neuroprotective pathways (Jeanneteau and Chao, 
2006; Skaper, 2008). For example, two GPCR ligands, adenosine and pituitary 
adenylate cyclase–activating polypeptide, activate Trk receptor activity and 
increase cell survival through stimulation of the neuroprotective Akt pathway. 
These alternative approaches to enhance neuronal survival may lead to new 
treatment for those neurological diseases that are associated with neuronal death.  
It was demonstrated that such BDNF mimetics act as BDNF agonists that 
promote the survival of cultured sensory neurons, although their drug-like 
properties, particularly their proteoliyic stability, their ability to function via TrkB 
receptors, and their capacity of crossing the cell membrane, still require analysis 
(O’Leary and Hughes, 2003; Fletcher and Hughes, 2006). A considerable amount of 
work remains to be done, but this approach may represent a valuable step towards 
the development of BDNF mimetics for clinical use. The compounds that have 
been found to be able to increase BDNF levels in the brain raise another possibility 
for the BDNF mimetics strategies. For instance, the antidepressants known to affect 
BDNF levels are selective serotonin reuptake inhibitors (SSRIs) (Tardito et al., 
2006) and lithium (Chuang, 2004). The latter induces the expression of BDNF and 
the subsequent activation of TrkB in cortical neurons (Fukumoto et al., 2001). In 
addition, memantine and riluzole (a non-competitive antagonist of ionotropic 
glutamate NMDA receptor) have been shown to upregulate BDNF and TrkB 
mRNA (Marvanova et al., 2001; Katoh-Semba et al., 2002), and also GDNF 
(Mizuta et al., 2001; Katoh-Semba et al., 2002). They are clinically used as 
neuroprotective agents to treat AD, PD and ALS. Similarly, cystamine and 
cysteamine have recently been shown to increase BDNF levels in the CNS and 
their potential therapeutic effects on HD have been analyzed (Borrell-Pages et al., 
2006).  
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5.3 Local delivery 
Despite the improvements that have been made to strategies for neurotrophin 
production and delivery, many difficulties still remain. Perturbations in BDNF–
TrkB signaling in the brain, such as decreased signaling in the hippocampus but 
increased signaling in the mesolimbic circuit, may baffle the systematic application 
of BDNF or BDNF mimetics. Therefore, it has become increasingly clear that the 
successful implementation of NTF therapy requires a targeted, localized, sustained, 
and safe delivery of NTFs to avoid unwanted adverse effects resulting from 
widespread receptor activation. Several promising strategies of local administration 
of NTFs have been described in preclinical studies. These include: 
1)  Local delivery of the polypeptide interstitially within the brain 
parenchyma; 
2)  Surgical implantation of cannulae into the cerebroventricular space 
(Williams et al., 1997);  
3)  Implantation of encapsulated NTFs in microspheres (Maysinger et al., 
1994); 
4)  Stereotaxic injection of virus mediating NTF gene transfer (Paradiso et 
al., 2009); 
5)  Local implantation of transfected cells secreting NTFs (Frim et al., 
1994);  
6)  Local implantation of encapsulated cells secreting NTFs (Fig. 3)(Lindner 
et al., 1995).  
These methods of local delivery of NTFs offer the advantages of bypassing the 
BBB and achieving high levels of drug at the therapeutic site, while reducing 
systemic exposure and avoiding unwanted side effects. 
 
Fig. 3. The strategy of local NTF delivery with the encapsulated cell 
secreting NTFs into the brain: (1) mechanical pump; (3) encapsulated 
cells; (2) cell transplantation; and (4) direct injection of viral vectors. 
(Patrick Aebischer. TRENDS in Neurosciences. 2001) 
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5.4 Gene therapy 
The dramatic advances made in the application of developments in molecular 
biology have offered new approaches to BDNF delivery. These involve gene 
therapy techniques. These techniques may be used to replace a faulty gene, or to 
introduce a new gene whose function is to cure or to favorably modify the clinical 
course of a disease. Researchers are testing several approaches to gene therapy, 
including: (i) replacing a mutated gene that causes disease with a healthy copy of 
the gene; (ii) inactivating, or “knocking out” a mutated gene that is functioning 
improperly; (iii) introducing a gene into the body to help fight a disease.  
To deliver the working copy of the gene to the target cells, a selection of in 
vivo and ex vivo approaches is available. The method for in vivo gene delivery into 
the brain is that a vector with targeting genes is administered directly to the host 
while, in the process of ex vivo technique, DNA is delivered to cells in vitro for 
subsequent transplantation into a target tissue. 
In vivo gene therapy 
One of the most promising methods currently being developed is the use of 
harmless viruses that can be used to carry genes into cells. The therapeutic DNA is 
injected directly into the body cells, usually via one of two types of viruses (Rex, 
2008). The most frequently used type is the very simple retrovirus. Using 
retroviruses is very safe and provides long-lasting effects. The second type of virus 
used for the in vivo technique is the adenovirus, the common cold virus. Nonviral 
vehicles for directly delivering genes into cells are also being explored, including 
the use of plain DNA and DNA wrapped in a coat of fatty molecules known as 
liposomes. 
Research is currently being undertaken to determine potential therapeutic 
effects with delivering NTFs to vulnerable regions of the CNS in neurodegenerative 
diseases. Preclinical studies using adeno-associated virus vectors for delivery of 
neurotrophic proteins in models of Parkinson’s disease (Bilang-Bleuel et al., 1997) 
and motor neuron disease (Haase et al., 1997) have been described, but do not 
appear to be viable strategies at present. Later studies confirmed that the viral 
delivery of BDNF can be protective in animal models of HD. In an elegant study, 
an adenovirus encoding BDNF was intrastriatally injected into the rat brains 
lesioned by a toxin quinolinic acid. One month after the lesion, histological 
analyses revealed that striatal neurons were protected only in the rats treated with 
the BDNF adenovirus, indicating that transferring the BDNF gene is of therapeutic 
value (Bemelmans et al., 1999). In a subsequent study, a delivery of the BDNF 
gene, by means of an adeno-associated viral (AAV) vector, to the striatum in the 
QUIN rodent model of HD also showed a significant increase in striatal neuron 
survival (Kells et al., 2004). Similarly, our previous BDNF gene therapy using 
lentivirus as a vector inhibited epileptogenesis after inoculating the recombinant 
virus into an epileptic rat brain (Paradiso et al., 2009). 
Ex vivo gene therapy 
In the ex vivo approach cells are cultured and used for gene transfer, by 
injecting or splicing the DNA that will correct the disease into the cells and letting 
them divide in cultures. These transfected cells are then introduced in a targeted 
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tissue. As compared with in vivo gene therapy, there are some advantages of an ex 
vivo approach: (i) gene transfer efficiency is generally high and retroviral vectors 
are particularly effective; (ii) the transduced cells can be enriched if the vector has a 
selectable marker gene and (iii) transduction efficiency can be assessed before 
re-implantation. 
Ex vivo gene therapy has been applied in the treatment of neurological 
diseases by introducing genes coding for members of the neurotrophin family. For 
instance, studies have shown that retroviral transfected fibroblasts, expressing NGF, 
rescue cholinergic neurons after a fimbria fornix lesion in the rat (Stromberg et al., 
1990). In a phase I trial of ex vivo NGF gene delivery, eight individuals with mild 
Alzheimer disease were implanted autologous fibroblasts genetically modified to 
express human NGF into the forebrain (Tuszynski et al., 2005). 
In summary, gene therapy offers an alternative to administration of exogenous 
NTFs. We can use in vivo or ex vivo gene therapy to transfer and express NTFs in 
neurons. The expression of the NTFs genes is essentially an intervention that alters 
the instruction set of a cell, consequently correcting the gene defect for some 
disorders or influencing the cell fate. It might compensate for an ineffective NTF 
gene, and provide an alternative approach for NTFs protein delivery as well. The ex 
vivo gene therapy allow introduction of cells that naturally, or through genetic 
modification, produce NTFs. After the transplantation, the NTFs secreted by the 
graft could produce favorable effects for the regeneration or neuroprotection and 
promote brain repair.  
 
5.5 Stem cell-based gene therapy 
To date, about 40 percent of the more than 450 gene therapy clinical trials are 
via ex vivo method, i.e. cell-based gene therapy. Of these, approximately 30 percent 
have used human stem cells as the means for delivering transgenes into patients. 
Stem cells are distinguished from other cell types by two important characteristics. 
First, they are unspecialized cells capable of renewing themselves through cell 
division, sometimes after long periods of inactivity. Second, under certain 
physiologic or experimental conditions, they can be induced to become tissue- or 
organ-specific cells with special functions. The reasons for the extensive 
application of stem cells in cell-based gene therapy include: (i) the ability to 
self-renew, which means that the need to provide repeated administrations of gene 
therapy can be reduced or even eliminated; (ii) the natural ability to produce a rich 
variety of growth factors, cytokines, and other bioactive molecules that have the 
potential to facilitate the survival of the graft, and foster regeneration, 
neuroprotection, and other compensatory and repair mechanisms in the host tissue; 
(iii) stem cells can ‘home’ or migrate, to a number of different spots in the body, 
which suggests the possibility of a local, targeted gene therapy. 
Given these unique abilities, stem cells offer new potentials for gene therapy. 
Moreover, stem cells have a great therapeutic potential in repopulating damaged 
tissues besides being genetically manipulated and used in cell-based gene therapy. 
To date, the transplantation of some types of stem cells has emerged as a restorative 
therapy for CNS disorders such as ischemic stroke (Kameda et al., 2007) and spinal 
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cord injury (Lu et al., 2003). In the CNS, stem cells could exert not only long-term 
functional integration (by giving rise to large numbers of properly functioning cells 
integrating into the brain circuitries) but also repair capabilities. Stem and 
progenitor cell-mediated gene delivery is emerging as a strategy to improve the 
efficacy and minimize the toxicity of current gene therapy approaches. 
There are two broad types of mammalian stem cells: embryonic stem cells that 
are isolated from the inner cell mass of blastocysts, and adult stem cells that are 
found in adult tissues. Embryonic stem cells could provide better maintenance of 
therapeutic effects in comparison with adult stem cells, because a greater potential 
for self renewal in embryonic stem cells make the repeated administrations of gene 
therapy less necessary. However, embryonic cell sources are confronted with 
ethical and legal complications (Joannides and Chandran, 2008).  
There are diverse types of stem cells that are studied as gene-delivery-vehicle 
candidates, such as myoblasts (Mohajeri et al., 1999), osteoblasts (Yudoh and 
Nishioka, 2004), fibroblasts (Stromberg et al., 1990), mesenchymal stem cells 
(Harper et al., 2009), hematopoietic stem cell (Rizvanov et al., 2008) and neural 
stem cells (Lu et al., 2003). For instance, the transplantation of the myoblasts 
containing the transgene for a human NGF into the muscles of the ALS mice 
successfully delayed the onset of disease symptoms, slowed muscle atrophy, and 
delayed the deterioration of motor skills (Mohajeri et al., 1999). Neural stem cells 
genetically modified to create a protein that activates a precursor drug appear to be 
effective in treating gliomas, which is a difficult type of brain tumor to treat (Li et 
al., 2005). Embryonic stem cells, neural stem cells, or neural progenitors constitute 
the most promising source for neural transplantation because they have a potential 
ability to differentiate into neurons (Kim and de Vellis, 2009). Embryonic stem 
cells isolated from developing blastocysts theoretically possess the greatest 
potential for uses in neural transplantation, as long as their differentiation fate can 
be controlled. Neuronal progenitors in human adults have been proposed as a 
source of transplantable neural cells. The adult derived transplantation approach is, 
however, limited by low in vitro proliferation potential of these cells (Kim and de 
Vellis, 2009). Human embryo-derived neuronal progenitors do not show the same 
limitations, with the exception of the ethical issue related to the use of human fetal 
tissue. So far, it had been revealed that most stem cells can be genetically 
engineered without modification of their fate after transplantation into the rodent 
brain (Sabate et al., 1995), opening the possibility of ex vivo gene therapy 
approaches. The promising results obtained from ex vivo gene therapy in CNS 
diseases have increased the efforts to find an ideal stem cell and generate modified 
stem cells producing NTFs or other substances (Martinez-Serrano and Bjorklund, 
1997; Boucherie and Hermans, 2009). These cells should readily survive 
transplantation and allow introduction of recombinant NTFs genes so that they can 
produce and deliver adequate amounts of growth factors in the brain.  
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5.6 Mesoangioblast: an alternative cell source for NTF 
delivery  
To date, multiple types of stem cells and progenitor cells have been identified 
as potential sources of NTF delivery, including autologous and allogeneic 
embryonic cells (Li et al., 2008; Rizvanov et al., 2008; Makar et al., 2009), fetal 
and adult somatic cells from neural (Martinez-Serrano and Bjorklund, 1996; Lu et 
al., 2003; Kameda et al., 2007) and mesenchymal tissues (Harper et al., 2009). Here 
we describe a novel type of vessel associated stem cell that may be developed as a 
vehicle for NTF delivery. These stem cells can differentiate into different 
mesoderm cell types and derive from the vasculature, probably a primitive luminal 
angioblast, therefore named “mesoangioblast” (MAB). MABs are firstly isolated 
from explants of dorsal aorta or other embryonic or juvenile postnatal vessels (De 
Angelis et al., 1999; Cossu and Bianco, 2003). The MABs clonal isolates can be 
grown and proliferated to at least 50 passages in vitro under certain conditions 
without obvious alterations of morphology and gene expression profile. MABs 
express two well-known stem cell markers: CD34, a cell surface sialomucin-like 
adhesion molecule expressed in hematopoietic stem cells, and Thy-1, a 25 kDa 
glycosylphosphatidylinositol-linked membrane glycoprotein, which is expressed in 
hematopoietic stem cells, T lymphocytes, neural cells and, during angiogenesis, in 
endothelial cells, pericytes and smooth muscle cells (Minasi et al., 2002). Moreover, 
MABs exhibit stem cell features, such as pluripotency and self-renewal ability, and 
can differentiate in vivo and in vitro into different mesoderm cell types, such as 
muscle, bone, and adipocytes, in response to specific extracellular cues (De Angelis 
et al., 1999; Cossu and Bianco, 2003). They are supposed to be involved in the 
development of the vasculature, and probably in the development of the nervous 
system since many of the genes expressed in MABs are neural genes, for example 
GPRC5B, which is expressed in brain and spinal cord; Tm4sf2, which has been 
implicated in activity-dependent brain plasticity and others (Tagliafico et al., 2004). 
Among genes selectively expressed by mesoangioblasts are many cytokines, 
chemokines and their receptors. This indicates a role of these cells in tissue 
regeneration and first inflammatory response to damage (Tagliafico et al., 2004). 
A significant improvement in understanding MAB biology in recent years has 
paved the way to their potential clinical use. There are several reasons for MABs 
being valuable candidates for cell-based gene therapy: (i) MABs are 
non-tumorigenic and stable cell lines capable of unlimited clonal expansion in vitro, 
and with the capacity of longterm survival, which allows the gene manipulation to 
the cells; (ii) they can be isolated from humans, cultured in vitro, and autologously 
transplanted into patients, thus overcoming the difficulties related to immune 
rejection of transplanted cells; (iii) the ability of migrating and homing to damage 
sites because of the expression of different cytokines and chemokines; (iiii) the 
multipotent differentiation. 
Owing to their general availability, higher abundance and ease of isolation, 
MABs may be convenient delivery vehicles for localized NTF delivery. 
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1. Overview of the research program 
1.1 Rationale 
As described above, neurotrophic factors are critical to survival, development 
and function of neurons in the mammalian central nervous system. Alterations in 
neurotrophic factors or their receptors can lead to neuronal death and contribute to 
the pathogenesis of neurodegenerative diseases such as Alzheimer disease (Connor 
et al., 1997), Huntington disease (Zuccato and Cattaneo, 2007), Parkinson disease 
(Bradford et al., 1999), and multiple sclerosis (De Santi et al., 2009). Many NTFs 
have been also implicated in diseases associated with damage, like stroke and some 
forms of epilepsy (Simonato et al., 2006). Based on these studies, the neurotrophic 
factors (NTFs) emerge as very strong candidates for a therapeutic role: not only 
they have trophic properties that suggest an involvement in cell death, neurogenesis 
and axonal sprouting but, also, they exert functional effects at synaptic level 
(Thoenen and Sendtner, 2002; Simonato et al., 2006). The use of neurotrophic 
factors as therapeutic agents is a novel approach aimed at restoring and maintaining 
neuronal function in the CNS. 
Among these NTFs, particular attention has been devoted to brain derived 
neurotrophic factor (BDNF). Compelling preclinical data show that BDNF exerts 
trophic and neuroprotective effects on neurons. However, its clinical use is 
hindered by a short biological half-life and a poor blood-brain barrier permeability 
(Thoenen and Sendtner, 2002; Boado, 2008). Given these difficulties, the attention 
turned into the development of techniques that allow localized and regulatable 
BDNF delivery. These may be based on gene therapy (Paradiso et al., 2009) or on 
cell-mediated approaches, in which engineered cells deliver the therapeutic 
biomolecules to the brain. 
 
1.2 Research Basis  
We have already evidenced that viral vector-mediated supplementation of 
FGF-2 and BDNF favors proliferation of neural stem cells and/or progenitors and 
their differentiation into neurons in vitro (Paradiso et al., 2009). In this previous 
experiment, the neural precursors isolated by buoyant density gradients were 
infected with the FGF-2 and/or BDNF vectors and maintained for one month in the 
same plate, in a medium deprived of any other supplement. The data show that 
FGF-2 and BDNF together potently favor proliferation, survival and neuronal 
differentiation of neural progenitors. The vector expressing FGF-2 and BDNF was 
also tested in an animal model in which an epileptogenic insult (an episode of SE 
induced by the peripheral administration of the muscarinic agonist pilocarpine) 
causes damage in the hippocampus and, in time, the occurrence of spontaneously 
recurrent seizures (SRSs), i.e. epilepsy. We injected the FGF-2 and 
BDNF-expressing vector in the hippocampus after the establishment of damage and 
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before the occurrence of SRSs. In keeping with our in vitro findings, we found that 
this approach prompts neuronogenesis, allowing a significant recovery from 
damage. A behavioral observation and the video EEG analysis conducted in a time 
span of several weeks during the chronic period following pilocarpine-induced SE 
also suggest a reduction in SRSs (Paradiso et al., 2009). These previous results 
from our group indicate that supplementation of FGF-2 and BDNF in the 
hippocampus lesioned by prolonged seizures leads to repair of existing damage and 
to highly significant improvement of the “clinical”  outcome (prevention of 
epilepsy). The local NTF delivery based on in vivo gene therapy is an effective 
treatment strategy to prevent brain damage, and mobilize self-recovery, 
consequently slow the progression of epileptogenesis. The strategy of local NTF 
delivery to exert trophic effects in the lesion area has also been applied in a number 
of neurodegenerative diseases and other types of insults in both the central and 
peripheral nervous system (Schulte-Herbruggen et al., 2007). 
The use of viral vectors in the local NTF delivery strategy of our previous 
studies has several advantages over any pharmacological approach: (i) it 
circumvents the blood–brain barrier to reach the targeted area; (ii) the high-level 
NTFs gene expression obtained with viral vectors provides a robust and long-term 
supplementation of the NTFs of interest in the lesion area without implant of 
permanent devices; (iii) it avoids pharmacodynamic issues; (iiii) the small 
administration volume of vectors makes it possible to limit brain diffusion, 
reducing side-effects associated with binding to extra-target receptors.  
 
1.3 Unsolved issues 
These studies demonstrated the efficiency of local NTF delivery in an acquired 
epilepsy model using an in vivo gene therapy strategy. However, the local NTF 
delivery using viral vectors are not totally satisfactory because of: (i) the potential 
risk of viral infection, even if it is demonstrated that gene therapy mediated by most 
of viral vectors are not toxic; (ii) the immunogenic properties of the virus (in our 
previous work, we found that the injected viral vectors produce a small, but clearly 
detectable, infiltrate of lymphocytes at the very site of inoculation); furthermore, 
(iii) the vector inoculation can be performed only in highly specialized centers, 
equipped for stereotaxical surgery, and it is, therefore, a very costly and 
time-consuming approach; (iiii) it is an invasive treatment which causes new 
damage to the brain. 
Based on these considerations, it is necessary to explore alternative 
approaches. Cell-based gene delivery, namely ex vivo gene therapy, is emerging as 
a strategy to treat chronic neurological disorders and injury related neural 
degeneration. In this strategy, cells are genetically modified with NTFs and then 
transplanted into the brain, where engineer cells continuously express and release 
the desired NTFs at safe doses. Cell-based delivery strategies may offer some 
degree of CNS targeting with minimal invasiveness. Stem and progenitor 
cell-mediated gene delivery is potentially interesting for drug manipulation, with 
improvement of the efficacy and minimization of the toxicity of current gene 
therapy approaches. The strategy has already been used and validated in several 
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lines of stem cells, including neural stem cells (Martinez-Serrano and Bjorklund, 
1996; Lu et al., 2003; Kameda et al., 2007), embryonic stem cells (Li et al., 2008; 
Rizvanov et al., 2008; Makar et al., 2009), and mesenchymal stem cells (Harper et 
al., 2009), which were engineered to produce neurotrophic factors and capable of 
ameliorating neurodegenerative disease pathology. Using genetically modified stem 
cells as grafts could exert not only long-term functional integration but also repair 
capabilities. As opposed to systemic delivery of therapeutic agents, stem cell-based 
therapy can as well offer a continuous and concentrated local delivery of secretable 
therapeutic molecules like BDNF, thus reducing the non-selective targeting, and 
allowing higher treatment efficiency and potency for a longer time period. 
These findings prompt the search for alternative cell sources that, unlike 
neural or embryonic stem cells, may be readily used in the clinics. Here, we 
explored the feasibility of a new approach for the local supplementation of BDNF 
in lesion brain areas. This approach is the use of multipotent, mesodermal stem 
cells (mesoangioblasts, MABs) that constitutively produce a subset of NTFs (e.g. 
bFGF, VEGFB, HGF, IGF) and can be engineered to produce others. MABs are an 
affordable cellular source. They can be isolated from the perivascular human adult 
tissue, and are already utilized for regenerative purposes in complex animal models, 
other than rodents. Their principal feature is the ability to differentiate, under 
appropriate conditions, in the different mesodermic tissues. The MAB-based 
therapy is now approaching the clinics (Sampaolesi et al., 2006). MABs have a 
high adhesin-dependent migratory capacity and, therefore, can reach perivascular 
targets. Their chemotactic ability is increased under inflammatory conditions, when 
the adhesin-integrin system and diapedesis moving are activated (Galvez et al., 
2006). Therefore, when peripherally administered, MABs may selectively cross the 
blood-brain barrier and home in the lesioned areas. These cells have many 
neuro-ectodermal genes, but they do not differentiate into neurons (Tagliafico et al., 
2004). Thus, we do not plan to use them for a restorative engraftment, but to exploit 
their migratory ability for targeting the lesion area: after infusion in the peripheral 
blood, MABs are expected to act as a reservoir and delivery system for NTFs.  
 
1.4 Aim 
In this context, we aim exploiting MABs as a novel delivery system by 
genetically engineering BDNF into MABs. The specific aims of this study are: (i) 
to examine the by-stander effects of MABs engineered to produce BDNF; (ii) and 
to perform a pilot transplantation into the lesion brain induced by status epilepticus.  
 
1.5 Scheme 
We began examining the by-stander effects of MABs in an in vitro culture 
systems, because the culture system allows maintenance of a constant level and a 
defined concentration of exogenously supplied BDNF during the entire treatment 
period. Considering the facts that BDNF can not only promote cell survival but also 
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regulate precursor proliferation and commitment, we studied the by-stander effects 
of MABs in two respects: neuroprotection and neurogenesis. Finally, we performed 
an attempt to systemically transplant MABs engineered with BDNF into the lesion 
brain induced by status epilepticus. Therefore, the program is divided into three 
parts: 
1) Part I: Assess the neuroprotection effects of MABs-BDNF in primary 
hippocampal neuron culture and organotypic hippocampal slice culture. 
2) Part II: Assess the neurogenesis effects of MABs-BDNF in organotypic 
hippocampal slice culture. 
3) Part III: MABs transplantation in seizure-induced damage brain.
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2. PART I - The neuroprotective effects of 
MABs-delivered BDNF  
2.1 Introduction 
Recent evidence suggests that neurotrophic factors that promote the survival 
or differentiation of developing neurons may also protect mature neurons from 
neuronal atrophy in the degenerating human brain (Schulte-Herbruggen et al., 
2007). Furthermore, it has been proposed that the pathogenesis of human 
neurodegenerative disorders may be due to an alteration in neurotrophic factors 
(NTFs) and/or Trk receptor levels (Dawbarn and Allen, 2003). The use of 
neurotrophic factors as therapeutic agents is a novel approach aimed at restoring 
and maintaining neuronal function in the central nervous system. Research is 
currently being undertaken to determine potential mechanisms to deliver 
neurotrophic factors to selectively vulnerable regions of the CNS. 
The importance of NTFs, especially brain-derived neurotrophic factor (BDNF) 
in the regulation of neuronal survival has been increasingly studied since their 
discovery. For example, shortly after BDNF discovery, Alderson et al. (1990) 
showed that BDNF promotes survival of rat embryonic septal cholinergic neurons 
in culture (Alderson et al., 1990). Other studies indicate that exogenous BDNF 
protects hippocampal and cortical neurons from injury (Kume et al., 1997; 
Nakagami et al., 1997; Wu et al., 2009a). Administration of BDNF protects 
hippocampal/cortical neurons from ischemic (Galvin and Oorschot, 2003) and 
excitotoxic injury (Lindholm, 1994). Howerver, a significant challenge to its 
clinical use is the difficulty associated with delivering these proteins to the CNS. 
Here we constructed modified MABs genetically engineered with BDNF in order 
to develop a cell-based BDNF delivery strategy. 
To assess the suitability of MABs for cell trophic factors delivery strategies, in 
vitro test is a necessary prerequisite to manifesting their efficiency on neurons and 
optimizing the intending cell-based therapeutic strategies as well. These results 
form the basis for developing potential MABs-based gene delivery of BDNF to 
treat neurological diseases associated with cell death. Therefore, the initial part of 
the study is to examine the by-stander effects of MABs engineered to produce and 
secrete BDNF. In this part, the media collected from MAB cultures (containing 
BDNF and other constitutively produced NTFs) was applied to two in vitro systems, 
primary hippocampal neuronal cultures and organotypic hippocampal slice culture 
(OHSC).  
We focused on the effects of MABs conditioned media in the OHSC because it 
preserves the morphological and physiological features of the hippocampal 
neuronal network and allows easy access and precise control of extracellular 
environment for a short or long period (Stoppini et al., 1991; Kristensen et al., 
2001). Organotypic cultures made from slices of explanted tissue provide an ideal 
in vitro model system to assess toxic or trophic effects of the test agents. In general, 
the OHSC is prepared from early postnatal animals not older than postnatal day 10 
64      PART I - The neuroprotective effects of MABs-delivered BDNF       Chapter II: THE FINDINGS 
(P10) (Gahwiler et al., 1997), whereas the organotypic cultures from adult 
hippocampal slices lead to spontaneous and continuous neuronal degeneration 
(Wilhelmi et al., 2002). A slice culture from adult animals would however be 
desirable to serve as a model system to assess neuroprotective or neurodegenerative 
influence, considering its better simulation of brain pathophysiology of adult 
patients. We elected to employ hippocampal cultures prepared from adult animals 
because they do not survive well in standard culture media (Xiang et al., 2000) and, 
thus, may provide a very convincing evidence of the favorable effects of the 
supplementation of NTFs if they survive when cultured in the MAB media. 
 
2.2 Methods 
Animals  
Swiss mice (Morini Co., Italy) were used in this study. Animals were housed 
in a 12-h light/dark cycle with food pellets and water available ad libitum. All 
procedures for animal care and treatment were in accordance with European 
Community and national laws and policies. All efforts were made to minimize 
animal suffering. 
 
MABs-BDNF and cell culture 
In order to achieve ex vivo cell-based gene delivery, MABs was transfected 
with a reporter green fluorescent protein (GFP) and with the human BDNF gene, 
obtaining a stable cell line (MABs-BDNF) that can constantly express BDNF. The 
control MABs were only engineered with GFP. These experiments were performed 
by Raffaella Scardigli and Antonino Cattaneo at the EBRI institute in Rome. 
Pure cultures of MABs were grown using a culture media (Medium-1) 
consisting of: 88% Dulbecco’s modified Eagle’s medium, 10% fetal bovine serum, 
0.5% GlutaMaxII, 22 mM mg/ml glucose, 1 mM sodium pyruvate, 100 U/ml 
penicillin and 100 mg/ml streptomycin (all from Gibco, Invitrogen). After 2 days in 
culture, the medium was collected and centrifuged for 5 min at 1000 rpm, and then 
the supernatant was collected. Thus, the supernatant consist of the media containing 
the soluble substances secreted by MABs, including BDNF in the case of 
MABs-BDNF.  
 
Enzyme-linked immunosorbent assay (ELISA) 
The soluble BDNF levels for either MABs-BDNF, MABs, and control media 
were quantified by ELISA at different culture days. An ELISA Kit (Chemicon) was 
used to measure the amount of BDNF in the supernatant according to the 
manufacturer’s instructions. Briefly, culture supernatants were divided equally into 
two Eppendorf tubes and stored at -80℃ till further processing. In order to 
standardize the total amount of protein from each experimental group used for 
ELISA, the content of one Eppendorf tube from each sample was used for 
measurements of protein content using Bio-Rad protein assay with BSA as standard. 
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ELISA microtiter plates were coated with anti-BDNF antibody (dilution 1:2000) in 
carbonated coating buffer (NaHCO3 0.025 M, Na2CO3 0.025 M) 14–18 h at 4℃. 
After washing in Tris–HCl-buffered saline with Tween-20 (TBST), the plates were 
incubated with blocking buffer (supplied by the manufacturer) for 1 h at RT and 
then washed in TBST, before the samples and standards (standards ranging from 40 
to 4000 pg/ml) were added in duplicates. The samples and standards were 
incubated for 2 hrs, the plates washed in TBST, and anti-human BDNF antibody 
(diluted 1:2000 in blocking buffer) applied for 2 h at room temperature. After 
gentle, but thorough washing in TBST, anti-Ig coupled to horseradish peroxidase 
(diluted 1:2000 in blocking buffer) was added for 1 h at room temperature, and 
washed again in TBST before the color developer (supplied by the manufacturer) 
was added. The color reaction was stopped after 10 min by 1 M phosphoric acid, 
and the intensity of individual wells measured in an ELISA reader (wavelength 450 
nm). BDNF levels in the media are reported in pg/ml ± standard error of the 
mean (SEM).  
 
Primary hippocampal neuron cultures 
Primary hippocampal neuron cultures were derived from P0 newborn Swiss 
mice. Hippocampi were dissected and minced with forceps, and then completely 
dissociated into a single-cell suspension using trypsin digestion. Isolated 
hippocampal cells were plated at a low density of approximately 5 × 104・cm-2 
viable cells in 24-well plates, which have been coated with poly-L-lysine (Sigma). 
Cells were grown in the Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), penicillin 50 U/ml and 
streptomycin 50 mg/ml. The culture media was replaced with the different 
conditioned media (shown below) supplemented with 5µM Ara-C at the day after 
plating. The cells were maintained at 37 ℃ under a humidified atmosphere of 
95% air and 5% CO2.  
 
Organotypic cultures from adult hippocampal slice 
Hippocampal organotypic slice cultures were prepared as described by 
Stoppini et al. (1991) with slight modifications. Young adult male Swiss mice (30
–50 g, 4 weeks old, Morini, Italy) were briefly anesthetized by diethyl ether and 
decapitated. The hippocampi rapidly dissected out in ice-cold artificial 
cerebrospinal fluid (aCSF) consisting of (in mM): NaCl 118, KCl 2.5, MgSO4 3, 
NaH2PO4 1.1, NaHCO3 26, CaCl2 1 and glucose 11 (all reagents from Sigma) 
bubbled with 95% O2/5% CO2. The corpus callosum was bisected above the 
thalamus and the posterior margin of each cortical hemisphere rolled back. 
Subsequently, 300 μm thick coronal slices were cut with a vibrotome (MA752, 
Campden Instruments). The hippocampi were carefully dissected in cold, 
oxygenated Hank’s balanced salt solution (Gibco, Invitrogen), transferred onto 
sterile porous membrane confetti (Millicell, Millipore), and cultured with their 
standard media (Medium-2) or with the MAB-conditioned media (see below). The 
incubation conditions were maintained in a humidified 5% CO2 atmosphere at 37℃. 
The culture media was changed the day after preparation and then every 2–3 days 
for the course of the experiment. 
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Preparation of the conditioned media  
The effects of the MABs delivering BDNF on cell survival were evaluated in 
several experimental groups cultured with a special conditioned media. In the 
groups “MABs” and “MABs-BDNF”, the condition media was composed by the 
mixture of equal volumes of fresh Medium-1 and of the 2-day-culture supernatant 
from MABs and MABs-BDNF, respectively. The group called Medium-1 served as 
a control, being challenged with the fresh Medium-1. Medium-2 is a standard 
culture media for OHSC from postnatal animals, consisting of 50% MEM, 25% 
horse serum, 18% HBSS, 4 mM L-glutamine, 12 mM glucose, 4.5 mM NaHCO3, 
20 mM sucrose, 100 U/ml penicillin and 100 mg/ml streptomycin (from Gibco or 
Sigma). The other conditioned media were based on the above media with different 
supplementations of reagents, like the recombinant human BDNF (ranged from 
0.03 ng/ml to 300 ng/ml, Immunological Sciences), the BDNF antagonist K252a 
(50 nM, Sigma) or TrkB-IgG (2 μg/ml, R&D Systems), a recombinant tyrosine 
kinase receptor B (TrkB) engineered as an immunoadhesin to sequester BDNF. 
Sister slices were randomly assigned to the different groups. 
 
FDA hydrolysis assay of cell survival 
The viability of the neurons in primary culture and the slices in organotypic 
culture was assessed in two ways. First, the fluorescein diacetate (FDA) hydrolysis 
assay was used to measure enzyme activity in cells. Living cells actively convert 
the non-fluorescent FDA into the green fluorescent compound “fluorescin”, an 
indication of cell viability. Slices were incubated with 10 μg/ml of FDA (Sigma) for 
30 min, then images were taken using a optical microscope (Leica, Germany) and 
the fluorescence intensity was quantified using the software Image-Pro Plus 6.0 
(Media Cybernetics, USA).  
 
Lactate dehydrogenase (LDH) assessment of cell death 
The lactate dehydrogenase (LDH) release assay was used to measure cell 
death in vitro. LDH is a stable cytoplasmic enzyme present in all cells that is 
rapidly released into the culture media upon damage of the plasma membrane; thus, 
LDH leakage to the media is a marker for cell damage. We measured LDH activity 
to quantify cell injury, according to the method outlined in (Noraberg et al., 1999). 
The culture media during the OHSC was all collected and then quantified the LDH 
leakage by using a LDH Cytotoxic Test kit (Clontech) according to the 
manufacturer’s instructions. In brief, samples culture media was collected from 
each well, whilst maintaining the total volume of media. Samples were stored at 
-20 ℃ until analysis. Samples of media were added to pyruvate and nicotinamide 
adenine dinucleotide (all provided from the kits) in TBS, and the absorbence of the 
mixture was measured, using a spectrophotometer (DU 530; Beckman, High 
Wycombe, UK), at 30 ℃.  
 
Tissue processing 
Cultured slices were fixed with 4% paraformaldehyde (PFA) in phosphate 
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buffer solution (PBS) for 1 h at room temperature. Cultures were transferred to a 
30% sucrose solution for 24 h. Single cultures were then placed on the flat base of a 
dish, and the excess liquid removed using filter paper. The membrane on the bottom 
of slices was detached carefully under optical microscope. The slices were then 
placed onto the stage made of OCT embedding matrix (Kaltek, Italy). A drop of 
OCT embedding matrix was applied to cover the slice until frozen. Slices were 
sectioned to a thickness of 30 μm in a cryostat (Leica, Germany), where the 
chamber temperature was maintained below -20 ℃. The embedded frozen culture 
was then mounted on an orientating chuck and careful approach sections were 
taken, correcting the orientation of the culture until cutting blade and culture lay in 
parallel planes. The initial two sections were discarded as they generally were 
incomplete and the topmost part of OHSC has a glial scar. The next sections were 
collected on separate gelatinised slides, this process was repeated collecting another 
section on each slide, and the sections stored at -20 ℃ for further processing. 
 
Immunohistochemistry  
Adjacent sections from each culture were taken from -20 ℃ and put in 4 ℃ 
for 30 min, and then incubated in PBS (pH 7.4) for 30 min. Sections were 
incubated with 0.3% triton in PBS for 1 h. PBS with 5% BSA and 5% normal goat 
serum was used to block the slices for 30 min, and after that they were incubated 
overnight with the primary antibodies anti mouse microtubule-associated protein 
(MAP2abc; 1:50; Immunological Sciences) Finally, they were rinsed with PBS and 
incubated with the secondary antibody Alexa 488 goat anti mouse IgG (1:100). The 
slices were mounted onto slides after staining with DAPI (1:1000). 
 
Western blot 
To identify the density of the survival neurons within a slice, we performed 
immunoblot analysis of the neuron-specific marker neurofilament 68. After 14 days 
in culture, slices were rinsed with ice-cold PBS and then lysed in sample buffer 
(ECL western blotting kit, Amersham). Aliquots from each sample (15 μg 
protein/lane) were subjected to 10% SDS-polyacrylamide gel electrophoresis and 
transferred onto polyvinylidine fluoride membranes (Millipore). The blots were 
blocked in blocking buffer (20 mM Tris-HCl, 137 mM NaCl, and 5% skim milk) 
for 1 h at room temperature and then treated with anti-neurofilament 68 antibody 
(diluted 1:500; Sigma) overnight at 4 ℃. Membranes were washed repeatedly in 
Tris-buffered saline containing 0.05% Tween 20, and then the HRP-conjugated 
secondary antibody (diluted 1:20000) was added for 1 h. Immunoreactive bands 
were detected using enhanced luminol-based chemiluminescence (ECL). The 
membranes were stripped and then immunoblotting for beta-actin (1:1000, Sigma) 
performed, as a loading control. Bands were scanned into digital images and 
analyzed with the software of Image-Pro Plus (Media Cybernetics, USA). 
 
Field potential recording 
After 7 days in culture, slices were transferred to a holding chamber for 1 hour 
at room temperature in aCSF, while continuously aerated with 95% O2 and 5% CO2. 
68      PART I - The neuroprotective effects of MABs-delivered BDNF       Chapter II: THE FINDINGS 
Slices were then placed in a submerged in vitro recording chamber and perfused 
with oxygenated aCSF. The temperature in the recording chamber was kept at 36±
1 ℃. Bipolar wire electrodes (tungsten with a tip diameter of 90 μm; WPI Inc.) 
were used for stimulation of the Schaffer collateral pathway in the CA3 region (70 
μs duration rectangular pulses at 0.05 Hz for 120 s). Glass microelectrodes filled 
with 0.9% NaCl were placed on the CA1 stratum radiatum to record field excitatory 
postsynaptic potential (fEPSP). A conventional electrophysiological technique of 
extracellular recordings was employed to identify the maximal response and to 
adjust the stimulus strength. The stimulus intensity that could repeatedly evoke the 
maximal synaptically evoked response/excitatory postsynaptic current (up to 900 
μA) was used in each slice. Signals were acquired under constant conditions, and 
off-line processed using the Patchmaster software (HEKA Instruments Inc., 
Germany). 
 
Statistical analysis 
All values are expressed as mean±S.E.M. Analysis of variance (ANOVA) and 
post hoc Bonferroni test or Newman-Keuls test were employed. 
 
2.3 Results 
2.3.1 Recombinant BDNF exhibits concentration-dependent 
protective effects on cell survival 
First, we tested if continuous application of recombinant BDNF (rBDNF) in 
the media exerted trophic effects on cell survival in low-density primary cultures of 
hippocampal neurons (PCs) and in organotypic cultures of adult hippocampus 
slices (OCs). Thus, culture media were supplemented with increasing 
concentrations of rBDNF, ranging from 0.03 ng/ml to 300 ng/ml.  
In PCs, neurons seeded at low density can hardly survive without the support 
of rBDNF. Quantification of survival, based on cell counting and on LDH release, 
showed that BDNF produces a significant beneficial effect in a 
concentration-dependent manner (Fig. 1A and 1B). The maximal effect was 
reached at a concentration of approximately 2×10-5 M (slightly more than 300 
ng/ml) and the EC50 was approximately 5×10-6 M (slightly less than 100 ng/ml). 
These data are in keeping with previous findings (Cheng and Mattson, 1994; 
Kokaia et al., 1994a). 
We also examined the neurotrophic activities of rBDNF in OCs. In the absence 
of rBDNF supplementation, OCs displayed degeneration aspects (like white spotted 
cell debris and uneven surface) after 6-8 DIV, that were clearly visible under phase 
contrast microscopy. Similar to PCs, rBDNF concentration-dependently reduced 
these signs of degeneration. Viability was quantified using two assays: FDA 
fluorescence intensity, to identify viable cells; LDH release, to identify the degree 
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of cell death. As shown in Fig. 1C and 1D, BDNF concentration-dependently 
increased FDA fluorescence, in line with previous observations reporting that 
BDNF (50-100 ng/ml) enhances the cell tolerance to serum-deprivation of 
organotypic culture from postnatal slices (Pringle et al., 1996; Nakagami et al., 
1997), and reduced LDH release. These effects were obtained in the same range of 
concentrations that proved effective for PCs. 
 
 
Fig. 1. Recombinant BDNF enhances cell survival in primary hippocampal 
neuronal cultures (PC, panels A and B) and in organotypic adult hippocampus 
slice cultures (OC, panels C and D) in a concentration-dependant manner. Neurons 
were cultured with the indicated concentration of BDNF for 7 days, slices for 14 
days. Panels A and C indicate viable cells, as quantified using cell counting for 
PCs and fluorescence intensity of the marker FDA for OCs. Panels B and D 
represent cell death, as estimated measuring the levels of released LDH. Data are 
expressed as the mean±SEM (n=6). * P<0.05, ** P<0.01 vs. control (0 ng/ml); 
ANOVA and post-hoc Newman-Keuls test. 
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2.3.2 Soluble mediators from MABs engineered to produce 
BDNF highly improve cell survival 
We engineered a line of MABs (MABs-BDNF) to stably produce and secrete 
human BDNF and the green florescence protein (GFP) as a tracer. These cells can 
be cultured long-term in vitro and constantly express BDNF and GFP (Fig. 2A and 
2B). The amount of BDNF secreted into the media (Medium-1) from MABs-BDNF 
after 2 days in culture was approximately 2 ng/ml, as measured using an ELISA 
assay (Fig. 2C). If MABs-BDNF were cultured with the media usually employed to 
culture OCs (Medium-2), the amount of secreted BDNF was approximately halved 
(Fig. 2C). Therefore, although controls were also performed using Medium-2, the 
conditioned media that we used in all experiments was based on Medium-1: 50% 
culture supernatant from 2-day-cultured MABs-BDNF and 50% fresh Medium-1. 
Thus, according to the ELISA measures, this conditioned media contained 
approximately 1 ng/ml BDNF, whereas no detectable of BDNF was present in the 
media conditioned with control, conventional MABs (Fig. 2C). 
We first screened the trophic effects of the MABs-BDNF conditioned media in 
the PC system. The MABs conditioned media increased the number of surviving 
neurons by about 80%, a level similar to the effect of 300 ng/ml rBDNF. The effect 
of the MABs-BDNF conditioned media was much greater (it enhanced neuronal 
survival by approximately 170%). We used the LDH assay to measure these effects: 
as shown in Fig. 2D, both 300 ng/ml rBDNF and the MABs media significantly 
(and to a similar extent) reduced cell death, but the MABs-BDNF media had a 
significantly greater effect. Interestingly, 1 ng/ml rBDNF (i.e. the concentration of 
BDNF present in the media) alone did not produce a significant effect on neuronal 
survival. Together with the observation of a significant effect of the MABs media, 
this indicates that other trophic factors are secreted by MABs that can synergize 
with BDNF to produce neuroprotection.  
We then extended and deepened this analysis in OCs. Adult OCs were cultured 
with different media and, after 14 DIV, cell death was measure using the LDH 
release assay. As shown in Fig. 2E, cell death was remarkable in control media 
(Medium-1 and Medium-2, see also Fig. 3A). As with PCs, the MABs-conditioned 
media significantly decreased cell death, to nearly the level of rBDNF 300 ng/ml, 
and the MABs-BDNF-conditioned media produced a significantly more 
pronounced effect. This extra-effect is mediated by the low concentrations (1 ng/ml) 
of BDNF produced by the MABs-BDNF, because (i) adding 1 ng/ml rBDNF to the 
MABs media produced an effect similar to the one produced by the MABs-BDNF 
media; (ii) the TrkB inhibitor K252a and the BDNF scavenger TrkB-IgG to the 
media conditioned by MABs-BDNF abolished the extra effect observed in the 
MABs-BDNF group, while these two BDNF blockers had no significant influence 
on the media conditioned by MABs (Fig. 2E). These data support the notion that 
the pro-survival effect of the MABs-BDNF media is mediated by a synergy 
between BDNF and other, yet unidentified, soluble substances constitutively 
produced by MABs. Accordingly, 1 ng/ml rBDNF alone did not reduce cell death at 
all, and much higher concentrations (300 ng/ml) were needed to almost reach the 
effect of the MABs-BDNF conditioned media. 
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Fig. 2. MABs-BDNF deliver BDNF and enhance cell survival in primary 
hippocampal neuronal cultures (PC) and in organotypic adult hippocampus slice 
cultures (OC). (A) and (B): genetically modified MABs-BDNF proliferate and 
constantly express GFP. (C) MABs-BDNF secrete BDNF. Concentration of BDNF 
in the medium of MABs and MABs-BDNF at various days in vitro (DIV), as 
measured using ELISA. MABs-BDNF were cultured in 2 different types of 
medium (Medium-1 and Medium-2, see text for details) as indicated. (D) Effect of 
different treatment procedures on the viability of hippocampal PCs, as estimated 
using the LDH release assay. Data are the mean±SEM of 6 replicates in separate 
experiments. ** P<0.01 vs. Control-1; ? P<0.05 vs. MABs; ANOVA and post-hoc 
LSD test. (E) Effect of different treatment procedures on the viability of adult 
hippocampus OCs, as estimated using the LDH release assay. Data are the 
mean±SEM of 6 replicates in separate experiments. * P<0.05 and ** P<0.01 vs. 
Control-1; ? P<0.05 vs. MABs; ? P<0.05 vs. MABs-BDNF; ANOVA and 
post-hoc Newman-Keuls test. Control-1 are slices treated with the typical medium 
for MABs culture (Medium-1). Control-2 are slices treated with the typical 
medium for postnatal slice culture (Medium-2). 
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2.3.3 The MABs-BDNF-produced mediators sustain neuronal 
structural integrity in adult organotypic slices 
The above findings have been confirmed at the light microscope and using 
FDA fluorescence, an indicator of viable cells. At the bright field observation, as 
compared with slice cultures in the control media (which, as described, display 
obvious signs of degeneration, Fig. 3A), the slices cultured in the media 
conditioned on MABs-BDNF remained thicker and preserved their structural 
organization for a long period, up to 25 days (Fig. 3C). Slices cultured in the 
MABs media appeared healthier that those cultured in control media but less 
healthy that those cultured in the MAB-BDNF media (Fig. 3B). In line with these 
findings and paralleling to the high levels of LDH release described above, FDA 
fluorescence was weak and uneven in OCs cultured with control media (Fig. 3D), 
indicating that most of the cells are indeed degenerating. OCs cultured with the 
MABs media displayed a better labeling quality (Fig. 3E), which was further 
improved in OCs cultured with the MABs-BDNF media (Fig. 3F). 
Cell counting, performed by using the DAPI nuclear stain, confirmed that, 
even if some cell loss was present in slices cultured with MABs-BDNF conditioned 
media (Fig. 3I), the number of surviving cells was much higher than in the control 
group (Fig. 3G). Slices treated with the media conditioned in MABs performed a 
little better that controls, but much worse than those treated with the media 
conditioned in MABs-BDNF (Fig. 3H). 
We also performed other morphological examinations and electrophysiological 
recordings. For morphological analysis, slices were fixed and immunostained with 
microtubule-associated protein 2 (MAP2). MAP2 is a cytoskeletal protein primarily 
found in neuronal dendrites. As shown in Fig. 3J, adult slices cultured in the control 
media for 14 days exhibit not only extensive cell loss, but also a grossly altered 
structure, with many lacunae in the pyramidal cell layer and just a few remaining, 
exclusively pyknotic neurons. MAP2 staining was essentially absent in control 
slices. While the MABs media only slightly improved this situation (Fig. 3K), the 
one conditioned in MABs-BDNF clearly attenuated the neuronal loss (Fig. 3L). 
The dendritic network and the cytoarchitectonic characteristics were essentially 
maintained in adult OCs treated with the MABs-BDNF conditioned media, 
although signs of neuronal degeneration could still be detected, with loss of 
neurons, decreased dendrites, and many condensed or swelling pyramidal cells. 
These signs of degeneration progressively increased in time. Nonetheless, this 
morphological analysis further confirms that the media conditioned in 
MABs-BDNF enhances neuronal survival and preserves structural organization.  
The density of neurons in the slices cultured with the different media was also 
assessed using Western blot analysis for the neuron-specific marker neurofilament 
68. We found that OCs cultured on MABs-BDNF conditioned media contained 
more neurofilament 68, thus more neurons, as compared with the slices cultured in 
the control media or in media from conventional MABs (Fig. 4). A statistically 
significant difference was also found between the MABs and the control group, 
indicating that supplementation of the soluble substances produced by MABs can 
slightly (but significantly less efficiently than with BDNF) attenuate neuronal loss. 
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Fig. 3. Morphological evidence of the beneficial effects of the medium 
conditioned in MABs-BDNF on adult organotypic cultures. Adult slices were 
cultured for 14 days with the control Medium-1, with medium conditioned in 
MABs, or with medium conditioned in MABs-BDNF. Note that slices cultured in 
the MABs-BDNF conditioned medium, compared with the other two groups, 
better maintain their integrity based on bright field observation (A-C), remain 
more viable based on FDA (D-E), DAPI staining (G-I) and MAP2 
immunohistochemistry (J-L). Nuclei in blue in G-I, neurons in green in J-L. Scale 
bar: 200 μm. 
 
 
 
Fig. 4. Density of neurons surviving in adult slices after 14 days in vitro, under the 
different experimental conditions. Neuronal density was quantified performing 
Western blot analysis for a neuron-specific marker, neurofilament 68. (A) 
Representative blot. (B) Data quantification. The data are mean±SEM of 4 separate 
experiments. * P<0.05 and ** P<0.01 vs. Control-1; ?? P<0.01 vs. MABs; ANOVA
and post-hoc LSD test. 
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2.3.4 Functional benefits afforded by the MABs-BDNF 
conditioned media in the cultured slices 
We performed electrophysiological recordings to demonstrate the viability of the 
surviving neurons and the persistence of synaptic connections at a functional level. 
We measured fEPSPs in CA1 pyramidal neurons after stimulation of the Schaffer 
collaterals. We chose 7 DIV as a checking time point, because adult slices in culture, 
even those cultured with the MABs-BDNF conditioned media, display a 
progressive decrease in the amplitude and stability of the extracellular field 
potentials in time (data not shown), such that currents could not be reliably 
measured at 14 DIV, when neurons are still visible using immunofluorescence: this 
is an indication that, as expected, the functional damage precedes the 
morphological one. As shown in Fig. 5A, adult slices cultured with the typical 
media exhibited very small (if any) synaptic response at 7 DIV, while relatively 
stable fEPSPs could be recorded in those cultured with the media conditioned in 
MABs or MABs-BDNF. However, the mean amplitude of the evoked fEPSPs in the 
MABs-BDNF group was much higher than in the MABs group (Fig. 5B). The 
presence of evoked synaptic currents, albeit lower and less stable than in acute 
slices or in cultured postnatal slices, in adult OCs cultured with the 
MABs-BDNF-conditioned media demonstrates that the neuronal activity and the 
hippocampal circuitry remain functional by virtue of the beneficial effects of the 
mediators secreted by MABs-BDNF. 
 
 
 
Fig. 5. Maintenance of synaptic connections in adult slices after 7 days in 
culture with the MABs-BDNF conditioned medium. Synaptic connections 
were identified by recording evoked fEPSP in CA1 after stimulation of the 
Schaffer collaterals. (A) Representative recordings of the evoked fEPSP in 
the different groups. (B) Peak amplitude of the fEPSPs, measured and 
statistically analyzed as described in the Materials and Methods. The data 
are the means SEM of 5 separate experiments. ** P<0.01 vs. Control　 -1; 
?? P<0.01 vs. MABs; ANOVA and post-hoc LSD test. 
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2.4 Discussion 
2.4.1 Protective Effects of rBDNF on Neurons 
We first showed that continuous application of recombinant BDNF promoted 
the survival of the cultured neurons seeded in low-density. These results are 
consistent with those of Lindholm et al. (1996), who showed that cultured 
hippocampal neurons die spontaneously when are plated at low (but not at high) 
density (Lindholm et al., 1996). Spontaneous death of hippocampal neurons plated 
at low density can be prevented by administration of BDNF. It was reported that 
addition of anti-BDNF antibodies (but not of antibodies to other NTs) to the culture 
media reduced survival of cultured cortical neurons (Matsumoto et al., 2003), but 
could not prevent the survival-promoting action of high potassium-induced 
depolarization (Armanino et al., 2005). The results highlight the pronounced 
promotion of neuronal survival by BDNF. However, several reports hold different 
opinions about the effect of BDNF on cultured hippocampal neurons. For instance, 
Ip et al. did not find any survival promoting effect of BDNF on embryonic 
hippocampal neurons, even though cultured hippocampal neurons express TrkB and 
show phenotypic changes after exposure to BDNF, such as an increased expression 
of c-Fos, calbindin, and AChE (Ip et al., 1993). Similar findings, in which 
BDNF-induced intracellular events lack survival-promoting effect, have been 
reported by Marsh and Palfrey (1996) in highly enriched cultures of rat 
hippocampal pyramidal neurons (Marsh and Palfrey, 1996). Lowenstein and 
Arsenault (1996) found evidence of increased survival of hippocampal dentate 
granule neurons in cultures treated with exogenous BDNF when dentate granule 
cells were plated at low density (Lowenstein and Arsenault, 1996). Furthermore, 
the authors found increased death rates for cultured hippocampal neurons from 
BDNF knockout mice relative to wild-type mice, and a survival promoting action 
of exogenous BDNF on cultured pyramidal neurons lacking the BDNF gene, 
suggesting an autocrine/paracrine effect of endogenous BDNF on survival of 
hippocampal pyramidal neurons (Lindholm et al., 1996). It seems that hippocampal 
neurons can survive and differentiate when plated at high density, thank to the 
existence of functional autocrine/paracrine trophic loops in the culture. Exogenous 
BDNF displays a noticeable effect only when hippocampal neurons are plated at 
low density, when autocrine/paracrine loops are presumptively not functional 
(Lindholm et al., 1996). All in all, the presence of either exogenous or endogenous 
BDNF is indispensable for neuronal survival. 
Moreover, we showed that continuous application of recombinant BDNF 
provided protective effects on the adult organotypic hippocampal slice culture in a 
concentration-dependent manner. The effective dose of the rBDNF is similar to the 
one in primary neuron culture (Lowenstein and Arsenault, 1996) and organotypic 
hippocampal slice culture from postnatal slices (Pringle et al., 1996; Nakagami et 
al., 1997). We here used the organotypic hippocampal slice culture from adult mice 
as a model of neurodegeneration. As we known, the age of the animal for OHSC is 
crucial for the maintenance of the cultured slices. Adult slices cultured in a typical 
media always result in rapid and continuous cell death within a slice. The 
spontaneous cell degeneration in cultured adult slices may be used as a model to 
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screen trophic or neuroprotective substances. There are also other models based on 
organotypic hippocampal slice culture from postnatal animals, in which cell death 
is induced by exogenous insults such as neurotoxins (Noraberg et al., 1998), 
oxygen-glucose deprivation (Wise-Faberowski et al., 2009), and trauma (Morrison 
et al., 2006). As opposed to these models based on postnatal slices, the cultured 
slices from adults display good regional morphology with less cell reorganization, 
and resemble the adult brain in gene expression profile, despite the unclear 
mechanisms of the spontaneous cell death. The consistent results in two 
independent assays, FDA hydrolysis and LDH release, suggest the feasibility of 
adult organotypic hippocampal slice culture as a model of degeneration. The 
mechanism underlying the pro-survival effects of BDNF in adult hippocampal slice 
cultures remains unclear. Nevertheless, these results suggest that hippocampal 
neurons may depend on BDNF support derived from their targets or exogenous 
supplementation for continued survival, not only during development but also in 
the adult nervous system. The pro-survival effects of BDNF found in adult neurons 
may be of great significance particularly for age-related neurodegeneration. 
 
2.4.2 Protective effects of MABs and MABs-BDNF produced 
factors 
The protective effect of rBDNF is of great interest for therapeutic purpose. To 
overcome the difficulties of rBDNF delivery in the brain, we pursue cell-base gene 
delivery strategy and generated the MABs-BDNF. We found that MABs-BDNF can 
be grown extensively in culture and stably secrete BDNF into the culture media. 
Although the secreting BDNF is at relative low concentrations, the conditioned 
media from the culture supernatant of MABs-BDNF still exerted extensive 
protective effects on the adult OHSC. According to our concentration-response 
assay with rBDNF, the concentration of rBDNF (1 ng/ml) equivalent to that of 
MABs-BDNF secreted BDNF, and even the highest dose of rBDNF (300 ng/ml) 
could not extend cell survival as much as MABs-BDNF, indicating the 
MABs-BDNF produced not only BDNF but also some other unknown survival 
factors. Indeed, the conditioned media from control MABs did enhance cell 
survival of the cultured adult slices when compared with the control media. The 
result that the MABs-BDNF beneficial effects could be simulated by the 
combination of MABs and 1 ng/ml of BDNF reinforced the assumption that 
MABs-BDNF can produce two pro-survival components: the secreted BDNF, and 
the unknown soluble substances inherently secreted by MABs. It also seems that 
there is a synergistic effect between BDNF and the MABs produced unknown 
factors. As seen in Fig. 2, MABs-BDNF increased cell survival to a much higher 
extent, while the equivalent dose of BDNF alone or MABs just show a minor 
increase. The synergic effect of NTFs is a general phenomenon in the nervous 
system. A proper combination of different NTFs could enhance the trophic abilities 
and reduce possible side effects. MABs seem to be ideal for delivering BDNF since 
the delivery was effective at a low dose, which would reduce the side effects in 
future clinical application. So far, the effective components in the culture 
supernatant of MABs have not been identified. A micro-array analysis of gene 
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expression in MABs revealed that several growth factors are expressed at high level 
in these cells, including vascular endothelial growth factor B (VEGFB), basic 
fibroblast growth factor (bFGF), FGF7, platelet-derived growth factor AA (PDGF 
AA), hepatomaderived growth factor, and stromal derived factor 1 (Galli et al., 
2005). It remains unknown which which of these factors may exert neuroprotective 
effects. It has been reported that various NTFs, growth factors, and cytokines have 
protective effects against neuronal degeneration (Lindsay, 1994). The benefit of 
MABs on adult slice survival is probably multifactorial, relating with various 
growth factors and chemokines, many of which may not even be known to us. It is 
worthy to note that MABs preferentially expressed many neural genes including 
receptors and transcription factors in spite of their mesodermal origin (Tagliafico et 
al., 2004). Therefore, it is reasonable that MABs could express some specific 
survival factors for neurons.  
Together with the morphological analysis and the immunoblot assay for 
neuron-specific markers, the beneficial effects of the conditioned media from 
MABs-BDNF on the adult slice culture are solid. Moreover, the cultured adult 
slices in the conditioned media of MABs-BDNF showed a better synaptic response 
with higher peak amplitudes of fEPSP compared to the groups of MABs and the 
control media. The facilitated synaptic responses may ascribe to the better 
preservation of synaptic connection or the potentiated synaptic transmission. It is 
reported that application of BDNF could modulate the strength of existing synaptic 
connections (Huber et al., 1998; Jiang et al., 2001) and acts in the formation of new 
synaptic contacts within the hippocampal circuit (Lauterborn et al., 2007). In the 
morphological examination using immunohistochemistry for MAP2, only cultured 
adult slices in the group of MABs-BDNF retained low density of dendrites in the 
stratum radium after 14 days in vitro culture. It’s necessary to know that the 
conditioned media from MABs-BDNF can reduce cell degeneration but completely 
prevent it. The cultured adult slices, even those in the MABs-BDNF conditioned 
media, exhibited continuous signs of degeneration during culture, such as PI-uptake, 
pyknotic cells, decreasing MAP2 signals and so on. The electrophysiological 
recordings also indicate that the cultured adult slices were not as healthy as the 
typically cultured postnatal slices, since the fEPSPs in adult slices were difficult to 
evoke relative to postnatal slices and almost disappeared after 10 days in vitro 
culture (data not shown). In the future, an improved culture method together with 
supplementation of the MABs-BDNF conditioned media might make it possible to 
achieve a successful organotypic culture from adult hippocampus slices, which is a 
technical bottleneck for many studies. 
 
2.4.3 The possible mechanism of BDNF protective effects 
Several inestigations indicate a pivotal role of BDNF in neuroprotection in 
different models of neurotoxicity, such as in vivo and in vitro ischaemic neuronal 
damage (Larsson et al., 1999; Kano et al., 2002), glucose deprivation (Tong and 
Perez-Polo, 1998) or glutamate-induced neuronal damage in neuronal cultures 
(Cheng and Mattson, 1994), kainate acid-induced excitotoxicity in the striatum 
(Gratacos et al., 2001) and hippocampal kindling (Larmet et al., 1995). In this study, 
we demonstrated the beneficial effects of rBDNF or MABs delivered BDNF on cell 
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survival in adult slice cultures. In fact, neuronal cell death as a result of 
neurotrophic factor deprivation is a physiological cell death mechanism which is 
commonly observed during neuronal development (Rich, 1992; Suzuki and Koike, 
1997; Vizuete et al., 2001; Roceri et al., 2004). Many neurons within the vertebrate 
nervous system require the presence of NTFs such as NGF or BDNF for survival 
(Koike and Tanaka, 1991; Roceri et al., 2004). Neurons which fail to obtain a 
sufficient quantity of the necessary neurotrophic factor die by a process of 
programmed cell death (Wozniak, 1993). This process is thought to regulate the 
number of neurons and neuronal connections within the developing CNS. While the 
mechanisms involved in the neuronal loss that occurs following a reduction in 
neurotrophic support have been determined in the developing nervous system, 
researchers are still uncertain as to what implications deficits in trophic support 
may have in the adult CNS. It has been observed that several neuronal populations 
within the adult CNS require the presence of neurotrophic factors to maintain 
neuronal function and phenotype (Binder, 2004). If mature neurons are still 
dependent upon the presence of neurotrophic factors for survival and function then 
the loss of transcriptional suppression of the ‘suicide programme’ due to a 
reduction in neurotrophic factor expression may result in the neuronal atrophy seen 
in normal aging or the neuronal loss observed in neurodegenerative disorders such 
as Alzheimer’s disease (Johnson et al., 1989). Indeed, it has been proposed that AD 
pathology may primarily be due to a deficit in neurotrophic factor protein and/or 
Trk expression (Hefti, 1983; Soontornniyomkij et al., 1999; Savaskan et al., 2000). 
Although it remains unclear if a similar reduction of BDNF and/or Trk expression 
occurs in the adult slice culture, the benefit of supplementation of exogenous 
BDNF might be a hint to reveal the mechanism underlying the cell death of adult 
neuron cultures. 
It is presumed that BDNF is an essential constituent of the microenvironment 
for neuronal survival in the adult hippocampus. Actually, BDNF administration to 
cultured slices potentiates presynaptic release (Li et al., 1998) and promotes 
dendritic and axonal growth (Labelle and Leclerc, 2000). Independently, other 
studies have provided insight into the effects of BDNF on potentiating excitatory 
transmission (Huber et al., 1998; Jiang et al., 2001). Moreover, BDNF have the 
potential to protect diseased and injured neurons from dying, induce neuronal 
sprouting and to increase neuronal metabolism and function (Labelle and Leclerc, 
2000; Chapleau et al., 2008). The signaling mechanisms underlying the 
pro-survival effects of BDNF appear to involve TrkB activation. A large part of 
hippocampal pyramidal and dentate granule cells co-express both BDNF and TrkB 
(Kokaia et al., 1993). In our results, the TrkB blocker K252a attenuated the 
protective effects of MABs-BDNF, indicating that the protection conferred by 
MABs-BDNF is mediated in part by the TrkB pathway. TrkB receptors have long 
been known to mediate trophic support of adult neurons (Ferrer et al., 1999), and a 
number of studies show that decreased expression of the receptor is associated with 
cell loss (Mesquita et al., 2002). TrkB regulates neuronal proliferation, survival, 
axonal and dendritic growth, assembly of the cytoskeleton, synapse formation and 
function (Barbacid, 1994). BDNF-TrkB signals have actions as anti-excitotoxins, 
antioxidants and can improve mitochondrial function. They upregulate calcium 
buffering proteins, antioxidant enzymes, and anti-apoptotic signals (Cui, 2006). 
High levels of intracellular Ca2+ which occuring during neurotoxic insults can cause 
mitochondrial dysfunction, free radical production, apoptotic signals, and activation 
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of many destructive proteases and lipases. By acting on intracellular calcium 
buffering proteins, BDNF can provide cells with a superior capacity to withstand 
dangerous cytosolic calcium effluxes and potential cell death (Cheng and Mattson, 
1994; Nonner et al., 2000). However, there is still considerable controversy 
regarding action of BDNF. Many potential effects of BDNF are still unresolved. 
Our data showing that the continuous presence of BDNF is required in the adult 
slice culture to sustain neuronal survival will at least contribute to elucidating its 
roles in neuronal activity. 
 
2.4.4 Neuroprotective strategies with NTFs 
In this study, we demonstrate that soluble mediators secreted by the 
MABs-BDNF have profound survival effects on neurons. We found a potential 
merit of using MABs to deliver BDNF, which were the survival factors inherently 
secreted by MABs. The coaction of BDNF and MABs-produced survival factors 
led to a higher resistance to cell death and a better maintenance of neuronal 
network, and allowed the delivered BDNF exert a profound protective effect at a 
low dose. Besides, MABs possess the other natural advantages for cell-based 
therapy: they can be expanded to virtually unlimited numbers in vitro; they are 
amenable to genetic modification; they have self-renewal and multipotent 
capacities; they may specifically home in the damage area. These advantages raise 
the possibility that the MABs-BDNF might be developed into a new cell-based 
strategy for BDNF delivery into CNS, thereby promoting neuronal survival and 
restoring network function in those neurological diseases associated with brain 
damages. Transplantation of MABs-BDNF might become an alternative and 
possibly more efficacious therapy for brain diseases caused by neurodegeneration, 
including multiple sclerosis, stroke, epilepsy and trauma. The transplanted 
MABs-BDNF may protect neurons from damage through a “bystander ” 
mechanism, by which MABs-BDNF chronically secrete low doses of BDNF and 
other survival factors to provide an optimal environment for neuronal survival and 
tissue repair in the damaged brain.  
There are a number of neuroprotective, as well as neurorestorative, strategies 
which are becoming available. Neuroprotection refers to the potential for reinforced 
defence against cell death, whereas neurorestoration refers to the recovery of 
functional variables, or symptoms, to levels comparable with pre-insult or 
"steady-state" levels. The objective of our study is to create a neuroprotective agent 
(MABs-BDNF) and meet the clinical necessities. Although the study just provides 
groundwork for future clinical application, it is conceivable that the MABs-BDNF 
will become a promising agent for neuroprotective strategies. 
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3. PART II -  Effects of MABs-delivered BDNF on 
neurogenesis 
3.1 Introduction 
In the adult mammalian brain, new neurons are continuously generated from a 
proliferating population of neural progenitor/stem cells and become incorporated 
into the existing neuronal circuitry via a process termed adult neurogenesis (Lee 
and Son, 2009). The existence of active functional adult neurogenesis raises the 
exciting possibility that manipulating endogenous neural progenitors, or 
transplanting the progeny of exogenously expanded neural progenitors, may lead to 
successful cell replacement therapies for various degenerative neurological diseases. 
Significant effort is being made to decipher the mechanisms regulating adult 
neurogenesis, which may allow us to translate this endogenous neuronal 
replacement system into therapeutic interventions for many neurological diseases 
(Kuhn et al., 2001; Ormerod et al., 2008). 
In rodents, there are two known neurogenic regions in the adult: the 
subventricular zone (SVZ) and the subgranular zone (SGZ) of the hippocampal 
dentate gyrus (DG) (Eriksson et al., 1998; Palmer et al., 2001; Alvarez-Buylla and 
Garcia-Verdugo, 2002). Growth factors are important components of stem cell 
niches (Horner and Palmer, 2003). Cells in the SVZ and DG respond to multiple 
extracellular factors, including EGF, FGF2, PDGF, BMPs, noggin, prolactin and 
erythropoietin, which influence SVZ proliferation and neurogenesis (Kuhn et al., 
1997; Lim et al., 2000; Shingo et al., 2001; Zheng et al., 2004; Jackson et al., 2006). 
Recent findings indicate that neurotrophic factors play a fundamental role in adult 
neurogenesis (Lee and Son, 2009).  
Particularly, BDNF has been hypothesized to play an important role in 
hippocampal neurogenesis. Evidentiary are reports indicating that BDNF enhances 
neurogenesis in the different regions of the brain (Benraiss et al., 2001; 
Chmielnicki et al., 2004; Scharfman et al., 2005). A tremendous amount of 
correlative data suggests that BDNF is critical for regulation of mammalian adult 
neurogenesis in the SGZ of the hippocampus (Xu et al., 2004b). Intraventricular 
(Yan et al., 1994; Anderson et al., 1995) and intra-hippocampal infusions of BDNF 
resulted in enhancement of neurogenesis (Scharfman et al., 2005). Altered cell 
proliferation and diminished enhancement of neurogenesis by antidepressant 
treatment or dietary restriction were found in the hippocampi of BDNF+/- mice 
(Lee et al., 2002a; Sairanen et al., 2005). In vitro, BDNF promotes proliferation of 
NPCs (Barnabe-Heider and Miller, 2003) and increases neuronal production in 
neurosphere cultures (Young et al., 2007). Our previous data also showed that 
FGF-2 and BDNF, when supplied together but not when supplied individually, 
potently favor proliferation, survival and neuronal differentiation of neural 
progenitors in vitro in neurosphere cultures, and in vivo, in an epilepsy model 
(Paradiso et al., 2009). Nonetheless, controversy still exists about how BDNF 
influences proliferation and differentiation in neural precursor cells (Lee et al., 
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2002b; Sairanen et al., 2005). More research is clearly needed to understand the 
role of this neurotrophin and its interplay with other growth factors in endogenous 
neurogenesis before it can be considered promising for therapeutic purposes.  
In addition to the neuroprotection effects described in Part I, the present study 
was also undertaken to investigate the neurogenesis effects of the MABs-BDNF 
conditioned media in the organotypic hippocampal slice cultures (OHSC). OHSC 
offers an attractive model for studying neurogenesis both in the early postnatal and 
in the adult hippocampus, as they retain much of their anatomical circuitry and 
intrinsic functional activity for a number of weeks (Gahwiler et al., 1997; De 
Simoni et al., 2003). A slice culture containing various neural and nonneural 
elements is a more suitable ex vivo model for postnatal neurogenesis than a 
neurosphere culture. The easy access to in vitro environment allows precise 
experimental manipulation that is not possible in vivo and the visualization of cell 
morphology or function using fluorescent markers/probes within the same cultures 
over prolonged periods (Kamada et al., 2004). Hippocampal slice cultures can 
generate new neurons in vitro, as suggested by the observation that neural 
progenitor-like cells are found in the slice culture (Miyaguchi, 1997). Recent 
studies have shown that OHSC from postnatal day 5– 10 pups preserved 
endogenous neuronal progenitor cells in the dentate gyrus, in which new neurons 
are spontaneously generated, and therefore are particularly suitable for studying 
neurogenesis (Kamada et al., 2004; Raineteau et al., 2004).  
The neurogenic abilities in hippocampal slice cultures were identified using 
the 5-bromodeoxyuridine (BrdU) labelling method (Raineteau et al., 2004). Here 
we also assessed cell division by measurement of the uptake of BrdU, which is 
incorporated into the nuclear DNA of dividing cells. In these cultures, BrdU uptake 
will, of course, reflect gliogenesis as well as neurogenesis (Dehghani et al., 2004; 
Kamada et al., 2004). To distinguish between the two, the neuronal maturation of 
the BrdU labeled cells was assessed using a neuronal marker, the neuron-specific 
DNA-binding protein neuronal nuclear (NeuN). The brain slice culture system was 
here applied to study the effects on neurogenesis of BDNF and FGF2, and more 
importantly the by-stander effect of MABs-BDNF. As it turns out that the neural 
progenitor cells in hippocampus may repair a damaged brain (Paradiso et al., 2009), 
the possible neurogenesis effects of the transplanted MABs-BDNF may serve as 
“regenerative medicine” in which hippocampal stem cells are coaxed into forming 
neurons and migrating to regions of injury or degeneration to treat disease.  
 
3.2 Methods 
Animal 
Adult pregnant females or male Swiss mice (Morini, Italy) were housed under 
constant temperature (21±1 ℃) and lighting (light on from 07:00 am to 07:00 pm) 
regimens. Food pellets and water were freely available throughout the experiment. 
Procedures involving animals and their care were conducted in conformity with 
European Community and national laws and policies. All efforts were made to 
minimize animal suffering. 
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Bromodeoxyuridine administration.  
To label the immediately post-mitotic cells, the DNA synthesis marker 
5-bromo-2-deoxyuridine (BrdU) was administered twice as previously described 
(Namba et al., 2007) with small modifications. Firstly, BrdU (Sigma) dissolved in 
0.9% NaCl was injected intraperitoneally at a dose of 50 mg/kg into postnatal (P6) 
mice 30 min before slice preparation; the second administration was at 3 days 
before slice fixation at a concentration of 0.5 μM BrdU in the culture media, that 
was maintained for 3 days.  
 
Organotypic hippocampal slice culture from postnatal mice 
Hippocampal organotypic slice cultures were prepared similar to the adult 
slice culture in the PART I except the animals are postnatal (P6) swiss mice. The 
pups were decapitated without anesthesia and the hippocampi were rapidly 
dissected out in ice-cold artificial cerebrospinal fluid (aCSF) as described in PART 
I. Subsequently, 400 μm thick coronal slices were cut with a vibrotome (MA752, 
Campden Instruments). 1-2 slices with dorsal hippocampal in each pup were 
collected for culture. The number of granule cells and proliferating cells in the 
dentate gyrus of slice cultures taken from the full septo-temporal extent of the 
hippocampus, with granule cell layer size increasing from temporal to septal ends. 
To correct for possible confounding effects of the site of origin of the culture on the 
number of proliferating cells, position-matched cultures were taken from the full 
extent of each hippocampus from each animal. Position-matched slices from each 
hippocampus were then grown in either Medium-2 or the condition media so that 
each animal contributed a slice from one position (coronal section with dorsal 
hippocampus) matched to the culture condition groups. The allocation of matched 
slices to each group was also randomized with respect to hippocampal side. 
The hippocampal slices were softer and more transparent in paleness. And 
they have to be carefully dissected in cold, oxygenated Hank’s balanced salt 
solution (Gibco, Invitrogen) under stereo microscope. Those slices without visible 
blemish were transferred onto sterile porous membrane confetti (Millicell, 
Millipore), and cultured with their standard media (Medium-2) or with the 
MAB-conditioned media (see below). The incubation conditions were maintained 
in a humidified 5% CO2 atmosphere at 37 ℃. The culture media was changed the 
day after preparation and then every 2-3 days for the course of the experiment. 
 
Preparation of the conditioned media  
As desribed in the PART I, the condition media in the groups “MABs” and 
“MABs-BDNF” was composed by the mixture of equal volumes of fresh 
Medium-2 and of the 2-day-culture supernatant from MABs and MABs-BDNF, 
respectively. The MABs and MABs-BDNF were cultured according to the methods 
described in PART I but replaced the Medium-1 with Medium-2, because we found 
Medium-1 is not as good as Medium-2 for the postnatal slice culture. Medium-2 is 
a standard culture media for OHSC from postnatal animals, consisting of 50% 
MEM, 25% horse serum, 18% HBSS, 4 mM L-glutamine, 12 mM glucose, 4.5 mM 
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NaHCO3, 20 mM sucrose, 100 U/ml penicillin and 100 mg/ml streptomycin (from 
Gibco or Sigma). The other conditioned media were based on the above media with 
different supplementations of reagents, like the recombinant human BDNF 
(Immunological Sciences), human FGF2 (Immunological Sciences) or their 
combination. Sister slices were randomly assigned to the different groups. 
 
Culture sectioning  
Following 1 hour in 4% PFA at room temperature, cultures were transferred to 
a 30% sucrose solution for 24 hours. The section protocol is described in PART 
I/Methods except the thickness was 10 μm.  
 
BrdU/NeuN immunostaining.  
Sections of control cultures and cultures exposed to different conditioned 
media were thawed and washed in PBS for 15 min. After washing in PBS, slices 
were exposed to 2 M HCl at 37 ℃ for 30 minutes and were subsequently washed 
in boric acid (0.1 M, pH 8.5,) for 10 minutes. Slices were then washed thoroughly 
in PBS, and blocked with 5% Goat serum and 5% BSA for 30 min. Subsequently, 
slices were incubated with rat anti-BrdU (1:50, Sigma) and mouse anti-NeuN (1:50, 
Chemicon) in 0.1% Triton PBS overnight. After thoroughly wash in PBS 3 times 
for 10 min, second antibodies goat anti-rat Tritc (1:50, Chemicon) and goat 
anti-mouse Alexa 488 (1:50, Chemicon) in PBS. Appropriate negative controls 
showed no nonspecific secondary antibody staining. Following multiple washes in 
PBS, the slices were cover-slipping with DPX (Sigma). 
 
Cell counting 
Unbiased stereological cell counting was carried out using a software (Leica) 
connected to a DMRA2 microscope (Leica) with a DFC300FX video camera 
(Leica) to obtain images at 10×, 20×, and 40× magnification. The number of 
proliferating of cells or newly born neurons was determined by counting the 
number of BrdU-positive cells and their colabeled with NeuN, respectively. The 
counting areas included the whole section, CA1, CA3, but mainly in the dentate 
gyrus. The border of interested area was first drawn with the mouse cursor. Within 
the counting frames, either BrdU single labeled cells or NeuN/BrdU double 
staining cells were counted. Cells in the granule cell layer that were obviously 
pyknotic were not counted when generating estimates of normal cell number. For 
all quantification, slides were coded and counts carried out with the examiner blind 
to the treatment of each section.  
 
Statistics 
Statistical analysis and graph composition was performed using the SPSS 
software (USA). All values are presented as means±SEM. A One-way ANOVA 
and post hoc Bonferroni test were used for multiple group comparisons. Statistical 
significance was established at P <0.05. 
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3.3 Results 
3.3.1 Neurogenesis in hippocampal slice cultures  
Organotypic cultures from the postnatal mouse hippocampal slices were 
maintained in vitro for 14 days, when they are believed to have matured to a near 
adult state. The cultured slices displayed well defined neuronal cell layers 
resembling sections of the hippocampus in vivo, except that the neuronal cell layers 
were more spread out. The structural changes in OHSC took place largely within 
the first week and were stable in the following 2 weeks. No discernable differences 
were observed among the groups cultured with different media in any of the 
hippocampal subfields under bright field microscopy. Similarly, no overall 
structural differences were observed between control cultures and the cultures 
treated with 300 ng/ml BDNF and FGF2, or the MABs-BDNF conditioned media 
by using anti-MAP2 immunohistochemistry (data not shown). 
To investigate in more detail neurogenesis and maturation of newly born 
neurons, BrdU was administered twice according to the Namba’s protocol (Namba 
et al., 2007): BrdU was first injected at a dose of 50 mg/kg 30 min before sacrifice; 
the second administration was at 3 days before slice fixation with a concentration 
of 0.5 μM, and maintained for 3 days. Cultured in vitro for two weeks, the slices 
were processed for BrdU and NeuN immunoreactivity. Numerous BrdU-positive 
cells were observed at the surface of all regions of the slices (Fig. 6). An average of 
213±29 BrdU-positive cells per 2500 μm2 were detected in the DG region, 178±
25 cells over the CA1 pyramidal cell layer and 189±24 over the stratum 
moleculare of the same region (n = 5). As already described by others (del Rio et al., 
1991), a large proportion of the BrdU positive cells (>80%) was immunoreactive 
for the astroglial marker GFAP. These proliferating astrocytes were present as flat 
type-1 astrocytes at the border of the culture facing the glass coverslip, but also as 
reactive astrocytes (type-2 astrocytes) at the tissue/media interface, forming a 
protective shield around the slice. Proliferation of astrocytes was less pronounced 
but also presented within the slices in the areas CA1 and CA3 as well as in the DG. 
The proliferation of astrocytes is, started very early and persisted during the entire 
culturing period, leading to the formation of a thin cell layer covering the slice, 
analogous to a glia limitans (del Rio et al., 1991; Gahwiler et al., 1997). 
Double immunostaining of the mitotic marker BrdU with the neuronal marker 
NeuN showed that BrdU/NeuN-positive cells were consistently observed in slices. 
On average, there were 9.2±1.8 BrdU/NeuN-positive cells in 10 μm thickness 
sections of the cultured slice. The cell bodies of these BrdU/NeuN-positive cells 
looked round and healthy, and the BrdU-immunoreactive signals were relatively 
light in contrast to other BrdU-positive cells (Fig. 6). These BrdU/NeuN-positive 
cells, representing the newly born neurons, were found throughout the entire depth 
of the hippocampal slices. The vast majority (over 90%) were distributed in the DG, 
especially in the inner layer, while a small proportion scattered in the other regions 
of the hippocampus such as hilus, CA1 and CA3. The distribution of these newly 
born neurons closely reflects the in vivo regional distribution in the adult 
hippocampus. On the basis of their morphological appearance and characteristic 
Chapter II: THE FINDINGS        PART II - Effects of MABs-delivered BDNF on neurogenesis       85 
location within the slice, these newly born neurons were mostly identified as 
granule cells.  
 
 
Fig. 6. Fluorescent immunohistochemistry for BrdU/NeuN in organotypic 
culture of postnatal mouse hippocampal slices, indication of spontaneous 
neurogenesis and proliferation of cells in the dentate gyrus at DIV 14. (A) shows 
the BrdU labeled cells. Note that only the cells with punctuate signals in nuclei 
are newly born neurons, indicated by arrows. (B) BrdU/NeuN double labeled 
cells (new born neurons), indicated by arrows. (C) Low magnification showing 
the numerous BrdU labeled cells, most of which are glia cells in proliferation. 
(D) New born neurons with punctuate BrdU signals in NeuN-positive nuclei. 
Abbreviation: po, polymorphic cell layer; gr, granule cell layer; ml, molecular 
layer. Scale bar: 150 μm. 
 
3.3.2 Modulation of neurogenesis by NTFs and MABs-BDNF 
We previously demonstrated BDNF and FGF2 gene delivery mediated by viral 
vectors could promote the survival of neural progenitors and induce more 
progenitors to differentiate into neurons in neurosphere culture. The 
pro-neurogenesis effects of the combined BDNF and FGF2 gene delivery were also 
shown in the hippocampus in an animal model of epilepsy. Here we confirmed the 
actions of BDNF and FGF2 on neurogenesis in the OHSC system by administration 
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of a defined dose of exogenous recombinant BDNF and FGF2. Moreover, we 
validated the hypothesis that the BDNF delivered by engineered MABs contribute 
to the proliferation and differentiation of endogenous neural stem cells, which 
suggests that MABs-BNDF might play a regenerative role in brain repair in future 
MABs-based therapy. To pursue the aims, different conditioned media (see the 
methods) were used in the OHSC, and maintained for 14 days. 
First, the overall proliferation rates of glial cells were determined by counting 
the number of BrdU positive cells (as stated above, over 80% of BrdU positive 
cells are glial cells)(See Fig. 7). BrdU positive cells were counted in the dentate 
gyrus from non-overlapping pictures. In control cultures, the mean number of 
BrdU-positive cell was 72±4.0 (n=5). Chronic combined supplementation of 
rBDNF and rFGF2 (300 ng/ml each) for 14 days upregulated the number of 
BrdU-positive cells to 102±6.6 cells. Similarly, significantly more BrdU-positive 
cells were observed in the slices cultured with the MABs-BDNF conditioned media 
(P<0.01), whereas slices cultured with the conditioned media from MABs without 
genetically expressed BDNF displayed a small increase without statistical 
significance (P>0.05). There was significant difference between the group of 
MABs-BDNF and the group of MABs (P<0.05), even though the concentration of 
MABs delivered BDNF was as low as 1 ng/ml. Interestingly, the single 
supplementation of rBDNF at low concentration (1 ng/ml) failed to significantly 
increase the number. While a high concentration (300 ng/ml) slightly increase the 
BrdU+ cells (P<0.05) indicating that BDNF alone at a high dose could promote 
proliferation of glia cells to a minor extent. If 300 ng/ml rBDNF was administered 
with FGF2 (300 ng/ml), the proliferation rate was highly increased (P<0.01). Thus, 
BDNF exerted a stronger mitogenic effect if combined with other factors like FGF2 
or MABs inherently produced factors. 
Next, more importantly, BrdU/NeuN double labeled cells were also counted. 
The number of BrdU/NeuN positive cells in dentate gyrus in control media were 
9.2±1.8 (n = 5). Supplementation of 1 ng/ml rBDNF did not induce a significant 
change in the number of BrdU/NeuN positive cells. The higher concentration (300 
ng/ml) induced a significant increase in the number of newly born neurons 
(P<0.01). The additional supplementation of 300 ng/ml rFGF2, did not further 
increase the effect of rBDNF. However, MABs delivered BDNF in the group of 
MABs-BDNF doubled the number of newly born neurons in control media, and 
also showed a significant increase compared to the MABs group (P<0.05). The 
conditioned media from MABs showed a moderate pro-neurogenesis effect 
compared to control. When comparing the MABs-BDNF group (consisting of 1 
ng/ml BDNF and other inherently produced factors) and the 1 ng/ml rBDNF group, 
a significant increase was found (P<0.05), confirming the pro-neurogenesis effect 
of soluble mediators inherently produced by MABs. There was no difference 
among MABs-BDNF, MABs, 300 ng/ml rBDNF, and 300 ng/ml rBDNF/rFGF2.  
These results demonstrate that both rBDNF and MABs-delivered BDNF can 
increase proliferation of glia cells and the number of newly born neurons 
differentiated from endogenous neural stem cells in the OHSC system. The 
additional supplementation of FGF2 to 300 ng/ml BDNF appears to be effective in 
proliferation of glia cells but not in the number of newly born neurons. The soluble 
mediators secreted from MABs contribute to proliferation of glia cells and 
neurogenesis to a small extent, but the effects can be augmented by the transgene 
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expression of BDNF. The conditioned media from the MABs-BDNF culture 
showed effects of gliosis and neurogenesis in the OHSC system, which may be due 
to the transgene expression of BDNF and inherently produced factors. 
 
 
 
 
3.4 Discussion 
3.4.1 Neurogenesis in OHSC 
In the present study, we used long-term hippocampal organotypic cultures as 
an ex vivo system for the study of neurogenesis, in which neurogenesis occurs 
spontaneously and maturation and regional distribution closely resemble those 
observed in living animals. Application of hippocampal organotypic slice cultures 
for the story of neurogenesis is relatively rare (Kamada et al., 2004; Raineteau et al., 
2004; Chechneva et al., 2005; Laskowski et al., 2005; Poulsen et al., 2005; Hoareau 
et al., 2006; Sadgrove et al., 2006; Lossi et al., 2009). These studies examined 
neurogenesis through BrdU incorporating method in the GCL/SGZ of OHSC in 
different species using different culture methods, demonstrating the presence of 
neurogenesis in the OHSC. Several lines of evidence indicate that the incorporation 
of BrdU in NeuN-positive cells reflects the birth of new neurons (Palmer et al., 
2000). Here we used BrdU/NeuN double positive cells to identify the newly born 
neurons. 
Consistent with the previous observations, we found that the vast majority of 
the newly born neurons were in the innermost layer of the DG, less in the outermost 
region. The distribution of newly born neurons closely matches that reported in 
adult rodents in vivo (Kempermann et al., 2003). In this study, we observed a few 
Fig. 7. Cell counting of BrdU+ and BrdU+/NeuN+ cells in the dentate gyrus of 
slices cultured with different conditioned media. (A) Number of cells 
incorporating BrdU per 10 μm section in the dentate gyrus of the slices cultured 
with the indicated medium. (B) Number of new born neurons labeled with BrdU 
and NeuN in the dentate gyrus. Data are the mean±SEM of 5 replicates in 
separate experiments. * P<0.05 and ** P<0.01 vs. Control; ? P<0.05 vs. MABs; 
? P<0.05 vs. 300 ng/ml rBDNF; # P<0.05 vs. 1 ng/ml rBDNF; ANOVA and 
post-hoc Student-Newman-Keuls test. 
A. B.
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newly born neurons (1~3) in regions other than the dentate gyrus (i.e., areas CA3 
and CA1), while the previous reports showed that neurogenesis was absent in these 
regions (Kamada et al., 2004; Raineteau et al., 2004). The discrepancy might be 
due to the reorganization of the cells during slice culture or the BrdU administration 
method. It was indicated that the three-dimensional structure of the neurogenic 
niche in the slice culture may be somewhat reorganized (Kamada et al., 2004). The 
rearrangements are probably a result of afferent deprivation (Robain et al., 1994; 
Gutierrez and Heinemann, 1999). It is worthy to note that some variables such as 
culture media composition, culture age, structural changes within cultures, and 
dorsoventral differences in the number of neuronal precursor cells, may affect 
neurogenesis in this in vitro model system. The highly pronounced proliferation of 
cells indicated by BrdU incorporation was different from the situation in vivo, in 
which proliferation of glia cells was much lower. Therefore, BrdU positive cells are 
mostly glia cells, rather than neural stem cells. Another variable is the BrdU 
administration regimen. To determine whether it could influence the identification 
of newly born neurons, we repeated this experiment following a different BrdU 
administration protocol. We found that the dose or timing of BrdU delivery must be 
controlled strictly.  
Generally speaking, hippocampal slice cultures retain endogenous neural 
progenitors in the dentate gyrus throughout the cultivation period that maintain the 
potential to differentiate spontaneously into neurons. The time course and pattern of 
maturation and incorporation into the dentate gyrus of these newly born neurons is 
highly comparable to the one described in vivo (Kuhn et al., 1996; Eriksson et al., 
1998). In vivo, the hippocampus is a region where neurons are generated 
intrinsically and spontaneously throughout postnatal life. Neurogenesis in the 
hippocampus is largely confined to the dentate gyrus, where it appears to play an 
important role in certain types of memory formation (Gould et al., 1999; Shors et 
al., 2001; Garthe et al., 2009), the behavioral effects of antidepressant drugs 
(Santarelli et al., 2003), and may serve as potential regenerative source for 
hippocampal damage (Ge et al., 2008). 
These results establish organotypic hippocampal slice as a intesting model to 
study neurogenesis. All types of neurons and glia are preserved with their specific 
morphologies and localizations, and the main network organization is very similar 
to the one of living animals. The culture permits direct chronic treatment with drugs 
and various factors to modulate neurogenesis and facilitates the use of 
electrophysiological recordings from newly born neurons, together with their target 
cells. Therefore, hippocampal slice cultures offer the attractive possibility of 
studying the mechanisms of modulation of neurogenesis. 
 
3.4.2 Neurogenesis modulated by NTFs 
For neurogenesis to occur, it has been hypothesized that an appropriate set of 
signals need to be present within the neurogenic regions (Gage, 2000). To date, 
however, the microenvironment present in neurogenic regions of the adult brain 
still remains largely unknown. Several growth factors are known to affect 
proliferation of endogenous neural stem cells and their differentiation into neurons 
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and glia. A decade of work with such neural stem cells both in vivo and ex vivo has 
revealed that exposure to various individual (or combinations of) growth factors 
[e.g., FGFs, epidermal growth factor (EGF), transforming growth factors (TGFs), 
IGF-1] and/or neurotrophic factors (e.g., BDNF and CNTF) influences cell 
proliferation and differentiation along either neuronal or astrocytic lineages. For 
example, FGF, EGF, and IGF all promote neurogenesis when added to cultures of 
precursor cells from hippocampus, forebrain, cerebellum, and spinal cord 
(Gensburger et al., 1987; Ray et al., 1993; Vescovi et al., 1993; Pixley et al., 1998; 
Jin et al., 2003b). Our previous study also revealed that overexpression of FGF2 
and BDNF mediated by herpes vectors promotes the survival, proliferation of 
neural stem cells, and induced more of them differentiate into neurons (Paradiso et 
al., 2009).  
Several lines of evidence show that BDNF promotes the survival, differentiation and/or 
maturation of neurons derived from adult neural progenitor cells both in vitro and in vivo 
(Kirschenbaum and Goldman, 1995; Goldman et al., 1997; Pincus et al., 1998; Whittemore et 
al., 1999; Pencea et al., 2001; Scharfman et al., 2005; Chan et al., 2008) and can direct the 
neuronal differentiation of endogenous adult neural progenitor cells into region-specific 
neuronal phenotypes in the normal adult rat (Benraiss et al., 2001).  
Consistent with these findings, we observed that exogonenous administration 
of BDNF in the OHSC system induced the number of newly born neurons in the 
dentate gyrus as indicated by the presence of BrdU and NeuN double labeling. We 
also observed an increase in glial proliferation in BDNF-treated slices, indicated by 
the presence of BrdU labeled cells when compared with the control group. We 
propose that this reflects the ability of BDNF and/or other NTFs (e.g. FGF2, 
MABs-produced growth factors) to create a mitogenic and neurogenic environment. 
However, there is some inconsistency among previous studies about BDNF effects 
on neurogenesis. For example, intra-ventricular infusion of BDNF yielded different 
results depending on the animal species, having no effect on neuron production 
from mouse SVZ, while decreasing it in rats (Galvao et al., 2008). BDNF germline 
heterozygous mice have been reported to have decreased (Lee et al., 2002b) or 
increased (Sairanen et al., 2005) proliferation of neural progenitor cells, as well as 
decreased (Sairanen et al., 2005) or unaltered (Rossi et al., 2006) long-term 
neurogenesis. Intra-cerebroventricular (i.c.v.) infusions of BDNF stimulated 
progenitor proliferation only on the side of the infusion (Givalois et al., 2006). 
Exposing the SVZ to BDNF increases production of olfactory bulb interneurons 
(Zigova et al., 1998; Berghuis et al., 2006) and induce new neurons from resident 
progenitor cells (Pencea et al., 2001; Chmielnicki et al., 2004). From these facts, it 
appears that the effects of BDNF on neurogenesis or cell proliferation are 
complicated. 
BDNF has high levels of expression in the dentate gyrus and has an 
established role in the regulation of proliferation in the hippocampus (Nibuya et al., 
1995). Using the OHSC, we demonstrated that chronic supplementation of BDNF 
can enhance proliferation of glia cells and neurogenesis in the dentate gyrus. The 
low concentration of BDNF (1 ng/ml) is not as efficient as 300 ng/ml BDNF in 
terms of mitogenic and neurogenic effects. However, 1 ng/ml BDNF produced by 
the MABs seemed to be much more efficient in increasing proliferation of glia cells 
but not the neurogenesis, indicative of a synergistic promitogenic effect between 
BDNF and MABs inherently produced factors. The combined administration of 
BDNF and FGF2 also highly elevated proliferation of glia cells. FGF2 is a potent 
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mitogen for adult neural progenitor cells in vitro (Gensburger et al., 1987; Vescovi 
et al., 1993; Gritti et al., 1999). In vivo, administration of FGF2 into both 
neurogenic or non-neurogenic regions increases cell proliferation (Kuhn et al., 1997; 
Kojima and Tator, 2000; Martens et al., 2002; Hagood et al., 2006). FGF2 has also 
been shown to alter the default glial state of adult neural progenitor cells from 
nonneurogenic regions by activating the neurogenic potential of these progenitor 
cells (Palmer et al., 1995; Shihabuddin et al., 1997; Palmer et al., 1999). In vivo, 
chronic infusion of FGF2 into the adult rat lateral ventricle results in an increase in 
proliferating cells in the SVZ and striatum and a subsequent increase in the number 
of neurons migrating from the SVZ to the olfactory bulb (Kuhn et al., 1997). 
Consistent with these results, we found that BDNF increased the number of 
BrdU/NeuN double positive cells much more when in the presence of FGF2, 
indicative of the neurogenic effects of FGF2 on the endogenous progenitor cells. 
Indeed, FGF2 was found to not only increase the population of progenitor cells but 
also induce an increased number of neurons in the olfactory bulb, which is the 
normal destination of neuronal progenitors (Kintner, 2002). When comparing the 
number of newly born neurons between the group of 300 ng/ml BDNF and 300 
ng/ml BDNF/FGF2, we did not find any significant difference, indicating that 
FGF2 did not contribute to the neurogenic effect. This suggests that FGF2 may not 
have the same potential as BDNF to induce neuronal differentiation of neural 
progenitor cells in the OHSC system. In vivo, newly generated cells resulting from 
FGF2 administration have been shown to differentiate into neurons in neurogenic 
regions of the adult brain including the SVZ, SGZ and olfactory bulb (Kuhn et al., 
1997; Wagner et al., 1999; Jin et al., 2003a) but differentiate predominantly into 
astrocytes in non-neurogenic regions such as the spinal cord and striatum (Kojima 
and Tator, 2000; Martens et al., 2002; Hagood et al., 2006). It was proposed that 
BDNF creates a neurogenic environment allowing for neuronal differentiation of 
adult progenitor cells, while FGF2 appears to support the proliferation and 
multipotentiality of progenitor cells in vivo. The interplay between BDNF and 
FGF2 is worthy to be further elucidated. 
Besides the results of BDNF and FGF2, we found that the MABs-BDNF 
conditioned media (which consisted of 1 ng/ml BDNF and MABs inherently 
produced factors) induces a shift of neurogenesis, whereas the MABs conditioned 
media leaved the hippocampal neurogenesis unaffected. However, individual 
supplementation of 1 ng/ml rBDNF was insufficient to induce an increase of 
neurogenesis in the dentate gyrus. A possible hypothesis to explain these results is 
the interplay between BDNF and MABs inherently produced factors. A micro-array 
analysis of gene expression in MABs revealed that several growth factors are 
expressed at high level in these cells, including vascular endothelial growth factor 
B (VEGFB), basic fibroblast growth factor (FGF-2), FGF7, platelet-derived growth 
factor AA (PDGF AA), hepatomaderived growth factor, and stromal derived factor 
1 (Galli et al., 2005). It had been shown that many growth factors like EGF, FGF-2 
and IGF-1 increase neuro- and gliogenesis, just as BDNF can modulate dentate 
neural precursor cell proliferation, as illustrated by increased incorporation of BrdU 
into glia cells and NeuN positive cells in the dentate gyrus. These growth factors 
include FGFs, IGF, and EGF also promote the proliferation of stem cells isolated 
from the adult brain and may direct them toward specific fates (Craig et al., 1996; 
Kuhn et al., 1997), which is worthy of more extensive study. 
We observed that supplementation of either rBDNF or MABs delivered BDNF 
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in the media increased the population of BrdU positive cells (representing glia cell 
proliferation) and BrdU/NeuN positive cells (representing newly born neurons) in 
the OHSC system. At this stage we are unable to conclude that these factors can 
direct the neural progenitors to neurons. The increased number of BrdU/NeuN 
positive cells may be either due to more neural progenitors proliferating and/or 
differentiating along neuron lineage, or due to more progenitors surviving from the 
culture procedure. Most of the growth factors, including BDNF and FGF2, are 
implicated in regulation of survival, proliferation, differentiation of progenitor cells. 
The regulation of BDNF on hippocampal neurogenesis is presumably via its 
primary receptor, TrkB. There are studies showing that BDNF-TrkB signaling 
impacts survival rather than proliferation (Lowenstein and Arsenault, 1996; 
Sairanen et al., 2005), but controversy exists about how BDNF affects neurogenesis 
(e.g. proliferation vs. survival/differentiation). From out data, it just appears that 
both BDNF and FGF2 induce dentate granule cell neurogenesis in cultured slices. It 
is known that BDNF and FGF2 by activation of their respective receptors can 
activate both common and separate intracellular pathways. Neural progenitor 
cell-derived neurospheres express genes for many growth factors and their 
receptors (Einstein et al., 2006), indicating that many growth factors and signaling 
pathways were involved in neural progenitor proliferation and survival. 
In conclusion, these results suggest that regional environmental cues present in 
the OHSC play a strong role in the proliferation of cells and neurogenesis. Growth 
factors including BDNF and FGF2 have been implicated in the control of adult 
neurogenesis based on effects on proliferation and fate choice of adult neural 
progenitor cells both in vitro and in vivo. Here we demonstrated that BDNF 
delivered by MABs was effective on neurogenesis. FGF2 is an essential mitogen 
for multipotent neural progenitor maintenance and proliferation in vitro. Here we 
also demonstrated that supplementation of FGF2 augmented the mitogenic effect of 
BDNF. These observations suggest that BDNF and FGF2 play a prominent role in 
the generation and maintenance of a mitogenic and neurogenic environment in the 
OHSC system. 
 
3.4.2 Potential application 
The data presented here suggest that (i) the controlled and bioactive delivery 
of BDNF by engineered MABs is technically feasible; (ii) MABs might secrete 
factors promoting neurogenesis and cell proliferation; and (iii) the BDNF secreted 
by MABs contribute to promoting neurogenesis from endogenous progenitor cells. 
Together with the intriguing properties of MABs (e.g. general availability, specific 
homing etc., detailed in Research Background), transplantation of MABs-BDNF 
may be attractive to enhance endogenous regeneration as a strategy for the 
treatment of injure-related neurological disorders, like neurodegenerative disorders, 
epilepsy, stroke etc.  
Cell therapeutic interventions might involve both transplantation of stem cells 
and stimulation of the endogenous neurogenic response. The persistent 
neurogenesis and the presence of quiescent neuronal progenitors in human adults 
have been proposed as a source of transplantable neural cells. The neuronal 
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progenitors derived transplantation approach is, however, limited by the 
invasiveness of the procedure and low in vitro proliferation potential of these cells 
(Marshall et al., 2006). Another strategy is to stimulate endogenous neurogenesis 
by manipulating the environmental cues around neural progenitors. For instance, 
administration of neurotrophic factors, which differs from cell-replacement 
therapies based on delivery of ex vivo-derived neural cells to areas of injury or 
degeneration, could promote proliferation, survival of endogenous neural stem cells, 
or direct them to differentiate into neurons or glia. Neurons derived from such 
neural stem cells are capable of migrating to various regions of the CNS, receiving 
afferent innervation, forming axonal projections, and expressing neurotransmitters 
(Goh et al., 2003; Garzon-Muvdi and Quinones-Hinojosa, 2009). Thus, these neural 
stem cells may serve as a self-repair mechanism by enabling the restoration of 
damaged CNS circuitry. Stimulation of endogenous neurogenesis by neurotrophic 
factors (e.g. BDNF) delivered through MABs-BDNF transplantation might be an 
intriguing therapeutic option to be explored.
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4. PART III - Transplantation of MABs-BDNF 
4.1 Introduction 
Stem cells are emerging as an encouraging strategy for repopulating damaged 
tissues, and can also be genetically manipulated and used in cell-based gene therapy. 
Cell-based therapy may offer some degree of organ targeting with minimal 
invasiveness. The vessel associated stem cell, the mesoangioblasts described here, 
hold a great therapeutic promise because of their special properties. 
For instance, transplantation of MABs, delivered intra-arterially, has been 
shown to restore to a significant extent muscle structure and function in animal 
models of muscular dystrophy (Sampaolesi et al., 2003; Sampaolesi et al., 2006). 
Muscle fibers that have incorporated mesoangioblasts, as well as surrounding fibers, 
are protected from damage (Berry et al., 2007). MABs are known to functionally 
express various chemokine receptors, which might be responsible for the homing in 
different organs following tissue damage (Cossu and Bianco, 2003). The specific 
homing to tissue damage of transplanted MABs was not only demonstrated in 
dystrophic mice and dogs but also in heart failure, in which MABs homed in the 
damage heart and protected the cardiac muscle by inherently secreting NTFs after 
myocardial infarction (Galli et al., 2005). 
 These special properties of MABs received great interest as a cell-based NTF 
delivery strategy. To exploit the therapeutic potential of MABs in treating CNS 
disorders, we engineered MABs to continuously secrete BDNF (MABs-BDNF). 
MABs-BDNF are non-tumorigenic and capable of unlimited clonal expansion in 
vitro (Cossu and Bianco, 2003), and have the capacity of longterm survival, which 
make them suitable for cell transplantation. Our in vitro results showed in PART I 
and PART II, demonstrate the beneficial effects of the conditioned media from 
MABs-BDNF cultures, including promoting cells survival, maintaining neuronal 
function, and increasing neurogenesis. Thus, transplantation of the MABs-BDNF 
could be a new therapeutic approach for CNS disorders, such as neurodegenerative 
diseases, spinal cord injury, epilepsy, ischemic stroke. In these injure-related CNS 
disorders, MABs are not designed to be used for a cell replacement strategy, 
because they can not differentiate into neurons. MABs-BDNF graft are expected to 
home in the damaged brain and function as “minipumps” for local BDNF delivery, 
where the transgene BDNF and other factors (as detailed in the discussion of PART 
I and PART II) may favor neuroprotection and neurogenesis. These considerations 
prompt further investigations to determine whether implantation of MABs-BDNF 
could be used as a therapy for injure-related CNS disorders. 
In this part of the study, we explored the possibility of transplanting 
MABs-BDNF into the lesion brain induced by status epilepticus (SE). We selected 
an epilepsy model of temporal lobe epilepsy as our first attempt of MABs 
transplantation because: (i) our previous studies demonstrated the efficiency of 
NTFs gene therapy mediated by viral vectors in this model; (ii) BDNF (especially 
in combination with other NTFs) can prevent or repair seizure-induced damage 
(Simonato et al., 2006).  
94             PART III - Transplantation of MABs-BDNF               Chapter II: THE FINDINGS 
Temporal lobe epilepsy (TLE) is among the most frequent types of 
drug-resistant epilepsy (Diehl and Luders, 2000; Engel, 2001). Individuals affected 
with TLE typically have comparable clinical description, including an initial 
precipitating injury (IPI) such as status epilepticus (SE), head trauma, encephalitis 
or childhood febrile seizures (Harvey et al., 1997; Fisher et al., 1998). There is a 
pressing need to develop alternative therapeutic approaches that prevent the 
epileptogenesis that followed IPIs. TLE is frequently associated with hippocampal 
sclerosis, mainly exemplified by significant neurodegeneration in the dentate hilus 
(DH), and the CA1 and CA3c subregions (Sloviter, 2005). From this perspective, a 
new therapy that is efficacious for providing neuroprotection to the hippocampus 
after the onset of SE may have great significance. Based on a body of evidence 
from in vitro experiments, including primary hippocampal neuron culture and 
organotypic hippocampal slice culture, showing that MABs-BDNF can secrete 
BDNF and other factors to promote hippocampal cell survival and neurongenesis in 
the dentate gyrus, it seems that transplantation of MABs-BDNF to the hippocampus 
might provide an efficient restoration of the damaged hippocampus in the TLE 
model, which is vital for minimizing the incidence of chronic epilepsy. 
MABs-BDNF therefore hold great promise for the treatment of TLE. To 
pursue this aim, we applied the TLE models initiated by prolonged status 
epilepticus as IPI. After the onset of IPI, we transplanted MABs-BDNF through 
infusion in the peripheral blood. MABs are expected to home in the damaged 
hippocampus, settle down, and survive. In the hippocampus, MABs-BDNF are 
expected to 1) differentiate in situ in endothelial cells and repair microvessel 
damage, a possible cause and/or consequence seizures (Krizanac-Bengez et al., 
2004); 2) at the same time, to act as a reservoir and delivery system for NTFs. Thus, 
the pilot trial is to trace the infused MABs-BDNF in the brain of TLE animals.  
 
4.2 Methods 
Animals 
Adult male SD rats (Harlan, Italy), Swiss mice (Morini, Italy), and C57BL 
mice (Harlan, Italy) were used in this part of study. They weighed around 200-300 
g (Rat) or 30-50 g (Mouse) at the start of the experiment. The animals were caged 
individually. Ambient temperature was maintained at 21 ℃ and humidity at 55% 
with ad libitum access to food and tap water. Animals were kept on reversed 
12/12-h light-dark cycles. All efforts were made to minimize animal suffering. All 
procedures were carried out under European Community and national laws and 
policies.  
 
TLE animal models 
For rats, 1 mg/kg scopolamine was injected intraperitoneally 30 min before the 
injection of pilocarpine (300 mg/kg). Scopolamine is used to reduce the peripheral 
consequences of pilocarpine. The rat’s behavior was observed for several hours 
thereafter. Within the first hour after injection, all animals developed seizures 
evolving into recurrent generalized convulsions (SE). SE was interrupted 2 h after 
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onset by administration of diazepam (10 mg/kg i.p.). Animals required special care 
until they recovered from the acute insult and were closely tended, hydrated and 
fed.  
For mice, the above protocol with pilocarpine was used. A group of mice were 
induced with 20 mg/kg kainate (i.p.). Mice showed higher mortality than rats. 
Animal survive 2 hours of status epilepticus received transplantation of 
MABs-BDNF. The control groups received saline instead of pilocarpine or kainate. 
 
Transplantation procedures 
MABs-BDNF were passaged and amplified using the method described in 
PART I. In brief, cells were washed with sterile DPBS when they grew into 
70%-80% confluence on the bottom of the flask. Following the wash, cells were 
digested with TrypLE Express (GIBCO) for 1 min at room temperature. After 
centrifuging, cells were resuspended with saline at a density of 1.0×107/ml.  
In a separate experiment, the cells were pretreated with 1 μg/ml bisbenzimide 
(Hoechst 33342, Sigma) for 30 min, which provides strong fluorescent staining of 
cell nuclei by binding to DNA. Hoechst 33342 staining does not impair the viability 
of the cells. Hoechst 33342  staining seems to be maintained for several 
generations (at least 8 days in vitro).  
Animals were anesthetized with ketamine, and cells were injected via tail vein 
or left heart ventricle at a dose of 3×106 (for rats) or 5×105 (for mice). 
 
Cell tracing 
As described, MABs-BDNF were constructed with GFP, and exhibited green 
fluorescence. Therefore, GFP became the tracing marker for the grafted 
MABs-BDNF. The Hoechst 33342 staining was also used as a marker. In each time 
point, animals were sacrificed and the brains were put immediately into the cryostat 
for sectioning. Coronal sections were observed under the microscope to trace the 
cells marked with GFP or Hoechst 33342. To amplify the GFP signal, we also used 
immunohistochemistry for GFP. For GFP immunohistochemistry, brains were fixed 
in the formaline and embedded with paraffin. After routine section procedures, the 
sections including the dorsal hippocampus received immunohistochemistry for GFP. 
The procedure of GFP immunohistochemistry was similar to the one described in 
PART I, except for the replacement of anti-GFP antibody (1:100, Chemicon). 
 
4.3 Results 
To exploit the beneficial effects of MABs-BDNF demonstrated in vitro, we 
tested the transplantation of MABs-BDNF via peripheral blood infusion in an 
animal model with neuronal loss induced by prolonged generalized seizures. The 
entity of hippocampal damage was very similar in all animals. We injected the 
MABs-BDNF into peripheral blood circulation after the establishment of 
hippocampal damage and before the occurrence of SRSs, according to our protocol 
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that used for NTFs gene therapy (Paradiso et al., 2009).  
After the establishment of damage with prolonged status epilepticus induced 
by either kainite acid or pilocarpine, MABs-BDNF were infused into the blood 
circulation and traced in the brain with GFP. Unfortunately, we did not find any 
clear deposition in the brain of the infused MABs-BDNF using different strains of 
animal, alternative infusion sites, different numbers of transplanted cells, and a 
range of injection and examination time points in this model (as indicated in Table 
1). The hippocampal damage is pronounced in this model, and we expected that 
MABs-BDNF could home to the damaged site. Thus, we examined extensively the 
hippocampus using immunohistochemistry for GFP in continuous sections. As 
shown in Fig. 8, no signal was present in the hippocampus. To find out whether the 
injected MABs-BDNF home in other regions of the brain, we marked the 
MABs-BDNF with chelated paramagnetic ions and scanned the whole brain after 
cell transplantation using nuclear magnetic resonance imaging. Still, there was no 
signal of the injected MABs-BDNF in the brain. 
 
 
Table 1 Systemic infusions of MABs-BDNF in the TLE model  
Animal/Strain Model Sample 
Size 
Days Injec.  Dose of 
cell 
Injection 
Methods 
Tracing 
Marker 
Days 
Exam. 
Rat/SD PILO 2 4 days 3×106 Intracardial GFP 5 days 
Rat/SD PILO 2 4 days 3×106 Tail vein Hoechst 5 days 
Rat/SD PILO 1 4 injections* 3×106 Intracardial Hoechst 10 days 
Mouse /Swiss KA 2 1 day 5×105 Intracardial Hoechst 2 days 
Mouse /Swiss KA 2 1 day 5×105 Intracardial GFP 5 days 
Mouse /C57BL KA 2 1 day 5×105 Tail vein Hoechst 2 days 
Mouse /C57BL PILO 3 2 day 5×105 Intracardial GFP 5 days 
Mouse /C57BL PILO 6 1 day 5×105 Intracardial GFP 2 days 
Annotate: Days Injec., intervals between Status Epilepticus (SE) and MABs treatment; Days Exam., intervals 
between MABs treatment and sacrificing. Abbrievation: KA, Kainate; PILO, pilocarpine. * The rat was 
pretreated with MABs 1 day before PILO-induced SE, and subsequently injected with MABs every 3 days (4 
injections). 
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Fig. 8 Cell tracing using immunohistochemistry to detect GFP-positive cells in a 
pilocarpine induced epilepsy mouse model. The figures illustrate the missing 
trace of MABs-BDNF deposition in the hippocampus, the main damage area 
after peripheral infusion. (A) Control in which MABs-BDNF were intracranially 
injected, in order to ascertain the validity of the method. As indicated by the 
arrows, the MABs-BDNF were located in the ventricle with green signals. 
However, we did not find such assured GFP signals in (B) the normal mice, and 
(C) the mice underwent status epilepticus, after peripheral infusion of 
MABs-BDNF.  
C 
A B
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4.4 Discussion 
4.4.1 Epilepsy and NTFs 
Epileptic seizures can have severe and lasting effects on the architecture of the 
brain (Diehl and Luders, 2000). Following an epileptogenic insult, a cascade of 
neurobiological events such as neuronal cell death, enhanced neurogenesis, axonal 
sprouting, and reactive gliosis occur in distinct but overlapping sequences, which 
lead to the occurrence of spontaneous seizures and to the diagnosis of epilepsy 
(McNamara, 1994; Beach et al., 1995). This phenomenon is termed 
“epileptogenesis”. One of the earliest consequences of prolonged seizure activity is 
the selective neuronal loss observed in specific subfields of the hippocampus 
(Schwob et al., 1980; Nadler, 1981; Mello et al., 1993; Lynch et al., 1996). NTFs 
are natural candidates for mediating these pathological events that follow seizure, 
as they have well-known roles in regulating neuronal birth, death, and the 
reorganization of connectivity, and more recent data show their functional effects at 
the synaptic level with distinct modulatory actions at excitatory and inhibitory 
synapses (Schinder and Poo, 2000). 
However, the epileptogenic or antiepileptogenic effects of various NTFs 
following brain insults like seizures are still being studied. With specific reference 
to the BDNF, epileptogenic insults have been reported to increase BDNF synthesis 
and activation of its high affinity receptor, TrkB (Binder et al., 1999a; Binder et al., 
2001), indicating an activation of the system during epileptogenesis. The effect of 
this activation, however, remains unclear. Many studies support the notion that 
BDNF play a pro-epileptogenic role. In particular, the observation that 
epileptogenesis is completely abolished in Synapsin-Cre conditional TrkB knockout 
mice, in which TrkB is ablated in hippocampal granule cells and CA3 pyramidal 
neurons, argues that TrkB activation plays an essential, and not merely regulatory, 
role in epileptogenesis (He et al., 2004). Another study showed that 
intracerebroventricular administration of BDNF accelerates the development of 
kindling (Xu et al., 2004a). It was also suggested that long-term suppression of 
BDNF after the SE  may be beneficial for diminishing the mossy fiber sprouting 
as well as the incidence of chronic epilepsy after an IPI (Scharfman et al., 2002b). 
BDNF may also exert beneficial effects at different times in the natural history of 
the disease (Palma et al., 2005). Furthermore, our groups previously demonstrated 
that BDNF favors survival and regeneration of hippocampal neurons damaged by 
SE (Simonato et al., 2006). In our previous studies, local NTFs (BDNF and FGF2) 
gene delivery into hippocampus, when administered after brain damage onset, 
could exert restorative actions via promoting neuronal survival, stimulating 
proliferation of endogenous neural progenitors and directing them to differentiate 
along the neuronal lineage, thus interrupting the development of chronic epilepsy 
with reduced occurrence of spontaneous seizures (Paradiso et al., 2009). Extensive 
studies testing whether the various conditions (e.g. time, location, concentration, 
combination etc.) of administration of distinct neurotrophic factors (or the other 
strategies that maintain higher levels of distinct neurotrophic factors in the brain) 
after the onset of the SE is effective for preventing epilepsy are needed for further 
advances in this field. 
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In general, it is thought that neuronal loss plays a causal role in 
epileptogenesis and progression and that increased neurogenesis after IPI represents 
an attempt to repair damage (McNamara, 1994). This concept leads to the 
development of two strategies: neuroprotective strategy and cell replacement 
strategy. Neuroprotective strategy aims to salvage, protect and repair neurons in 
post-SE condition, while cell replacement is to reconstruct the disrupted circuitry 
via self-repair mechanism of endogenous neural progenitor cells or integration of 
transplanted stem cells (or neural tissue). An increased focus for developing 
neuroprotective and/or proneurogenesis interventions is vital for minimizing the 
incidence of chronic epilepsy (Bonde et al., 2006; Acharya et al., 2008). 
Transplantation of MABs-BDNF seems likely to be suitable for the strategy 
according to our in vitro results. 
 
4.4.2 Ineffectiveness of MABs-BDNF systemic infusion in the 
TLE model 
MABs have been reported to home in damage areas like skeletal muscle 
(Sampaolesi et al., 2006) and myocardial tissue (Galli et al., 2005) after systemic 
infusion, but have never been tested in CNS. We aimed to exploit the application of 
MABs in the CNS. In the pilot attempt of MABs-BDNF transplantation using a 
brain damage model induced by prolonged status epilepticus, we failed to find the 
deposition of MABs-BDNF after peripheral infusion in blood circulation. The 
reasons for the absence of MABs-BDNF in the damage brain might be multiple. 
The homing mechanism of MABs to the damage areas remains unclear, possibly 
relating with various cytokines and adhesion molecules. In particular, it was shown 
that a cytokine, high mobility group box 1 (HMGB1), which is released in the 
extracellular milieu by necrotic and inflammatory cells, induces migration and 
proliferation of MABs, and promotes their homing to damage area (Palumbo et al., 
2004). To date, the released cytokines or inflammatory response in seizure-induced 
brain damage have not been elucidated. Cells in the CNS that can produce 
cytokines upon activation include macrophages, microglial cells, astrocytes, and 
cerebral endothelial cells (de Boer and Breimer, 1998). It was proposed that 
cytokines produced by these cells after seizures may influence the transport of 
compounds into the brain by opening the blood-brain barrier (BBB) (de Boer and 
Breimer, 1998). The BBB is a physical and metabolic barrier which serves to 
regulate and protect the microenvironment of the brain (Zlokovic, 2008). The 
tightness of the BBB is a serious hindrance to the entry of both immunocompetent 
cells and graft cells. Thus, the permeability of the BBB might be one of the factors 
leading to the failure of deposition of MABs-BDNF from the blood. It is well 
known that epilepsy or seizures are linked with not only neurodegeneration in 
several areas of the brain but also with the compromised integrity of the BBB 
(Wasterlain and Shirasaka, 1994; Jacobs et al., 2000; Armstrong, 2005). The BBB 
plays an active role in the mediation of neuroimmune responses, either by the 
production of inflammatory mediators or by expression of adhesion molecules. In 
in vitro studies, MABs were able to efficiently cross endothelium-coated filters in 
vitro when the other side held either mature myotubes (because the mature mytubes 
100             PART III - Transplantation of MABs-BDNF               Chapter II: THE FINDINGS 
secrete sufficient cytokines) or muscle-associated cytokines, such as SDF-1 
(Galvez et al., 2006; Palumbo et al., 2007). In addition to cytokines, adhesion 
molecules also improved migration (Peault et al., 2007). We expected that 
MABs-BDNF could be attracted by the adhesion molecules or inflammatory 
mediators and migrate across the endothelial cell monolayer. However, the 
MABs-BDNF in the blood vessels could not be detained in the epileptic brain, 
possibly due to the insufficient release of molecules in response to the damage or 
exclusion by the BBB. Thus, it is important to create a permissible, biocompatible 
environment that allows for cell infiltration, which is the prerequisite for 
MABs-BDNF to exert their by-stander effects. Studies revealed that the 
administration of IL-1, IL-6, TNF-α, and IFN-γ, increase endothelial permeability 
(Freyer et al., 1999; Rivest, 1999; Schilling and Wahl, 1999), which might be 
helpful for the MABs-BDNF transplantation in brain. In fact, transfection of 
mesoangioblasts with L-selectin or α4 integrin increases the cells’ migration 
efficiency across endothelium-coated filters. L-selectin and α4 integrin are not 
normally expressed by mesangioblasts, but are known to help leukocytes migrate 
through vessel walls into nearby tissues (Galvez et al., 2006). These strategies, 
which were demonstrated to improve the homing ability of MABs in a mouse 
model of muscular dystrophy, might also be applied to improve the MABs-BDNF 
transplantation in the CNS in future exploration. 
Another possible cause for the failure of MABs-BDNF transplantation might 
be the immune rejection. A common problem with cell transplants is their limited 
survival and interaction with the host tissue. It is important to enhance survival and 
integration of donor cells in the host tissue to further advance cell transplantation 
therapy. During the exploration of MABs-BDNF transplantation, we have tried to 
avoid allogeneic transplantation by using C57BL mice (the MABs-BDNF was 
isolated from C57BL embryonic aorta). However, the uncertain brain damage in the 
model established from C57BL mice confounded the analysis. The type, duration 
and intensity of seizures relating with brain damage and BBB integrity may be 
additional confounding factors in this experiment. Moreover, there are still other 
hurdles to be taken in considerations such as the number of injected cells, the route 
of administration, the time of transplantation and so on.  
 
4.4.3 Alternative MABs-based NTF delivery strategies 
In spite of the ineffectiveness of MABs-BDNF transplantation via peripheral 
vessels in the TLE model, MABs-BDNF are still promising for future applications, 
based on the findings in vitro of their markedly beneficial effects on brain tissue. 
Up to now, the peripheral infusion of the MABs-BDNF did not meet our 
expectation to target the damaged area in the TLE model. However, the 
neuroprotective and neurogenic therapy using NTF delivery strategy is efficient in 
the treatment of the TLE model according to our previous report. Together with the 
present data showing the beneficial effects of MABs delivered NTFs, further 
explorations on the transplantation of MABs-BDNF are worth carrying on by 
changing graft strategy. 
Intravenous (i.v.) injection is less invasive, and can be more readily carried out 
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in the clinic compared with the intracerebral injection. However, it has been 
estimated that less than 1% of i.v.-injected stem cells reached and survived in the 
lesioned brain after stroke (Chen et al., 2001b). The local intracerebral 
transplantation can reduce the number of transplanted cells and target directly the 
lesioned area, despite the surgical risk. In our case, intracerebral transplantation 
may be an alternertive route to seed MABs-BDNF in the leasioned brain. 
Compared with intraparenchymal injection, the intracerebroventricular delivery of 
cells allows more cells to be delivered, and produces more extensive cell seeding. 
In a preliminary experiment, the MABs-BDNF were found seeding along the 
ependyma and surviving for at least 4 weeks after the intracerebroventricular 
injection of the MABs-BDNF in a normal mouse brain (data not shown). 
Ependyma is the thin epithelial membrane lining the ventricular system of the brain. 
The seeded MABs-BDNF might secrete NTFs into the CSF and change the 
extracellular milieu throughout the brain and spinal cord. The central delivery of 
NTFs in the CSF may not be suitable for the local NTF delivery strategy for 
epilepsy, but may represent an alternative means of enabling neuroprotection or 
neuronal regeneration in diseases such as stroke, trauma etc. If trophic factors prove 
to be a worthwhile therapeutic strategy, the method of delivery via the MABs 
intracerebroventricular transplantation will certainly be intestesting. To date, 
administration of trophic factors has been limited to intraventricular infusions using 
pumps or cannulae.  
To compromise the ineffective homing ability of MABs-BDNF in the TLE 
model, cell encapsulation technology might be another option. This strategy 
involves the use of genetically engineered producer cells that secrete a protein with 
therapeutic potential (Maysinger et al., 1994). The cells are encapsulated initially in 
an immunoisolating material that makes them suitable for transplantation. The 
capsules, or bioreactors, permit the release of recombinant proteins like NTFs that 
may assert their effects in altering the microenvironment. There has been 
significant progress in the development of encapsulation technologies that comprise 
devices for both macro- and microencapsulation (Visted et al., 2001). In a 
macroencapsulation like encapsulated cell biodelivery (ECB) strategy, the 
MABs-BDNF might be placed in semipermeable capsules and implanted into the 
targeted area (e.g. hippocampus in the case of TLE), where the cells release the 
necessary NTFs while the capsule protects the implanted cells against the host 
immune system (Maysinger et al., 1994). The dose and the duration of treatment 
can be conveniently controlled in the delivery system. A wide spectrum of cells and 
tissues has been encapsulated and implanted, both in animals and humans, 
indicating the general applicability of this approach for both research and medical 
purposes, including CNS disorders (Visted et al., 2001). For example, 
transplantation of immortalized cell lines genetically engineered to produce γ 
-aminobutyric acid(GABA) appears to reduce excitability in chronic epilepsy 
models (Gernert et al., 2002; Thompson and Suchomelova, 2004). Similar results 
were also seen after transplantation of encapsulated fibroblasts genetically 
engineered to produce adenosine (Guttinger et al., 2005). 
The MABs-BDNF transplantation via systemic circulation may be tested for 
treating other injury-related CNS disorders, like neurodegenerative diseases, stroke, 
trauma etc. Because of the inability of CNS neurons to regenerate injured axons 
unaided, the vulnerability of injured neurons, and the non-permissive nature of the 
CNS environment, damage to brain and spinal cord produces devastating 
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consequences with, until recently, little hope of significant recovery. Using MABs 
as NTF delivery vehicles offers a new option to treat CNS injury. Trials of 
cell-based NTF delivery have now been performed in Parkinson’s disease (Nakao 
et al., 2000; Kakishita et al., 2003; Villadiego et al., 2005; McKay et al., 2006), 
Huntington’s disease (Martinez-Serrano and Bjorklund, 1996), spinal cord injury 
(Lu et al., 2003), stroke (Kameda et al., 2007). MABs-BDNF transplantation might 
meet the demands of targeted drug delivery strategies for NTFs in these CNS 
diseases.  
As a whole, the strategy of using MABs as a local delivery vehicle of NTFs is 
promising in many CNS disorders, despite a number of difficulties that need to be 
overcome. The present transplantation trial is preliminary, and more comprehensive 
investigations are in program. Much effort for the application of MABs-BDNF will 
mainly in the fields of improving the homing ability, testing intracranial 
transplantation, and attempting treatment of injury-related CNS disorders.
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5. Conclusion 
In conclusion, our study reveal that BDNF exerts a dose-dependant protective 
effect in the low-density primary hippocampal neuron culture and in the adult 
organotypic hippocampal slice culture. MABs genetically engineered with BDNF 
can secrete bioactive BDNF in culture. Our data also demonstrate that treatment 
with conditioned media derived from MABs-BDNF cultures highly prevents the 
death of neurons in vitro due to a synergy between the engineered BDNF and other 
factors produced intrinsically by MABs. Moreover, the MABs-BDNF conditioned 
media allowed retention of morphologic characteristics and functional connections 
in adult slice cultures in comparison with the MABs media and the control. 
Neurogenesis analysis in the cultured slice showed that the combination of BDNF 
and FGF2 promoted gliosis and neurogenesis, while the MABs-BDNF conditioned 
media promoted neurogenesis and proliferation of glia cells. The present data 
indicate that MABs-BDNF may be a potential donor source for cell-based 
protective and regenerative therapy for injure-related CNS disorders. Although 
evidence of MABs-BDNF deposition in the brain was not obtained in a first 
attempt in which the MABs-BDNF were infused via peripheral blood vessels in the 
TLE model, the beneficial effects of the MABs-BDNF on neurons encourage a 
more extensive exploration of their therapeutic potential of the MABs-BDNF. 
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6. Future outlook: opportunities and challenges 
In the study, we demonstrate the neuroprotective and neurogenesis effects of 
exogenous BDNF including BDNF genetically delivered by engineered MABs. 
These findings raise the possibility that exogenous administration of BDNF might 
be developed into a strategy for functional preservation and restoration in 
neurological diseases associated with brain damage. The supplementation of BDNF 
and other NTFs could be essential to sustain the survival and functional recovery of 
neurons by modulating the post-injury microenvironment. Ideally, neurotrophin 
delivery to the nervous system should be target-specific, regionally restricted, 
chronic, safe, well-tolerated and of sufficient concentration to elicit responses from 
target neurons. Cell-based NTF delivery may be optimal to meet these criteria. In 
recent years, implantation of genetically modified cells for supplementation of 
NTFs has been tried. In most of these paradigms, the cells only functioned as the 
vehicles for the NTFs secretion. MABs seem to be an attractive alternative cell 
source for NTF delivery. These cells are able to expand to virtually unlimitedly in 
vitro, so that they are amenable to genetic modification. Indeed, we found major 
advantages of BDNF delivery using the MABs engineered with BDNF 
(MABs-BDNF), which proved very efficient in neuroprotection and neurogenesis. 
We also demonstrated that it was the coaction of BDNF and MABs inherently 
produced factors that led to the markedly beneficial effects on neurons. Although 
further studies are required to identify these factors, our study suggests that the 
soluble mediators from MABs might play a role in the future as therapeutic agents 
or in transplantation.  
Exploiting stem cells for NTF delivery offers great potential, with cells 
functioning as biologically active systems to produce specific beneficial factors or 
to replace lost cells and tissue. Though MABs may not replace lost neurons by 
themselves according to the present knowledge, the transplantation of 
MABs-BDNF may stimulate and augment endogenous neural stem cell populations 
with more neurons being formed through a ‘bystander’ mechanism that is 
alternative to cell replacement. The endogenous neurogenesis and migration of 
precursor cells have been reported to replace some lost neurons in brain structures 
such as striatum, and a significant portion of the new neurons seems to reestablish 
the connection to the striatum with supplementation of the appropriate NTFs 
(Arvidsson et al., 2002). The findings that the secreted factors from MABs-BNDF 
promote neurogenesis are of significant interest for regenerative therapies. 
Together with the data showing that the conditioned media from MABs-BDNF 
greatly improved the survival of neurons in culture, the advantages of transplanting 
MABs-BDNF in the damaged brain seem to include the ability to target multiple 
neuroprotective and neuroregenerative mechanisms and the ability to provide a 
sustained treatment. The transplanted MABs-BDNF may provide an optimal 
environment for tissue repair in the damaged brain, with low chronic dosing of 
BDNF and other beneficial factors. MABs-BDNF may migrate to inflammatory or 
injure sites, produce BDNF and change the environment of nearby neurons, thus 
improving the bioavailability of the main neurotrophins. This is a potentially novel 
therapeutic approach which might be used in the injury-related diseases of the CNS 
in which drug access is limited. However, there are many difficulties before its 
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clinical application. First, slice culture (from which the data were obtained) cannot 
duplicate all the features of the brain. Some of these differences may limit the 
neuroprotective qualities of the BDNF delivered by MABs-BDNF in intact animals 
compared with brain slices. Second, the homing ability of MABs may probably be 
lost because of the differences of inflammatory mechanism between CNS and 
muscle tissue (it was indicated that the inflammatory molecules were one of the 
homing mechanism of MABs in muscular dystrophy and myocardiac infarction). In 
this study, we tried to use prolong-seizure induced brain damage as a model to 
transplant MABs-BDNF through peripheral infusion. The lack of evidence of 
MABs-BDNF deposition in the brain reminds us that the homing ability of MABs 
is more complicated than expected. Even if we directly intracranially transplant 
MABs-BDNF in damage area, there are still some drawbacks which may be 
encountered in animal experiments including surgical grafting process, 
non-specificity of the transduced cells, unstable expression of the transgene, 
disruption of host circuitry, aberrant fiber growth, and the potential for graft 
rejection or tumor formation. Another problem associated with cells transplantation 
relates to the quasi-impossibility of retrieving the cells once implanted, a 
problematic limitation in the case of occurrence of serious adverse effects. This 
limitation could be corrected by the use of encapsulated cell biodelivery systems or 
using inducible promoters that allow controlled transgene expression through the 
intake of a small molecule that can cross the BBB. 
Nevertheless, the data presented here suggest that transplantation of 
MABs-BDNF is an alternative, and possibly more efficacious, therapeutic approach. 
that may be further developed as a neuroprotective and neurogenic therapy to treat 
brain diseases caused by neurodegeneration, including multiple sclerosis, epilepsy, 
stroke, and spinal cord trauma. Another possible exploitation of the beneficial 
effects of MABs-BDNF might be the combination with biomaterial scaffolds. 
Biomaterial-based strategies include those where the biomaterial itself has some 
therapeutic benefit or serves as a delivery vehicle for growth factors and 
extracellular matrix proteins, with the goal of recruiting host cells or enhancing 
axonal growth. When used as a delivery vehicle for cells, biomaterials must provide 
a suitable microenvironment for cell survival, tissue regeneration, and host tissue 
integration. For example, the development of encapsulated cell biodelivery (ECB) 
might provide a way for the application of MABs-BDNF. The delivery of cells in 
suitable biomaterials may lead to greater donor cell survival and thus greater 
benefit. However, this technique is invasive since it involves the stereotactic 
surgical injection and delivery of cells into a limited area or into the cerebral 
ventricles for a more global delivery. In terms of the routes of cell transplantation, 
an effective global delivery of cells to the brain is almost impossible when treating 
neurological disorders with diffuse neuropathology, such as Alzheimer’s disease, 
most malignant brain tumors and inherited metabolic disorders. Direct 
intraparenchymal injection may generally restrict the diffusion of the MABs-BDNF, 
but restrict the number of the graft cells at the same time. Intraventricular injection 
to achieve more global delivery results in bihemispheric distribution through the 
ventricles, but the adverse effects of NTFs might be more serious. Therefore, in the 
future exploitation of MABs-BDNF cell therapy in the CNS diseases, the routes of 
transplantation should be seriously considered.  
MABs-BDNF so far can be viewed as candidates for cell-based NTF therapy, 
but there are several obstacles before clinical application. This study is of heuristic 
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value for future development of cell-based NTF delivery. Using this study as a 
template, advances can be made. For example, stem cells can be engineered to 
produce other genes such as transmitters, anti-apoptotic genes. Other cell sources, 
like neural progenitor cells, or embryonic stem cells, might also be exploited into a 
neuroprotective or neurogenic agent by genetically engineering them to produce 
suitable NTFs.  
Despite the numerous challenges that exist in the definition of the conditions 
for a successful treatment, MABs-BDNF hold great promise in the treatment of 
brain damage. 
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A loss of neurons is observed in the hippocampus of many patients
with epilepsies of temporal lobe origin. It has been hypothesized
that damage limitation or repair, for example using neurotrophic
factors (NTFs), may prevent the transformation of a normal tissue
into epileptic (epileptogenesis). Here, we used viral vectors to
locally supplement two NTFs, fibroblast growth factor–2 (FGF-2)
and brain-derived neurotrophic factor (BDNF), when epileptogenic
damage was already in place. These vectors were first character-
ized in vitro, where they increased proliferation of neural progen-
itors and favored their differentiation into neurons, and they were
then tested in a model of status epilepticus-induced neurodegen-
eration and epileptogenesis. When injected in a lesioned hip-
pocampus, FGF-2/BDNF expressing vectors increased neuronogen-
esis, embanked neuronal damage, and reduced epileptogenesis. It
is concluded that reduction of damage reduces epileptogenesis
and that supplementing specific NTFs in lesion areas represents a
new approach to the therapy of neuronal damage and of its
consequences.
epilepsy  gene therapy  neurotrophic factors
Epilepsies originating in the temporal lobe of the brain are themost common in adults. In patients with these diseases, focal
pathological abnormalities can be observed, the most prominent
of which is a loss of neurons in the hippocampus termed
hippocampal sclerosis. These abnormalities develop in a previ-
ously healthy tissue, often after an initial ‘‘epileptogenic’’ event
that can produce damage (for example, an episode of prolonged,
uncontrolled seizures know as status epilepticus [SE]). After a
latent period of weeks to years, epileptogenic events my be
followed by the occurrence of spontaneous recurrent seizures
(SRS), i.e., epilepsy (1). Unfortunately, currently available an-
tiseizure drugs do not prevent this process.
It can be hypothesized that embanking or repairing damage
may lead to antiepileptic effects (1). To date, however, the
treatment of diseases associated with neuronal death has been
restricted to attempts to prevent or limit the damage. More
recently, the discovery of neural stem cells disclosed two new
approaches: the transplantation of stem cells and the recruit-
ment of endogenous stem cells for generating new neurons by
means of extracellular proliferation/differentiation factors (2).
In view of all approaches, key extracellular regulators of neuron
survival and of stem cell proliferation and differentiation into
neurons are the neurotrophic factors (NTFs) (3).
Endogenous NTFs are actually produced after an epilepto-
genic insult, but they remain insufficient or inadequate for
neuroprotection and/or for providing the endogenous stem cells
with the proper cues to proliferate, differentiate into neurons,
and restore function (4, 5). In fact, damage ensues and a reactive
neurogenesis occurs but fails to repair it (1). The aim of this study
was to attempt suppressing neuronal damage and preventing the
development of epilepsy by means of a local supplementation of
specific NTFs within the lesioned, epileptogenic tissue.
To pursue this aim, we generated a viral vector expressing a
combination of fibroblast growth factor–2 (FGF-2) and brain-
derived neurotrophic factor (BDNF). We chose this combina-
tion because: (i) both these NTFs have neuroprotective prop-
erties; (ii) FGF-2 potently induces proliferation of hippocampal
progenitors (6, 7); (iii) BDNF is required for neuronogenesis in
the hippocampus (8–10). We used replication-defective herpes
simplex virus–1 (HSV-1) vectors, for multiple reasons (11): they
efficiently infect nonreplicating cells such as neurons; they can
accommodate large inserts; they do not integrate their genome
into the host DNA (that is, there is nomutagenesis risk); they can
be transported retrogradely in neurons (therefore, transgene
expression can occur in remote areas through nerve terminals
afferent to the injection area); and finally, they produce a
transient transgene expression: It is desirable to obtain transient
expression of NTFs, because NTFs can trigger plastic changes
that remain detectable when they are no longer expressed,
whereas their long-term expression may be detrimental for brain
function (12).
Results and Discussion
Vectors.A schematic representation of the vectors we used is shown
in supporting information (SI) Fig. S1. For FGF-2, we used a
previously characterized vector, TH-FGF2 (13), in which the
transgene was under the control of the human cytomegalovirus
(HCMV) immediate-early (IE) promoter. For BDNF, we used a
vector, T0-BDNF, in which the transgene was under the control of
the ICP0 promoter. The double mutant (TH-FGF2/0-BDNF) was
obtained by crossing over TH-FGF2 and T0-BDNF. Promoters
were chosen to promote a synergy between the NTFs, making use
first of the FGF-2 property of potently inducing proliferation of
hippocampal progenitors and then of the BDNF property of
inducing their neuronal differentiation: the HCMV IE promoter
driving FGF-2 is known to ensure robust, but transient, transgene
expression, whereas the ICP0 promoter driving BDNF provides a
longer-lasting expression (14).
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The vector-induced transgene expression and the biological
activity of the NTF proteins produced by infected cells were first
studied in vitro. The data we obtained (SI Text ‘‘In vitro
Characterization’’ and Fig. S2) indicate that: (i) vectors induce
production and release of FGF-2 and BDNF at biologically
active levels; and (ii) FGF-2 and BDNF supplied together, not
individually, potently favor survival, proliferation, and neuronal
differentiation of neural progenitors. Therefore, we elected to
test the vector expressing FGF-2 and BDNF together in vivo.
The efficiency of infection and the time-course of transgene
expression in vivo was examined after a single stereotaxical
inoculation of the vector in the hippocampus of adult rats (SI
Text ‘‘Transgene Expression in Vivo’’ and Fig. S3). The data
show that inoculation of TH-FGF2/0-BDNF provides a bilateral,
short-term (1 week) increase in FGF-2 expression accompa-
nied and followed by a bilateral, slightly longer-lasting (at least
11 days) increase in BDNF expression, and that these events are
not associated with significant toxicity.
Effects on SE-Induced Cell Death and Neurogenesis. We tested
TH-FGF2/0-BDNF on the pilocarpine SE–induced neurodegen-
eration and epileptogenesis. In this epilepsy model, an episode
of SE produces intense neuronal damage and, after a latent
period of 2–3 weeks, SRSs, i.e., epilepsy (15).
In the present experimental series, pilocarpine (300mg/kg i.p.)
rapidly induced a robust convulsive SE (latency, 15 2 minutes)
that was interrupted after 2 hours through administration of the
anticonvulsant diazepam (10 mg/kg i.p.). Based on behavioral
observation and EEG recordings, the severity of SE in the
different animals was indistinguishable. This procedure caused
damage in several brain areas: in particular (16, 17), hippocam-
pal damage closely resembled human hippocampal sclerosis and
was invariably remarkable. Typically, 3 days after pilocarpine
administration, Fluoro-Jade C (FJC) staining allowed identifi-
cation of several degenerating cells in CA1, CA3, and the hilus
of the dentate gyrus. A pronounced edema with cell loss was also
evident. A three-dimensional structural reconstruction demon-
strated a 27.8  3.1% reduction of hippocampal volume 3 days
after pilocarpine administration, as compared with the response
on control animals (P  0.001, Mann-Whitney U test for
unpaired data).
Three days after SE, these lesioned animals were randomly
assigned to three groups: one group was injected in one hip-
pocampus with the vector expressing FGF-2 and BDNF; the
second group was injected with a control vector; and the third
group was not treated at all (no difference was observed between
these latter two groups in any of the parameters examined, and
therefore they have been pooled together for statistical analysis,
and collectively termed ‘‘control’’). To explore the mitogenic
effect of the vectors, animals were treated with bromo-
deoxyuridine (BrdU, four 50-mg/kg i.p. injections, one every 2
hours) 6 days after SE (i.e., 3 days after vector inoculation, Fig.
S4). This time point was chosen because it is both within the peak
of SE-induced proliferation of neural stem cells (18) and of
vector-induced overexpression of FGF-2 (see above). A subset of
animals in each group was killed 14 days after SE (i.e., 11 days
after vector inoculation) to examine possible effects on cell
survival and neurogenesis, and another subset was killed 28 days
after SE (25 days after vector inoculation) to examine tissue
morphology. These latter animals also underwent 20 days be-
havioral and EEG monitoring, to examine the outcome of the
treatment (Fig. S4).
Although the bulk of SE-induced damage is in the first few
days and, thus, was already in place when we injected the vector,
several degenerating cells were still observed 14 days after
pilocarpine administration in different hippocampal subfields
(CA1, CA3, hilus of the dentate gyrus; Fig. 1Aa and Ac).
Administration of the vector expressing FGF-2 and BDNF did
not alter this ongoing cell loss, except for a slight, nonsignificant
attenuation in the injected hippocampus (Fig. 1), indicating that,
in vivo, the neuroprotective effect of this vector is limited or may
require more prolonged or higher-level transgene expression.
In contrast to the limited effect on cell death, the effect of the
vector expressing FGF-2 and BDNF on neurogenesis was quite
remarkable. In the adult hippocampus, neural progenitors are
found both in the subgranular zone (SGZ) and in the caudal
subventricular zone (SVZ). SE has been reported to increase
proliferation of hippocampal progenitors in both areas, but SGZ
progenitors differentiate into neurons that, in large part, migrate
ectopically to the hilus and SVZ progenitors differentiate into
glial, not neuronal, cells: that is, SE-induced neurogenesis is
aberrant and may contribute to epileptogenesis (19, 20).
We used pulse-chase BrdU labeling and immunohistochem-
istry for markers of progenitors to determine the mitogenic and
differentiative activity of the NTFs supplemented by the vectors.
To explore the mitogenic effect, we counted BrdU-positive cells
in the dorsal hippocampus 14 days after pilocarpine. As ex-
pected, SE per se induced a significant increase in the number of
Fig. 1. (A) Effect of the treatmentwith the vector expressing FGF-2 andBDNF
together (TH-FGF2/0-BDNF) on SE-induced ongoing damage. Degenerating
cells aremarkedwith FJC (green); nucleimarkedbyDAPI (blue). Fourteendays
after pilocarpine (pilo)–induced SE (14d), ongoing hippocampal damage was
still detectable in animals injectedwith the control vector (control), especially
in the CA3 area (Aa) and in the dentate (Ac). This pattern was identical to the
pattern observed in untreated animals (not shown). In animals treated with
TH-FGF2/0-BDNF (FGF2-BDNF), a reduction, but not the abolishment of dam-
agewas observed (Ab andAd). Horizontal bars, 25m in (Aa) and (Ab) and 50
m in (Ac) and (Ad). (B, C) Quantification of neurodegeneration. Shown is the
percentage of FJC-positive pixels in the hippocampus (B) and the degenera-
tion index (C), calculated as described inMaterials and Methods, in naïve rats
(yellow bars) and pilocarpine-treated rats, injected with either the control
vector (gray bars) or TH-FGF2/0-BDNF (green bars). I, injected (ipsilateral)
hippocampus; C, noninjected (contralateral) hippocampus. Data are means
SE for seven to eight animals per group. *P  0.05, **P  0.01 vs. naïve;
Kruskal-Wallis test. No significant difference was observed between pilo –
control vector and pilo – FGF2-BDNF.
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mitotically active cells (Fig. 2 and Fig. S5). In keeping with
previous reports (6, 18, 20), this increase was observed in the
dentate gyrus and in the pyramidal gyrus (especially CA1 strata
oriens and lacunosum-molecularis, near the SVZ). Inoculation
of the control vector did not alter this pattern. In contrast,
inoculation of the vector expressing FGF-2 and BDNF produced
a further, bilateral, highly significant increase in the number of
BrdU-positive cells (Fig. 2A), indicating proliferation of pro-
genitors. Notably, an increased number of positive cells was also
observed in the ventral hippocampus (Fig. S6).
In both the SGZ and SVZ, a series of differentiation steps
have been described: from early, glia-like progenitors (termed
type-1 for SGZ and type-B for SVZ), to transiently amplifying
cells (type-2 and type-C), to late, migrating cells (type-3 and
type-A) (21, 22). Type-1 and type-B cells are positive to GFAP,
nestin, and Sry-related HMG box transcription factor (Sox2);
type-2 and type-B cells to nestin and Sox2, but not to GFAP;
type-3 and type-A cells to doublecortin (DCX) (22, 23). Pilo-
carpine SE per se significantly increased the number of nestin-
positive cells in the hippocampus as compared with naïve
controls, but treatment with TH-FGF2/0-BDNF dramatically
potentiated this effect, more markedly in the injected hippocam-
pus (Fig. 2A). Many (20%) of these nestin-positive cells were
also BrdU-positive, indicating that part of them were actively
proliferating at the time of BrdU administration (Fig. 2A).
Furthermore, a subset of these cells was also GFAP-positive
(Fig. S5B), an indication of the presence of early progenitors.
Finally, we observed an increased number of Sox2-positive cells
in pilocarpine animals treated with TH-FGF2/0-BDNF, 7 days
after SE (Fig. S5D). These data indicate that SE per se causes
proliferation of hippocampal early to intermediate progenitors
and that vector-mediated supplementation of FGF-2 and BDNF
greatly increases this phenomenon.
In the subsequent steps of neurogenesis, progenitors begin to
migrate and become DCX-positive. As stated above, this mi-
gration is partly aberrant after SE, because many SGZ progen-
itors do not head toward the granular layer but toward the hilus
(19). Therefore, we also analyzed DCX-positive cells. Under
control conditions (naïve animals), a limited number of DCX
cells, with elongations projecting across the granular layer, was
found in the SGZ (Fig. 2Ba) and even less so in the SVZ
(essentially, just a few, weakly labeled DCX-positive cells in the
CA1 stratum oriens). SE per se caused a robust increase in the
number of DCX-positive cells in the dentate gyrus (Fig. 2Bb).
However, these cells did not often produce elongations, tended
to aggregate into clusters, and were often ectopically located
(Fig. 2Bb). These observations are consistent with the aberrant
aspects of SE-induced neurogenesis (19, 24). A slightly increased
number of DCX-positive cells was also observed in the pyrami-
dal gyrus (CA3 and CA1). This pattern was not modified by the
administration of the control vector. In contrast, administration
of TH-FGF2/0-BDNF in pilocarpine-treated animals caused a
greater increase in the number of DCX-positive cells compared
with pilocarpine alone or pilocarpine and control vector (Fig.
2B). Moreover, it increased the length and number of elonga-
tions, reduced cluster formation, and reduced the number of
ectopic cells (Fig. 2Bc). An increased number of DCX-positive
cells was also observed in the pyramidal gyrus, indicating
commitment to neuronal differentiation (Fig. S5E).
Finally, we checked whether, consistent with our in vitro data,
a subset of these new cells were differentiating into neurons and
migrating into the appropriate location to possibly restore
function. Thus, we performed double-label immunofluorescence
with BrdU and MAP2abc, a marker of immature and mature
neurons. SE per se did not significantly increase the number of
BrdU-MAP2–positive cells; in contrast, we found several dou-
ble-labeled cells in the hippocampus of pilocarpine animals
treated with the double mutant (Fig. 2A).
Fig. 2. Effect of the vector expressing FGF-2 and BDNF together on cell proliferation. (A) Average number of BrdU-positive, nestin-positive, double-labeled
BrdU-positive and nestin-positive, double-labeled BrdU-positive and MAP2abc-positive cells in the dorsal hippocampus of naïve rats (yellow bars) and of
pilocarpine-treated rats 11 days after inoculation of control vector (pilo – control vector, gray bars) or of the vector expressing FGF-2 andBDNF (pilo – FGF2-BDNF,
green bars) in the right, ipsilateral to inoculation (I) and in the left, contralateral (C) hippocampus. Data are the means  SE of four to five animals per group.
** P 0.01 vs. naïve; F P 0.05, FF P 0.01 vs. pilo – control vector; analysis of variance (ANOVA) and post hoc Newman-Keuls test. (B) The vector expressing
FGF-2 and BDNF together induced proliferation of DCX-positive cells in vivo. Immunofluorescence (dentate gyrus region) for DCX (green) in control (naïve) rats
(Ba), in pilocarpine-treated rats given the control vector (Bb) and in pilocarpine-treated rats given the vector expressing FGF-2 and BDNF (Bc). Nuclei aremarked
by DAPI (blue). It should be noted that DCX-positive cells in the naïve animal dentate gyrus area are located in the subgranular zone and present detectable
elongations projecting across the granular layer (Ba Inset); pilocarpine-induced SE (both in untreated animals and in animals administered the control vector)
caused an increase in DCX-positive cells (Bb), which tended to produce relatively fewer elongations (Bb, inset), to group into clusters (example in red circle), and
to localize ectopically (white circles). Treatment with the double mutant (Bc) further increased the number of DCX-positive cells while reducing their aberrant
features, i.e., lower numbers of ectopic cells and presence of numerous elongations across the granular layer (arrowheads, Bc, inset). Horizontal bar, 25 m.
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These data suggest that injection of the vector expressing FGF-2
and BDNF in a SE-damaged hippocampus favors proliferation of
early progenitors according to a pattern that, at variance with what
was observed in untreated animals, appears to follow the physio-
logical pattern more faithfully, leading to the production of cells
that enter the neuronal lineage of differentiation and reducing the
aberrant aspects of SE-induced neurogenesis.
Outcome: Pathology and Behavior. To evaluate the outcome of the
treatment, we compared the different experimental groups for
the morphology of the hippocampus. First: compared with naïve
controls, the dorsal hippocampus of pilocarpine animals re-
mained smaller 4 weeks after SE (approximately 30%, like 3
days after SE: see above). Treatment with the double mutant
produced a significant increase in hippocampal volume, with a
recovery of approximately a third of the loss (Fig. S7A).
Importantly, the SE-damaged hippocampus presents a clearly
reduced density of neuronal cells, most notably hilar and pyramidal
cells, that was not observed in animals treated with the double
mutant (Fig. S7). We measured the density of astrocytes and
neurons in the hippocampus using GFAP and NeuN immunoflu-
orescence. The density of GFAP-positive cells in the entire hip-
pocampus was significantly increased in pilocarpine-treated ani-
mals compared with naïve controls, an indication of reactive
astrocytosis (25). In the pilocarpine group of animals treated with
the vector expressing FGF-2 and BDNF, the density of GFAP-
positive cells decreased slightly in comparison with untreated
animals, but was still greater than in naïve animals (Fig. S7B).
Neuronal density was measured using NeuN. Putatively excitatory
dentate gyrus granule cells were not significantly decreased by SE
and treatment with the double mutant did not alter the situation
(Fig. 3A). In contrast, putatively excitatory pyramidal neurons were
dramatically decreased in animals that experienced SE, and the
double mutant significantly increased their number (Fig. 3A).
Putatively inhibitory neurons in the dentate hilus and in the stratum
oriens of CA1 were even more dramatically decreased in animals
that experienced SE; and, again, TH-FGF2/0-BDNF significantly
improved the situation (Fig. 3B).
These data suggest that treatment with the vector expressing
FGF-2 and BDNF partially heals the damage induced by SE,
maintaining a good ratio between excitation and inhibition in the
circuit. However, some inhibitory cells are present in the pyra-
midal layer and excitatory cells are present in the hilus (for
example, the glutamateric mossy cells). Thus, we deepened the
investigation analyzing some of the main populations of
GABAergic interneurons, namely parvalbumin, somatostatin,
and calbindin. Parvalbumin-containing interneurons exert peri-
somatic, whereas somatostatin and calbindin exert dendritic
inhibition; calbindin also labels a subpopulation of principal,
glutamatergic cells, both in the pyramidal and in the granular
layer (26). In keeping with previous reports (27–29), we found
that the number of parvalbumin-positive cells in epileptic ani-
mals was similar to that in controls (Fig. S8A), while that of
somatostatin-positive cells was halved (Fig. S8B). Also, calbi-
ndin-positive principal neurons in the pyramidal and granular
layer, but not calbindin-positive interneurons in the strata oriens
and radiatum and in the dentate gyrus hilus, were significantly
decreased in the pilocarpine group (Fig. S8C) (30, 31). Treat-
ment with TH-FGF2/0-BDNF effectively corrected these cell
losses (Fig. S8).
Avoiding the loss of somatostatin cells may implymaintenance of
dendritic inhibition and, therefore, decreased susceptibility to sei-
zures. This leads to the key question: do these beneficial effects
ameliorate the outcome in terms of SRSs? We performed behav-
ioral andEEGanalyses: animals were video-EEGmonitored for 20
days and the occurrence, severity, and duration of SRSs were
recorded. As expected, all non vector-injected pilocarpine-treated
rats exhibited SRSs beginning 2 weeks after SE. On average, we
observed in this group four seizures per day (Fig. 4A) lasting about
1 minute each and with a mean severity score (32) of 2.5 (Fig. 4B).
Administration of the control vector did not modify this pattern. In
contrast, rats treated with the double mutant displayed a highly
significant improvement: (i) a subset of animals (two of 11) never
developed SRSs during the time frame of observation; (ii) the
average number of seizures per day in this group was highly
significantly reduced compared with the other two groups (Fig.
4A); (iii) the seizure severity was also significantly decreased (Fig.
4B). Thus, the FGF-2 and BDNF-expressing vector, injected in the
hippocampus after the establishment of hippocampal sclerosis,
provided both significant recovery from damage and significant
reduction of SRSs. These results are striking, considering that this
epilepsy model is accompanied by extensive damage also in extra-
Fig. 3. Neuropathological outcome of the treatment with the vector expressing FGF-2 and BDNF (TH-FGF2/0-BDNF), 28 days after pilocarpine-induced status
epilepticus. (A) Measure of the density of NeuN-positive, presumably excitatory neurons in selected subareas of the dorsal hippocampus: dentate granule layer
(DG GCL), CA3c pyramidal layer (CA3c), CA3a pyramidal layer (CA3a), and CA1 pyramidal layer (CA1). I, injected (ipsilateral) hippocampus; C, noninjected
(contralateral) hippocampus. (B) Measure of the density of NeuN-positive, presumably inhibitory neurons in selected subareas of the dorsal hippocampus: hilus
of the dentate gyrus (DG hilus) and stratum oriens of CA1 (CA1 oriens). Data are the means  SE of 10–12 animals per group. *P  0.05, **P  0.01 vs. naïve;
F P  0.05; FF P  0.01 vs. pilo – control vector; ANOVA and post hoc Newman-Keuls test.
Fig. 4. EEG and behavioral analysis. Average frequency (A) and severity (B)
of spontaneous seizures in the chronic period (14–28 days after pilocarpine-
induced SE). Data are the means SE for 10–12 animals per group. *P 0.05
and ***P 0.001 vs. pilo;F P 0.05 andFF P 0.01 vs. pilo – control vector;
ANOVA and post hoc Newman-Keuls test for (A), Kruskal-Wallis test for (B).
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hippocampal regions (33), such that only a subset of SRSs may
actually originate in the hippocampus (34), i.e., where we docu-
mented favorable effects by the vector. In other words, SRSs
originating in the hippocampus may be essentially abolished by
vector treatment.
Finally, to test whether the vector has a truly antiepileptogenic
effect and is not merely dampening SRSs (i.e., blocking icto-
genesis), we investigated whether the vector expressing FGF-2
and BDNF was effective in controlling seizures when injected in
animals that were already experiencing SRSs. To address this
question, a group of pilocarpine-treated rats was video-EEG
monitored beginning 2 weeks after SE. Three weeks after the
first spontaneous seizure, these animals were injected either with
the control vector or with TH-FGF2/0-BDNF, and monitoring
was continued for 4 more weeks. The frequency, duration, and
severity of SRSs were then comparatively analyzed in the 2 weeks
preceding vector inoculation and in the third and fourth weeks
after inoculation. Inoculation of the FGF-2/BDNF expressing
vector did not affect any of the parameters examined (Fig. S9),
indicating that supplementation of FGF-2 and BDNF can in-
terfere with epileptogenesis but not with ictogenesis.
In conclusion, the main finding of this study is that supple-
mentation of FGF-2 and BDNF in the hippocampus lesioned by
prolonged seizures effectively limits or repairs damage, main-
taining a good ratio between excitation and inhibition, and
significantly improves the natural history of the disease.
Understanding in depth the mechanistic basis of these effects
will require further studies, but the present data provide some
initial insights. FGF-2 and BDNF may provide protection
against damage or gain of function of partially damaged neurons.
Even if the present study did not provide support to this idea,
subtle effects on specific cell populations that could not be
detected with the techniques that we used cannot be excluded.
Nonetheless, another hypothesis, namely, that FGF-2 and BDNF
exert effects on neural stem cells and progenitors to generate
new neurons, seems more plausible. The phenotype(s) of these
new neurons remain uncertain, but we identified one interesting
candidate in a subtype of interneurons (somatostatin). GABA-
somatostatin interneurons play an important role in dendritic
inhibition, and their loss may favor the development of epilepsy
(28); thus, the replacement of these neurons may explain the
favorable effects of FGF-2 and BDNF supplementation.
Some aspects of the present findings are worthy of note. First,
virus injection was performed under conditions compatible with
the clinical settings of patient observation (after the epilepto-
genic insult), conditions that reproduce those that may allow
therapeutic intervention. Second, the disease-modifying effect is
striking and can be interpreted as anti-epileptogenic, an effect
that is not achieved by the currently available therapy. Further
studies will be required in both respects, to establish how long the
effect lasts and to challenge the hypothesis that it is truly
anti-epileptogenic. Last but not least, these findings may have a
heuristic value for the many other neurological diseases associ-
ated with neuronal damage.
Materials and Methods
Adetaileddescriptionof all of themethodsused in this study is provided in the
SI Text ‘‘Materials and Methods.’’
Animals. Male Sprague-Dawley rats (240–260 g; Harlan Italy) were used for
experiments. All procedureswere carriedout in accordancewithguidelines by
the European Community and national laws and policies.
Hippocampal Volumetry. Paraffin-embedded brains were cut in successive 10
m sections across the entire hippocampus and one of every five sections was
stained with hematoxylin and eosin. Sections were scanned and digitalized
using a Nikon Coolscope. Segmentation and orientation were obtained by
Amira TM 4.0 (Mercury Computer Systems), by two researchers blind to the
animal groups. Three-dimensional reconstructions were then calculated and
averaged using the same software.
HSV Infusion. Under ketamine and xylazine anesthesia, a glass needle con-
nected to a perfusion pumpwas implanted in the dorsal hippocampus. A total
of 1.6  106 pfu of vector were injected in a volume of 2 l at a flow rate of
0.1 l/min.
FJC Staining. FJC stainingwas performedon6-mparaffin-embedded sections
as previously described (35).
Immunohistochemistry and Immunofluorescence. For BrdU immunostaining,
cellular DNAwas denatured with HCl. The primary antibodies used for immu-
nohistochemistry were as follows: BrdU mouse monoclonal (1:100, Roche
Molecular Biochemicals); nestin mouse monoclonal (1:100; Chemicon);
MAP2abc mouse monoclonal (1:100; Chemicon); GFAP rabbit polyclonal
(1:100; Sigma); parvalbumin mouse monoclonal (1:50; Swant); and calbindin
rabbit polyclonal (1:50; Swant). Detection was obtained using the biotin-
streptavidin system (Ultra Vision Detection System, Lab Vision Corporation).
The reaction product was detected using a 3,3-diamino-benzidinetetrahydro-
chloride (DAB) substrate kit for peroxidase (Vector Laboratories).
For immunofluorescence, the primary antibodies were: BrdU (rat mono-
clonal, AbD Serotec) and nestin (mousemonoclonal, Chemicon) 1:10 and 1:10
respectively; BrdU (as above) andMAP2abc (mouse monoclonal, Immunolog-
ical Sciences) 1:10 and 1:10; nestin (mouse monoclonal, Chemicon) and GFAP
(rabbit polyclonal, Sigma) 1:25 and 1:100; NeuN (mouse monoclonal, Chemi-
con) and GFAP (as above) 1:25 and 1:100; MAP2abc (mouse monoclonal,
Immunological Sciences) and GFAP (as above) 1:25 and 1:100; Sox2 (rabbit
polyclonal, Immunological Sciences) and GFAP (mouse monoclonal, Immuno-
logical Sciences) 1:25 and 1:100; DCX (rabbit polyclonal, Cell Signaling) and
nestin (as above) 1:20 and 1:20; DCX (goat polyclonal, Santa Cruz Biotechnol-
ogy) 1:25; somatostatin-14 (rabbit polyclonal, Peninsula Laboratories) 1:25.
Telemetry. Seizure onset, severity, and duration were assessed by video-EEG
monitoring of the animals, performed bymeans of Phenotyper cages (Noldus
Information Technology), using telemetric technology (Dataquest A.R.T. Data
Acquisition, Data Sciences International).
Quantification and Statistical Analysis. All experiments were performed
strictly under double-blind conditions. The volume of the dorsal hippocam-
pus was calculated using a stereological approach based on the principle of
Cavalieri (36). The degree of cell damage was quantified using two ap-
proaches: the ‘‘neurodegeneration score’’ (37) and a thresholding of dig-
ital images (38). Counting of cells positive for the different markers was
conducted on one of every 26 sections across the entire dorsal hippocampus
(i.e., nine regularly spaced sections per animal). Quantification of GFAP-
positive and NeuN-positive cells was performed in frames taken from the
various hippocampal subareas. Behavioral alterations and seizure scoring
were performed by means of the Observer (Noldus). Seizure detection
(frequency, duration and severity), as well as single ictal events (2 sec-
onds) were scored for each individual rat for the whole analysis period (24
h/day for 20 consecutive days).
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bstract—The A-type voltage-gated potassium channels
Kv4) have been proved to play a major role as modulators of
omatodendritic excitability. Recent studies indicate that
euronal hyperactivity in epilepsy is associated with changes
n Kv4. However, the precise regulation of Kv4 in the devel-
pment of epilepsy and its underlying mechanism remain
nclear. In this study, we investigated whether the expres-
ion of the Kv4.2 channel and of its major modulator, voltage-
ependent potassium channel-interacting protein (KChIP1),
s altered following lithium-pilocarpine induced status epilep-
icus (SE) and the chronic-epilepsy phase in the rat model.
e found that Kv4.2 and KChIP1 expression was transiently
p-regulated following SE, whereas it was down-regulated
uring the chronic phase: this was most prominent in the
A1 and CA3 regions. The time-course analysis of the protein
xpression level showed that the peak Kv4.2 up-regulation
as between 6 and 24 h after SE, whereas KChIP1 expression
as increased earlier and for a shorter period. The temporo-
patial changes in Kv4.2 were very similar to those of its
ajor modulator KChIP1. We compared the difference in
-aminopyridine (4-AP)-induced intracellular calcium
[Ca2]i) elevation between model and control brain slices.
he results showed that the [Ca2]i elevation induced by the
v4 channel blocker 4-AP was aggravated and prolonged in
he model slice after SE. The functional relevance of these
hanges in Ca2 homeostasis and Kv4.2 and KChIP1 expres-
ion may be associated with intrinsic neuronal excitability
egulation and epileptogenesis. © 2008 IBRO. Published by
lsevier Ltd. All rights reserved.
ey words: pilocarpine, Kv4 potassium channel, KChIP, in-
racellular calcium concentration, hippocampus, epilepsy.
tatus epilepticus (SE) is a common epileptogenic brain
njury that can cause acquired epilepsy (AE) (Raza et al.,
001). The recurrent or continuous seizure activity that
Corresponding author. Tel: 86–2034152625.
-mail address: wpliao@tom.com (W.P. Liao).
bbreviations: aCSF, artificial cerebrospinal fluid; AE, acquired epi-
epsy; [Ca2]i, intracellular calcium concentration; CICR, calcium-in-
uced calcium release; DAB, 3,3=-diaminobenzidine; EPSP, excitatory
ostsynaptic potential; IA, A-type potassium current; KChIP, voltage-
ated potassium channel-interacting protein; Kv, voltage-gated potas-
ium channel; PBS, phosphate-buffered saline; PTZ, pentylenetetra-
ol; ROI, region of interest; SE, status epilepticus; SRS, spontaneoust
ecurrent seizures; TLE, temporal lobe epilepsy; 4-AP, 4-aminopyri-
ine.
306-4522/08 © 2008 IBRO. Published by Elsevier Ltd. All rights reserved.
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566ccurs during SE, is thought to result in structural and
unctional changes in the brain, thus leading to the devel-
pment of chronic epilepsy (Sloviter, 1999). Epileptogen-
sis is the process by which injuries such as SE, stroke, or
raumatic brain injury produce short- and long-term plastic
hanges in the neurons, resulting in spontaneous recurrent
eizures (SRS) in previously normal brain tissue (Sun et
l., 2001; Brandt et al., 2006; Swartz et al., 2006). These
lastic changes have been recognized as the most impor-
ant determinants of neuronal excitability (Bliss and Col-
ingridge, 1993), and thereby contribute to the develop-
ent of AE. Selective and coordinate changes in certain
oltage- and transmitter-gated ion channels have been
ound to be involved in this process (Faas et al., 1996; Su
t al., 2002; Nishimura et al., 2005).
Fast transient (A-type) voltage-gated potassium chan-
els (Kv) recently attracted special attention because they
ontribute to controlling the amplitude of back-propagating
ction potentials and the neuronal action potential firing
roperties (Hoffman et al., 1997; Korngreen et al., 2005).
-type potassium current (IA) can be generated by Kv1.4,
v3.4, or any of the Kv4 family subunits (Kv4.1, Kv4.2, and
v4.3) (Pongs et al., 1999; Song, 2002). Kv4.2 subunit is
ne of the key components underlying IA (Serodio et al.,
996). Changes in the properties of these physiologically
mportant IA by the transcriptional and posttranscriptional
egulation of Kv4.2 could lead to the dysregulation of neu-
onal excitability, which is a hallmark of epilepsy. Elemen-
ary evidence for the role of Kv4 channels in epilepsy is
rovided by studies that use Kv4 channel blockers, such
s 4-aminopyridine (4-AP) (Psarropoulou and Avoli, 1996),
r other highly selective blockers (Ebbinghaus et al.,
004), which lead to convulsions in mice (Juhng et al.,
999). Furthermore, altered Kv4.2 expression has been
bserved in several epilepsy models (Tsaur et al., 1992;
rancis et al., 1997; Castro et al., 2001; Bernard et al.,
004). Physiological studies evidenced the relation of de-
reased Kv4.2 expression with the functional conse-
uences of IA reduction in CA1 pyramidal cells in pilo-
arpine-induced epilepsy (Bernard et al., 2004) and in the
eterotopic neurons of cortical malformation models that
ere associated with epilepsy (Castro et al., 2001). In
umans, a marked down-regulation of classical IA was
bserved in dentate granule cells isolated from patients
ith lesion-associated temporal lobe epilepsy (TLE) (Beck
t al., 1997). Even in the case of idiopathic epilepsy, a
runcation mutation of Kv4.2 has been found in a TLE
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Page 8atient, with attenuated potassium current density on the
ell surface (Singh et al., 2006). These data strongly sug-
est that Kv4.2 is an important determinant of neuronal
xcitability and is implicated in epilepsy. However, thus far,
imited information is available on the dynamic regulation
f Kv4.2 and its underlying mechanisms. Recent studies
ave emphasized the importance of voltage-dependent
otassium channel interacting proteins (KChIPs) in regu-
ating the expression levels and physiological properties of
v4 channels (An et al., 2000; Bahring et al., 2001; Beck et
l., 2002). KChIPs are calcium binding proteins that belong
o the family of EF-hand neuronal calcium sensor (NCS)
roteins (An et al., 2000). KChIPs appear to transduce
a2 signals to actively altering neuronal membrane ex-
itability by modulating the properties of Kv4 (Nakamura et
l., 2001). It is implied that the intracellular Ca2 concen-
ration ([Ca2]i) may influence Kv4 channels activities
hrough the KChIP pathway. KChIPs have 4 subtypes,
amely, KChIP1-4. KChIP1 is prominently expressed in
he brain and is tightly associated with Kv4.2 (Strassle et
l., 2005). Currently, information regarding a possible in-
olvement of KChIPs in epilepsy is insubstantial. We were
articularly curious about the association of Kv4.2 with
ChIP1 and their involvement in short- or long-term plas-
icity in epileptogenesis. Thus, the present study was un-
ertaken to examine the possible plasticity changes in
v4.2 and KChIP1 expression after SE, and explore the
ossible relationship between changes in A-type potas-
ium channels and disturbed intracellular calcium ho-
eostasis.
EXPERIMENTAL PROCEDURES
nimals
dult female Sprague–Dawley rats (200230 g) were obtained
rom the Laboratory Animal Center of Guangdong Province
Guangzhou, China), housed at a constant temperature of
22 °C with a 12-h light/dark cycle, and given free access to food
nd water. Care and handling of the animals were approved by the
thics Committee for the Use of Experimental Animals of Guang-
hou Medical College. All efforts were made to minimize animal
uffering and to reduce the number of animals used.
ntibodies and reagents
he anti-Kv4.2 antibody was purchased from Upstate Biotechnol-
gy, Inc. (Lake Placid, NY, USA), the anti-KChIP1 antibody was a
ift from Dr Z. H. Zhang (University of California, USA), and
nti--actin was obtained from Cell Signaling Technology (Dan-
ers, MA, USA). Alexa Fluor 568–conjugated cholera toxin sub-
nit B and Texas Red–labeled goat anti-rabbit IgG were obtained
rom Molecular Probes (Eugene, OR, USA). Pilocarpine, lithium
hloride, horseradish peroxidase–conjugated goat anti-mouse
gG and goat anti-rabbit IgG were obtained from Sigma-Aldrich
St. Louis, MO, USA). Atropine and diazepam were purchased
rom Tianjin Pharmaceutical Co. (Tianjin, China). BCA Protein
ssay Kit was obtained from Biocolor (Shanghai, China), the
hole protein extraction kit was obtained from Active Motif (Carls-
ad, CA, USA). The ABC immunohistochemistry kit was pur-
hased from Martianit (Fuzhou, China). Chemiluminescence re-
gents were obtained from Applygen Technologies Inc. (Beijing,
hina), and Fluo-3-AM, from Molecular Probes. vithium–pilocarpine protocol
nimals were divided into experimental and control groups. All
ats administered lithium chloride (3 mEq/kg, i.p.). After 24 h, the
xperimental group received 1 mg/kg atropine sulfate, followed by
he s.c. injection of pilocarpine (30 mg/kg) after 30 min. Atropine
as used to reduce the peripheral effects of pilocarpine. Diaze-
am (10 mg/kg, i.p.) was administered at 1 h after the onset of SE
n order to terminate convulsions in the responsive rats. The
nimals required special care until they recovered from the acute
nsult, and they were closely tended, hydrated and fed. The rats
hat did not show seizures of grades over 4–5 (Racine) were
llocated to another group. Following SE, the rats underwent a
eizure-free period, namely latent period, and then exhibited SRS.
he behavior of the Li-Pilo-treated rats that underwent SE was
bserved daily in the following 5–9 weeks in order to detect SRS.
hose rats exhibiting SRS, known as being in chronic epilepsy
hase, were sacrificed 50 days after SE The control group re-
eived atropine sulfate, but saline was used instead of pilocarpine.
he behavioral characteristics of SE were similar to those ob-
erved in previous studies (Roch et al., 2002).
estern blot
n adult rat was anesthetized, and its brain was rapidly excised.
resh brain tissue was homogenized in lysis buffer according to
he protocol of the manufacturer (Active Motif). The protein con-
entration was determined in the supernatant using BCA method,
s recommended by the manufacturer (Biocolor, Belfast, UK). To
erform Western blot analysis, the supernatant (2 g/lane) was
esolved by SDS-PAGE, and the protein was transferred to PVDF
embranes. Membranes were blocked with Tris-buffered (50 mM)
aline solution (pH 7.6) with 0.05% Tween containing 5% milk
owder at room temperature for 1 h. The membranes were incu-
ated with the primary antibodies and subsequently with the sec-
ndary antibodies; they were then incubated with the chemilumi-
escence reagents. The membranes were exposed to a radio-
raphic film immediately after incubation. To be reprobed with
nother primary antibody, the membrane was incubated with a
tripping buffer (62.5 mmol/L Tris pH 6.8, 2% SDS, and
00 mmol/L dithiothreitol) at 70 °C for 30 min, washed extensively,
eblocked with 5% nonfat milk, and reprobed with the other anti-
ody as described above.
mmunohistochemistry
he rats were anesthetized and perfused intracardially with 0.9%
aline followed by 4.0% paraformaldehyde. Following perfusion,
he brain was excised, postfixed for 16 h, and sectioned on a
ryotome at a thickness of 30 m along the coronal plane. Fol-
owing a thorough washing in phosphate-buffered saline (PBS; pH
.4), the free-floating sections were blocked with 3% normal goat
erum and incubated overnight at 4 °C with the KChIP1 mono-
ntibody (1:1000 dilution in 1% normal goat serum in PBS con-
aining 0.25% Triton X-100). On the following day, the samples
ere washed in PBS before being incubated for 1 h with a biotin-
lated secondary antibody. After washing, the sections were pro-
essed with the avidin biotinylated complex (ABC) and the reac-
ion was developed using 3,3=-diaminobenzidine (DAB). The sec-
ions were mounted on slides.
lice preparation and calcium imaging
t 24 h after Li-Pilo-induced SE, 11 rats (six models, five controls)
ere anesthetized and the brains were excised, placed in ice-cold
rtificial cerebrospinal fluid (aCSF; 122 mM NaCl, 25 mM
aHCO3, 3.1 mM KCl, 1.8 mM CaCl2, 12 mM MgSO4, 0.4 mM
H PO , and 10 mM D-glucose, at pH 7.4), and quartered. Trans-2 4
erse brain slices (400 M), cut on a vibratome (Hitachi, Japan),
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Page 9ere placed in an incubation chamber containing gassed (95%
2/5% CO2) aCSF. The slices corresponded to horizontal plates
8–100, as described by Paxinos and Watson (1986). They were
ransferred to a dish containing aCSF, loaded with the calcium
uorescent probe Fluo-3-AM (5 mol/L) and incubated at 37 °C for
0 min. Individual slices were washed and transferred to a home-
ade glass bottom chamber. The slices were gently pressed with
metal web to prevent them from floating in the water. The
hamber was placed on the stage of an inverted microscope. The
lices were maintained at 37 °C, submerged in aCSF, and con-
inuously gassed with 95% O2/5% CO2. Calcium imaging was
erformed by using a laser scanning confocal system (Leica SP2,
annheim, Germany). Sequential scanning was initiated immedi-
tely after the addition of 10 mM 4-AP in the aCSF, and it was
ontinued for 7 min at 10 s intervals. 4-AP was washed out using
CSF at 2 min after it was added. During image acquisition, the
arameters of the confocal system were kept constant.
ata analyses
or immunostaining and Western blot, densitometric analysis for
he quantification of the staining strength or the bands was per-
ormed using image analysis software (Kontron, Germany). For
ChIP1-postive cell counting, cells were quantified at the coronal
ection levels (between 3.0–4.0 mm posterior to bregma) on
oded slides by a researcher who had no knowledge of the
reatment received by the animals. Within certain hippocampal
ubregion, the number of immunoreactive cells was estimated by
ounting the neurons in which the reaction product was present
ithin a clear and regular-shaped cytoplasmic border. The anat-
my of rat brain was identified with the Stereotaxic Atlas of the Rat
rain (Paxinos and Watson (1986)). For [Ca2]i measurements,
ve pyramidal cells in the microscopic field were randomly se-
ected. The neuronal calcium transient was determined by drawing
region of interest (ROI) around the cell and averaging the
uorescence intensity within the delimited area. Fluorescence
ntensity, which represented [Ca2]i, was converted to numerical
alues and imported to a spreadsheet. A measurement control
nd real-time data acquisition, and analysis were performed using
he confocal system program (Leica SP2). To analyze the ampli-
ude and decay of the calcium transients, the fluorescence traces
ere expressed as relative fluorescence changes (F/F0), where F0
as the background-corrected pre-stimulus fluorescence of the
OI. All data were expressed as meanS.D., and the statistical
ignificance was determined by one-way ANOVA or the two-tailed
tudent’s t-test.
RESULTS
hanges in the expression of Kv4.2 and KChIP1
ollowing SE
s an initial experiment, we examined the localization of
v4.2 and KChIP1 in the normal rat brain. The expression
atterns of Kv4.2 and KChIP1 in the hippocampus and
eocortex resembled those previously reported (Rhodes et
l., 2004). In the hippocampus, enriched and punctate
v4.2-postive signals were detected in the strata oriens
nd radiatum of CA1–CA3, corresponding to the apical
nd basal dendrites of pyramidal cells, and in the molec-
lar layer of the dentate gyrus (Fig. 1). In the cerebral
ortex, Kv4.2 staining was observed primarily in the so-
ata and dendrites of the prefrontal, lateral orbital, frontal,
arietal, and cingulated cortices, particularly within layers
and VI (data not shown). KChIP1-positive signals were
ainly detected in the somatodendritic domains. The en-
uing quantitative analyses were thus based on the num- der of KChIP1-stained cells in the somata. In the brain of
he controls, cells strongly stained for KChIP1 were ob-
erved to be scattered throughout the hippocampus and
eocortex. The CA1 region of the hippocampus showed
he strongest KChIP1 staining.
As described above, two main phases were observed
ollowing Li-Pilo-induced prolonged SE: the seizure-free
atent period and the chronic epileptic phase with SRS. To
xplore the changes in the expression of Kv4.2 and
ChIP1 during these two phases, we selected two time
oints (2 and 50 days) to perform immunohistochemical
xaminations. As shown in Fig. 1, Kv4.2 staining in the
tratum oriens and stratum radiatum of the hippocampus
ncreased 2 days after SE. The increase was most pro-
ounced in the stratum oriens of the CA1 region. However,
he intensity of Kv4.2 staining decreased slightly during the
hronic phase, i.e. 50 days after SE in this experiment, and
eached the statistical significance only in CA1 and CA3
ubregions. Intriguingly, as a candidate of Kv4.2 modula-
or, KChIP1 also showed a similar change in its expres-
ion, which increased 2 days after SE and decreased
uring the chronic phase. However, the increase in
ChIP1 staining at 2 days after SE was not as conspicu-
us as that in Kv4.2 staining; this was confirmed by the
ChIP1-positive cell counting analysis (Fig. 1). The under-
ying reason, as shown in the next experiment (Fig. 2), was
hat the peak increase in KChIP1 expression reached ear-
ier and lasted less than that of Kv4.2. On the other hand,
ecreased KChIP1 staining with fewer positive cells was
bserved 50 days after SE. Cell counting analysis also
evealed a significant reduction in the number of KChIP1
mmunoreactive cells in the CA1 and CA3 regions of the
ippocampus (Fig. 1). No statistically significant change
as observed in the other regions of the hippocampus.
he cellular distribution and intracellular localization of
v4.2 and KChIP1 were not found to be altered with SE
nd were similar to those observed in the control group.
To evaluate the expression levels of Kv4.2 and KChIP1
ollowing SE, Western blot was used to analyze the ex-
racts from bilateral hippocampus and cerebral cortex.
ince many rapid and complicated alterations may occur in
he intrinsic neuronal properties during the acute phase of
eizure-free latency in the Li-Pilo model, the time-course of
ynamic regulation of Kv4.2 and KChIP1 expression in the
cute phase following SE was examined. The expression
evel was traced by measuring the relative optical density
f each band. Rats that failed to exhibit seizures after
i-Pilo treatment were also investigated. As shown in Fig.
, the expression level of Kv4.2 was found to increase at
h and was significantly higher at 6, 24 and 48 h, with a
eak between 6 and 24 h. KChIP1 also showed a signifi-
ant increase after SE. However, the peak in KChIP1
xpression was observed at 3 h, earlier than that in Kv4.2
xpression. Subsequently, it gradually reduced, and no
ignificant difference was observed at 48 h. The controls
nd the rats that failed to exhibit seizures after Li-Pilo
njection showed no significant changes, indicating that the
levation in Kv4.2 and KChIP1 expression was seizure
ependent. Fig. 3 shows the changes in the expression of
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Page 10v4.2 and KChIP1 in the hippocampus and neocortex
uring the latent (2 days after SE) and chronic phases (50
ays after SE). Generally, the expression levels of Kv4.2
nd KChIP1 in the hippocampus were lower than that in
he cerebral cortex of the controls. Increased Kv4.2 ex-
ression in both the hippocampus and cortex, as well as an
ncreased level of KChIP1 expression in the hippocampus,
as observed at 1 day after SE; this is in agreement with
he abovementioned results. A slight decrease in the av-
rage expression level of Kv4.2 and KChIP1 in the hip-
ocampus and neocortex was observed at 50 days after
ig. 1. Expression pattern of Kv4.2 and KChIP1 in the hippocampus i
ections are stained by DAB. Left images, in a low power view, show th
n the hippocampus. Right images, in a high power view, highlight the
n the CA1 region. The bottom graphs show the group data respect
mmunoreactive cell counting. Data are shown as meanS.D. The as
P0.05, t-test). n8 for models and n12 for controls. Abbreviations
c, pyramidal cell layer; sr, stratum radiatum. Scale bar1 mm (right)E, but no statistical difference was observed. In addition, [t appeared that the changes in the hippocampus were
ore apparent than those in the neocortex for both Kv4.2
nd KChIP1.
ifference in [Ca2]i elevation induced by the
otassium channel blocker 4-AP after SE
o characterize the involvement of [Ca2]i changes during
pileptogenesis in this Li-Pilo-induced epilepsy model and
xplore its possible relationship with A-type potassium
hannels, we analyzed the dynamics of the changes in
ly latent (2 days) and chronic phase (50 days) of the Li-Pilo model. All
intensities of Kv4.2 (A–C) and KChIP1 (D–F) immunoreactive signals
(upregulation in latent period and downregulation in chronic phase)
densitometric measurement of Kv4.2 immunostaining and KChIP1
icate statistically significant differences to control values (** P0.01,
fields CA1-4 of Ammon’s horn; DG, dentate gyrus; so, stratum oriens;
(left).n the ear
e altered
changes
ively from
terisks ind
: CA1-4,Ca2]i in the CA1 pyramidal neurons after SE. We chose
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Page 114 h after SE as the time point for observation, because
he expression of Kv4.2 and KChIP1 was significantly in-
reased at that time point. No difference was observed in
he resting level of [Ca2]i in the CA1 pyramidal neurons of
he hippocampal slices between Li-Pilo and controls. The
xposure of CA1 neurons to 10 mM 4-AP resulted in an
brupt increase in [Ca2]i (Fig. 4). In the control slices, the
-AP-induced elevation in [Ca2]i could be observed in
oth the soma and dendrites of the pyramidal neurons.
ithin 1.5 min 4-AP exposure, the [Ca2]i level reached a
lateau, with an average increase of 29365% from the
esting level. The [Ca2]i then gradually began returning to
he resting level gradually with the washing out of 4-AP. In
ome cases of the models, the elevated [Ca2]i could not
eturn to the resting level even at the end of the 7-min
bservation period. Therefore, the decay time for the
Ca2]i to reach 180% of the resting level was used as an
ndex for performing statistical analyses. The amplitude of
he [Ca2]i elevation and the latency to the peak value
ere comparatively measured in control and Li-Pilo. As
hown in Fig. 4, a sharper and higher elevation in [Ca2]i
as found in Li-Pilo slices, with a peak value of 52473%.
ig. 2. Dynamics of Kv4.2 and KChIP1 expression in hippocampus fol
fter seizures. Zero hour refers to the time when rats were administrat
xperiments described in A, values of relative optical density had b
tatistically significant differences vs. control values (* P0.05). The g
fter Li-Pilo injection.he latency to the peak response was similar in control e8813.2 s) and Li-Pilo (10217.5 s). The [Ca2]i recov-
ry curve and the decay time (93.427.3 s vs. 51.124.5
, P0.05) showed that the [Ca2]i recovery was slower in
i-Pilo, even after 4-AP washout. These data indicate that
he pyramidal neurons that underwent SE are more sen-
itive to 4-AP exposure, and were less capable of restoring
he normal [Ca2]i level.
DISCUSSION
ince IAs that are mediated mainly by Kv4.2 play a crucial
ole in the regulation of neuronal membrane excitability,
he changes of Kv4.2 in relation to epileptic activity have
requently been investigated. The altered expression of
v4.2 has been inconsistently observed in previous stud-
es. Some investigators have shown that the Kv4.2 mRNA
evels were transiently reduced in the granule cell layer of
he dentate gyrus following pentylenetetrazol (PTZ)-
Tsaur et al., 1992) or kainate-induced generalized sei-
ures (Francis et al., 1997). Similarly, a recent study
howed reduced Kv4.2 expression in the CA1 subregion in
pilocarpine-induced spontaneously epileptic rat (Bernard
. (A) The dynamics of Kv4.2 and KChIP1 expression at different time
am to terminate the generalized seizures. (B, C) Group data from the
alized and presented as meanS.D. (n6). The asterisks indicate
odel without seizures” represents those rats that failed to exhibit SElowing SE
ed diazep
een normt al., 2004). Other studies have reported that unaltered
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Page 12v4.2 mRNA levels in the dentate gyrus during the chronic
hase of pilocarpine-induced epilepsy in rats (Ruschen-
chmidt et al., 2006). The present data show that the Kv4.2
xpression was transiently upregulated at the level of the
ntire hippocampus during the latent period of Li-Pilo-
nduced epilepsy in rats; however, it exhibited a reducing
rend during the chronic phases in which spontaneous
eizures could occur. It is suggested that the alterations in
v4.2 expression may be a common yet complex process
hat occurs during the development of epilepsy. The time
ourse of Kv4.2 expression following Li-Pilo-induced pro-
onged SE has not previously been investigated. In the
resent study, observation of the dynamic changes in
v4.2 expression in the hippocampal formation showed
hat Kv4.2 expression started increasing from 3 h after the
eizures, reached a maximum at 6–24 h; then, it began
eturning to its normal levels. The present data are com-
arable with that presented in a report on the kainate
pilepsy model (Francis et al., 1997), in which the Kv4.2
RNA expression levels in the dentate granule cell layer
ig. 3. Expression levels of Kv4.2 and KChIP1 in hippocampus and
hanges in Kv4.2 and KChIP1 in the cerebral cortex are similar but le
rom experiments as described in A with signals normalized to control.
ontrols (n6, * P0.05. t-test).ecreased 3 h after the seizures, but rebounded to levels rreater than those of the controls at 24 h; however, Kv4.2
RNA expression was significantly decreased in CA3 at
he same time point. An increase in Kv4.2 expression was
bserved in both the studies, but with differences in the
ubstructures. It is possible that different substructures in
he brain may be involved, or that different dynamic
hanges may occur due to different convulsants. More-
ver, Kv4.2 is an important regulator of electrical signaling
n the brain. Thus, it is not surprising that it exhibits various
ynamic regulations in different epilepsy models.
It is reported that the A-type current can influence
ctive discharge properties and the processing of synaptic
nput by limiting the amplitudes of backpropagating action
otentials, decreasing the amplitude of excitatory postsyn-
ptic potentials (EPSPs), and raising the threshold for
endritic spike initiation (Hoffman et al., 1997; Magee and
arruth, 1999); this finally limits the excitability of individual
eurons. From these data, the most pronounced effect that
s expected following the up-regulation of the Kv4.2 chan-
els as observed here would be the suppression of neu-
cortex in the early latent and the chronic phase. (A) The expression
icuous as compared with that in the hippocampus. (B, C) Group data
es statistically significant differences between Li-Pilo-treated rats andcerebral
ss consponal excitability in the brain, assuming that the levels of
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Page 13v4 expression reflect the density of the A-type current in
he membrane. In our opinion, such suppression would
epresent a homeostatic mechanism following severe and
ersistent seizures. The available evidence suggests that
ome expression changes in various channels serve to
tabilize the properties of neural circuits (Stemmler and
och, 1999; Turrigiano, 1999). For example, the immuno-
eactivity of KCNQ2, another type of Kv that mediates the
-current, was found to be up-regulated both in both the
mygdala kindling model and the spontaneous epilepsy
nitiated by SE; the up-regulation was only induced by
evere generalized seizures (Penschuck et al., 2005). In
ddition, electroshocks in humans (Krystal et al., 1998;
egenold et al., 1998) and animals (Bolwig et al., 1999)
esult in a 40–100% increase in the seizure threshold and
30–90% decrease in the seizure duration; this reflects
hat generalized seizures possibly induce a suppression in
euronal excitability. Considerable interest has recently
een generated in such seizure-induced neuronal excit-
bility suppression by pre-exposure to generalized sei-
ures in order to exert anti-convulsive effects via modula-
ion of neuronal excitability (Andre et al., 2000). Therefore,
t is plausible that the up-regulation of Kv4.2 expression
ould adjust the neuronal excitability to a suppressed
tate, which might act as a sort of self-protective mecha-
ism following prolonged SE. It is noteworthy that the time
ig. 4. Alterations in 4-AP-induced [Ca2]i transients in Li-Pilo rats an
or 2 min and then washed out (see the bar in A). [Ca2]i was measu
Ca2]i. (B–D) The statistical analyses on the amplitude of [Ca2]i ele
Indicates statistically significant differences (** P0.01, * P0.05, t-f maximal Kv4.2 overexpression was 6–24 h after sei- sures, when many neurons in the hippocampus are mor-
hologically dying in the model used here. Therefore, the
p-regulation of Kv4.2 after SE may be thought to protect
eurons from seizure-induced damage by counteracting
yperexcitability.
In agreement with the reduced Kv4.2 expression ob-
erved in the CA1 region during the chronic phase of the
ilocarpine model (Bernard et al., 2004), our immunostain-
ng, also in the chronic phase, showed that Kv4.2 expres-
ion decreased, although the reduction did not reach a
alue of statistical significance in the protein analysis by
estern blot. The lack of significance may be due to the
egions selected. In our studies, the Western blot data
epresent Kv4.2 expression at the level of the whole hip-
ocampal formation. Therefore, it is possible that the re-
uction might become less considerable when different
ubregions are included, considering the fact that Kv4.2
xpression is highly variable among different subregions of
he hippocampus, as we found in the immunostaining. The
esults of immunohistochemistry which showed that the
ignal of Kv4.2 immunoreactivity was weaker and the num-
er of KChIP1-positive cells was less in the CA1 and CA3
egions suggested that the expression of Kv4.2 was down-
egulated during the chronic phase of the Li-Pilo-induced
odel. Although not directly tested, such reduction in
v4.2 expression during the spontaneous seizure period
s 24 h after SE. Slices were perfused with Kv4 channel blocker 4-AP
min from the time of 4-AP application. (A) The dynamic changes of
he latency to the amplitude, and the decay time after 4-AP washout.
een models (n6) and controls (n5).d control
red for 7hould lead to an increase in the amplitude of the back-
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Page 14ropagating action potentials and boost dendritic EPSPs,
hereby producing a general increase in dendritic excitabil-
ty. This increase in CA1 or CA3 is likely to lower the
hreshold for seizure initiation in the hippocampus, which is
frequent site of limbic seizures. Therefore, abnormalities
n Kv4.2 expression could contribute to the generation of
eizures and epilepsy.
The abundance and distribution of Kv4.2 channels are
egulated by multiple molecular mechanisms (Birnbaum et
l., 2004). First, the gene is activated at the transcriptional
evel by various stimuli. Second, a large variety of Kv4.2-
nteracting proteins, including Kv, KChIPs, and DPPX,
egulate the expression and trafficking of Kv4.2. Third,
hannel proteins undergo posttranslational modifications,
uch as glycosylation, methylation, and phosphorylation.
ecent data suggest that KChIPs are one of the most
mportant factors that determine the level of the Kv4-en-
oded current in various excitable cells. Coexpression
tudies have shown that surface expression of the Kv4.2
rotein is highly dependent on the presence of KChIP1
Shibata et al., 2003). KChIP1 can dramatically increase
his surface expression, slow the turnover of the Kv4 pro-
ein, slow the inactivation kinetics, and increase the rate of
ecovery from the inactive state of Kv4 channels (An et al.,
000; Shibata et al., 2003; Jerng et al., 2004). However,
he functional contributions of KChIPs to channels in neu-
al circuits are not well understood. Recently, a decrease in
ChIP3 expression in the hippocampal tissue was shown
n human chronic epilepsy (Hong et al., 2003). Our previ-
us data have also shown that the number of KChIP1-
ositive cells was increased in an acute PTZ-induced ep-
lepsy model (Su et al., 2006). We therefore hypothesize
hat the Kv4–KChIP complex may be involved in epilepsy.
ndeed, one of the most prominent findings with respect to
he changes in Kv4.2 in the present study is the significant
hange of KChIP1 following SE. Time-course analysis of
he elevation in KChIP1 and Kv4.2 expression in the early
atent period following SE showed that the altered expres-
ion of Kv4.2 precisely followed the change in KChIP1,
ith the elevation in KChIP1 occurring a little earlier than
hat in Kv4.2.
Although KChIP1 staining is most intense on the so-
ata of cells that resemble interneurons and Kv4.2 stain-
ng is most intense on the dendrites of the pyramidal
eurons of all the CA subfields and dentate granular neu-
ons, a considerable level of overlap is observed. A colo-
alization experiment show that Kv4.2 and KChIP1 are
ostly colocalized in the neocortex and less in the hip-
ocampus (data not shown). In the immunohistochemistry
xperiment, however, we found that the changes in Kv4.2
ere marked in CA1 and CA3, but were observed to a
esser extent in the other regions. Interestingly, KChIP1
xpression is also selectively up-regulated in the CA1 and
A3 subregions of the hippocampus after SE. These re-
ults suggest that the regulation of Kv4.2 and KChIP1 is
ighly related to the subfield and the cell type. On the other
and, in most other brain regions, like the neocortex, the
hanges in Kv4.2 and KChIP1 were not as apparent as
hose observed in the hippocampus; this was shown by the besults of both immunohistochemical staining and Western
lot analysis. Such subregion-specific regulation of ion
hannels has also been demonstrated for Kv4.2 channels
Francis et al., 1997) and other voltage- or transmitter-
ated ion channels (Becker et al., 2003). All these data
uggest that in Li-Pilo-induced epilepsy models, the hip-
ocampus is preferentially affected, as compared with
ther limbic regions or the cerebral cortex. It is also re-
orted that the neurodegenerative processes initiated by
rolonged SE occur prominently in the hippocampus
Roch et al., 2002), particularly in the pyramidal cells in
A3 and CA1 (Peredery et al., 2000). We found a de-
reased number of KChIP1-immunoreactive cells in CA1
nd CA3 as well as a decreased level of the KChIP1
rotein in the hippocampus during the chronic period. We
annot exclude the possibility that the decrease in the
umber of KChIP1-positive cells is a result of neurodegen-
ration caused by prolonged SE. Considering that KChIP1
s mainly located on GABAergic interneurons, as revealed
n our previous data (Su et al., 2006), it is likely that the
bserved decrease in KChIP1 was associated with the
oss of GABAergic neurons, possibly resulting in deficient
elease of the inhibitory neurotransmitter and, conse-
uently, hyperexcitability during the chronic period. How-
ver, we cannot confirm this without additional evidence.
It is well accepted that the expression and trafficking of
v4 channels are regulated by KChIPs, that act as neuro-
al calcium sensor. Calcium, which is a major signaling
olecule in neurons, regulates a wide variety of cellular
rocesses, including ionic channel permeability, neuro-
ransmitter release, enzyme activity, and gene transcrip-
ion. Alterations in neuronal calcium homeostasis are be-
ieved to play an essential role in the development of
pilepsy (Delorenzo et al., 2005). This prompted us to
xtend our investigation by measuring the [Ca2]i transient
hat is induced by the potassium channel blocker 4-AP in
he epileptic hippocampal slices, with the aim of improving
ur understanding of the signaling cascades underlying
he up-regulation of KChIP1 and Kv4 expression after SE
nd the role of calcium homeostasis in epileptogenesis.
lthough it is known that increased [Ca2]i can be induced
y 4-AP administration in the normal brain (Grimaldi et al.,
001), the effect of 4-AP on the brain after prolonged SE
as not yet been studied. Thus, we compared the differ-
nces in elevated [Ca2]i, which was preloaded by 4-AP,
etween the SE slices and the control slices. Statistical
nalysis revealed that the amplitude of [Ca2]i elevation in
he CA1 pyramidal cells, which was induced by 4-AP, was
igher in the epileptic slice than in the control slice. Al-
hough several classes of potassium channels are sensi-
ive to 4-AP (Coetzee et al., 1999), Kv4.2 is expressed
ore strongly in CA1 pyramidal cells (Serodio and Rudy,
998). Thus, the effect of 4-AP on the CA1 pyramidal cells
ainly reflects the blocking of Kv4.2. Based on these
bservations, one of the causes of the higher elevation of
Ca2]i induced by 4-AP after SE may be the blockage of
v4.2 channels in CA1 pyramidal cells. Because Kv4.2
hannels expression was up-regulated after SE, as shown
y the Western blot and immunohistochemistry experi-
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Page 15ents, it is reasonable to see an enlarged elevation of
Ca2]i. It is also possible that the calcium influx and
elease is facilitated by the changes in multiple calcium
omeostatic mechanisms after SE, including VSCC, li-
and-gated ion channels, Mg2/Ca2 ATPase, and calci-
m-induced calcium release (CICR) (Pal et al., 2001; Raza
t al., 2001; Parsons et al., 2001).
We have also demonstrated that 4-AP-induced [Ca2]i
levation is potently prolonged in the epileptic slice. This
elayed restoration of [Ca2]i may be caused by an im-
airment in neuronal Ca2 homeostatic mechanisms. Sev-
ral sequestration mechanisms function in the physiologi-
al condition, such as the activity of the sarcoendoplasmic
eticulum calcium ATPase (SERCA) and IP3-stimulated
ICR, that has been demonstrated to undergo chronic
hanges in epileptic neurons (Pal et al., 2001). Calcium-
inding proteins are one of the critical elements that main-
ain the stability of intracellular calcium (Missiaen et al.,
000). Changes in the expression level and/or in the sub-
ellular localization of Ca2-binding proteins may affect
he regulation of cytosolic calcium-buffering capacity
Baimbridge et al., 1992; Chard et al., 1993). For example,
he loss of the Ca2-binding protein calbindin-D28K im-
airs Ca2-buffering in epileptic neurons (Kohr et al.,
991), and it is associated with the development of epi-
epsy (Hwang et al., 2004). In the present study, the ex-
ression of KChIP1, a calcium-binding protein, was also
ound to be altered during epileptogenesis. Although it is
ifficult to define the effect of KChIP1 on calcium-buffering
apacity by using the present data, the possibility that
ChIPs function not only as regulators of Kv4 but also as
ontributors to calcium buffering cannot be excluded.
Regardless of the mechanisms underlying calcium in-
ux and buffering, the potentiation and prolongation of
-AP-induced [Ca2]i elevation may reflect disturbed cal-
ium homeostasis and may be related to abnormal potas-
ium channel expression in the membrane in the hip-
ocampus after prolonged SE, probably with a consequent
evelopment of limbic epilepsy. Since the neuronal free
Ca2]i is highly regulated, any change in [Ca2]i dynam-
cs may affect neuronal function, including potassium
hannel expression, trafficking and properties (Adams and
ill, 2004; Jow et al., 2004). KChIPs are calcium binding
roteins, sensing the subtle changes in [Ca2]i and trans-
ucing the calcium signals into changes of membrane
xcitability by modulating Kv4 activity (Burgoyne and
eiss, 2001). Considering the close relationship between
a2 and the Kv4–KChIPs complex under physiological
onditions, it is possible that disturbed Ca2 homeostasis
ffects the regulation of A-type potassium channels. It is
lso conceivable that altered Ca2 dynamics trigger patho-
ogical changes, such as gene transcription, protein ex-
ression, neurogenesis, neuronal sprouting (Delorenzo et
l., 2005) and so on, leading to the development of epi-
epsy; however, at present, it is difficult to determine which
f these processes is involved.
In a word, the present study shows that the expression
f Kv4.2 and KChIP1 is increased at the early latency
tage and decreased during chronic phase of the Li-Pilopilepsy model. Based on their close modulation relation-
hip and important physiological function on neuronal net-
ork excitability, the plastic changes in Kv4.2 and KChIP1
ay collaborate to influence the intrinsic neuronal excit-
bility, thereby contributing to the development of epilepsy.
he altered transient of [Ca2]i, elicited by the Kv4 channel
locker 4-AP, has been found in the model, and this sug-
est the disturbed calcium homeostasis, which might be
elated with Kv4 modulation, involved in epileptogenesis.
t the present stage, we were unable to reveal the exact
unctional significance of altered Kv4.2 and KChIP1 ex-
ression or a clear correlation between the calcium signal
nd A-type channels during epileptogenesis. Further stud-
es in this field will be helpful in understanding the mech-
nism underlying epileptogenesis.
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producing the neurotrophin BDNF  
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of organotypic hippocampal slices prepared from the adult brain 
 
Tao Su,1 Beatrice Paradiso,1 Anna Binaschi,1 Roberta Bovolenta,1 Mario Barbieri,1 Antonino Cattaneo,2 
Giulio Cossu,3 Michele Simonato1
 
1 Department of Clinical and Experimental Medicine, Section of Pharmacology, Neuroscience Center, 
University of Ferrara, Ferrara 44100, Italy; National Institute of Neuroscience, Italy 
2 European Brain Research Institute (EBRI), Rome, Italy 
3 Division of Regenerative Medicine, San Raffaele Scientific Institute, Milan, Italy 
 
Abstract 
Nerve growth factors, especially brain-derived neurotrophic factor (BDNF) are involved in the regulation of 
neuronal survival and function and, thus, they may be applied to treat neurological diseases associated with 
neuronal death. One of the major keys for a successful clinical application of neurotrophic factors is the mode 
of delivery. Stem cell-based gene therapy is a potential delivery option by which cells are engineered to produce 
neurotrophic factors in vitro and then transplanted to the target area where neurotrophic factors are secreted to 
exert protective effects on host tissue. To pursue this aim, we generated a genetically modified stem cells 
(mesoangioblasts) to produce BDNF (MABs-BDNF) and assessed their neuroprotective effects in vitro using 
organotypic cultures of adult hippocampal slices, in which slices exhibit continuous and extensive 
neurodegeneration. The viability of the cultured slices was assessed in several ways: fluorescein diacetate (FDA) 
hydrolysis assay, lactate dehydrogenase (LDH) release assay, immunohistochemistry for MAP2, immunoblot 
for neurofilament 68, and field potential recording. We found that the engineered MABs maintained transgene 
expression and secretion of bioactive BDNF in time. Direct exposure of recombinant BDNF to the adult slices 
resulted in a concentration-dependent protective effect. Surprisingly, the addition of culture supernatant from 
MABs-BDNF reduced cell death to a much greater extent, while the conditioned media from the control cells 
(MABs) or an equivalent amount of rBDNF showed smaller beneficial effects. The protective effects of 
MABs-BDNF could be attenuated by adding either the TrkB receptor blocker K252a or the BDNF scavenger 
TrkB-IgG. These data indicate that the conditioned media from MABs-BDNF can foster the adult slice culture 
through secretion of BDNF and other, unknown pro-survival factors produced intrinsically by MABs. In terms 
of preservation of the basic cellular and connective organization, as visualized by MAP2 immunolabeling and 
field EPSP, the slices cultured with MABs-BDNF conditioned media better retained their morphologic 
characteristics and functional connections. These findings demonstrate that MABs-BDNF can be an effective 
vehicle for BDNF delivery, capable of promoting the survival of adult neurons. Transplantation of the 
MABs-BDNF might be a potential therapeutic approach to treat neurodegenerative diseases. 
Key words: mesoangioblasts, BDNF, organotypic hippocampal slice culture, cell viability, drug delivery 
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INTRODUCTION 
 
Neurotrophic factors (NTFs) are critical for the 
survival, development and function of neurons in 
the mammalian central nervous system (Huang and 
Reichardt, 2001). Alterations in NTFs or their 
receptors leading to loss of function can cause 
neuronal death and contribute to the pathogenesis of 
neurodegenerative diseases such as Alzheimer 
disease (Connor et al., 1997), Huntington disease 
(Zuccato and Cattaneo, 2007), Parkinson disease 
(Bradford et al., 1999), and multiple sclerosis (De 
Santi et al., 2009). Many NTFs have been also 
implicated in diseases associated with damage, like 
stroke and some forms of epilepsy (Simonato et al., 
2006). It is not surprising, therefore, that they 
received considerable interest as therapeutic agents 
for neurological diseases (Thoenen and Sendtner, 
2002; Simonato et al., 2006).  
A particular attention has been devoted to brain 
derived neurotrophic factor (BDNF). A vast 
literature shows that BDNF exerts trophic and 
neuroprotective effects on neurons, but its clinical 
use is hindered by a short biological half-life and a 
poor blood-brain barrier permeability (Boado, 2008). 
Given these difficulties, the attention turned into the 
development of techniques that allow local BDNF 
delivery. These may be based on gene therapy 
(Paradiso et al., 2009) or on cell-mediated 
approaches.  
Stem cell-mediated gene delivery, by which 
stem cells are genetically modified with NTFs and 
then transplanted into the brain, is emerging as a 
strategy to treat chronic neurological disorders and 
injury-related neural degeneration. This strategy has 
already been used and validated in several lines of 
stem cells, including neural (Martinez-Serrano and 
Bjorklund, 1996; Lu et al., 2003; Kameda et al., 
2007), embryonic (Li et al., 2008; Rizvanov et al., 
2008; Makar et al., 2009) and mesenchymal stem 
cells (Harper et al., 2009): when engineered to 
produce NTFs, these cells were found to ameliorate 
experimental neurodegenerative diseases. The 
advantages of using genetically modified stem cells 
as grafts include the fact that they could exert not 
only long-term functional integration but also repair 
capabilities and that they can ensure a continuous 
and concentrated local supplementation of diffusible 
therapeutic molecules (like BDNF), reducing 
non-selective delivery and allowing high treatment 
efficiencies for long time periods.  
These findings prompt the search for 
alternative cell sources that, unlike neural or 
embryonic stem cells, may be readily used in the 
clinics. Here, we explored the feasibility of a new 
approach for the local supplementation of BDNF in 
lesioned brain areas. This approach is the use of 
multipotent, mesodermal stem cells 
(mesoangioblasts, MABs) that constitutively 
produce a subset of NTFs (e.g.VEGFB, FGF-2, 
FGF7) and can be engineered to produce others. 
MABs are an affordable cellular source. They can 
be isolated from the perivascular human adult tissue, 
and are already utilized for regenerative purposes in 
complex animal models, other than rodents. Their 
principal feature is the ability to differentiate, under 
appropriate conditions, in the different mesodermic 
tissues. The MAB-based therapy is now 
approaching the clinics (Sampaolesi et al., 2006).  
MABs have a high adhesin-dependent 
migratory capacity and, therefore, can reach 
perivascular targets. Their chemotactic ability is 
increased under inflammatory conditions, when the 
adhesin-integrin system and diapedesis moving are 
activated (Galvez et al., 2006). Therefore, when 
peripherally administered, MABs may selectively 
cross the blood-brain barrier and home in the 
lesioned areas. These cells have many 
neuro-ectodermal genes, but they do not 
differentiate into neurons (Tagliafico et al., 2004). 
Thus, we do not plan to use them for a restorative 
engraftment, but to exploit their migratory ability 
for targeting the lesion area: after infusion in the 
peripheral blood, MABs are expected to act as a 
reservoir and delivery system for NTFs. 
Aim of this study was to examine the 
by-stander effects of MABs engineered to produce 
and secrete BDNF. To pursue this aim, the medium 
collected from MAB cultures (containing BDNF 
and other constitutively produced NTFs) has been 
applied to hippocampal organotypic cultures. The 
organotypic hippocampal slice culture (OC) 
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provides an ideal in vitro model system to assess 
toxic or trophic effects of the test agents since it 
preserves the morphological and physiological 
features of the hippocampal neuronal network and 
allows easy access and precise control of 
extracellular environment for a short or long period 
(Stoppini et al., 1991; Kristensen et al., 2001). In 
general, OCs are prepared from early postnatal 
animals, not older than postnatal day 10 (P10) 
(Gahwiler et al., 1997) because, when prepared 
from adult hippocampal slices, they rapidly undergo 
neuronal degeneration (Wilhelmi et al., 2002). We 
elected to employ hippocampal cultures prepared 
from adult animals (Xiang et al., 2000) because they 
do not survive well in standard culture media and, 
thus, may provide a very convincing evidence of the 
favorable effects of the supplementation of NTFs if 
they survive when cultured in the MAB medium.  
 
METHODS 
MABs-BDNF and cell culture 
In order to achieve ex vivo cell-based gene delivery, 
MABs was transfected with a reporter green 
fluorescent protein (GFP) and with the human 
BDNF gene, obtaining a stable cell line 
(MABs-BDNF) that can constantly express BDNF. 
The control MABs were only engineered with GFP. 
These experiments were performed by Raffaella 
Scardigli and Antonino Cattaneo at the EBRI 
institute in Rome. The control MABs were only 
engineered with GFP. The two cell lines were 
cultured with the ordinary methods, using the 
following culture medium (here referred to as 
Medium-1): 88% Dulbecco’s modified Eagle’s 
medium, 10% fetal bovine serum，0.5% GlutaMaxII, 
22 mM mg/ml glucose, 1 mM sodium pyruvate, 100 
U/ml penicillin and 100 mg/ml streptomycin (all 
from Gibco, Invitrogen). After 2 days in culture, the 
medium was collected and centrifuged for 5 min at 
1000 rpm, and then the supernatant was collected. 
The supernatant consists of the medium containing 
the soluble substances secreted by MABs, including 
BDNF in the case of MABs-BDNF. An ELISA Kit 
(Chemicon) was used to measure the amount of 
BDNF in the supernatant.  
 
Primary hippocampal neuronal cultures 
Primary hippocampal neuronal cultures (PCs) were 
derived from P0 newborn Swiss mice. Hippocampi 
were dissected and minced with forceps, and then 
completely dissociated into a single-cell suspension 
using trypsin digestion. Isolated hippocampal cells 
were plated at a low density of approximately 5 × 
104・cm-2 viable cells in 24-well plates coated with 
poly-L-lysine (Sigma). Cells were grown in the 
Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 
penicillin 50 U/ml and streptomycin 50 mg/ml. The 
culture medium was replaced with the different 
conditioned media (see below) supplemented with 5 
µM Ara-C at the day after plating. The cells were 
maintained at 37°C under a humidified atmosphere 
of 95% air and 5% CO2.  
 
Organotypic hippocampal slice cultures 
Hippocampal organotypic slice cultures (OCs) were 
prepared as described by Stoppini et al. (Stoppini et 
al., 1991) with slight modifications. Male Swiss 
mice (4 weeks old, Morini Co., Italy) were briefly 
anesthetized by diethyl ether and decapitated. The 
brains were removed into ice-cold artificial 
cerebrospinal fluid (aCSF) consisting of (in mM): 
NaCl 118, KCl 2.5, MgSO4 3, NaH2PO4 1.1, 
NaHCO3 26, CaCl2 1 and glucose 11 (all reagents 
from Sigma) bubbled with 95% O2/5% CO2. 
Subsequently, 300 μm thick coronal slices were cut 
with a vibrotome (MA752, Campden Instruments). 
The hippocampi were dissected in cold, oxygenated 
Hank’s balanced salt solution (Gibco, Invitrogen), 
transferred onto sterile porous membrane confetti 
(Millicell, Millipore), and cultured with their 
standard medium (here referred to as Medium-2) or 
with the MAB-conditioned media (see below). The 
incubation conditions were maintained in a 
humidified 5% CO2 atmosphere at 37°C. The 
culture medium was changed the day after 
preparation and then every 2–3 days for the course 
of the experiment. 
 
Preparation of the conditioned media  
The effects of the MABs delivering BDNF on cell 
survival were evaluated in several experimental 
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groups cultured with a special conditioned media. In 
the groups “MABs” and “MABs-BDNF”, the 
condition media was composed by the mixture of 
equal volumes of fresh Medium-1 and of the 
2-day-culture supernatant from MABs and 
MABs-BDNF, respectively. The group called 
Medium-1 served as a control, being challenged 
with the fresh Medium-1. Medium-2 is a standard 
culture medium for OHSC from postnatal animals, 
consisting of 50% MEM, 25% horse serum, 18% 
HBSS, 4 mM L-glutamine, 12 mM glucose, 4.5 mM 
NaHCO3, 20 mM sucrose, 100 U/ml penicillin and 
100 mg/ml streptomycin (from Gibco or Sigma). 
The other conditioned media were based on the 
above media with different supplementations of 
reagents, like the recombinant human BDNF 
(ranged from 0.03 ng/ml to 300 ng/ml, 
Immunological Sciences), the BDNF antagonist 
K252a (50 nM, Sigma) or TrkB-IgG (2 μg/ml, R&D 
Systems), a recombinant tyrosine kinase receptor B 
(TrkB) engineered as an immunoadhesin to 
sequester BDNF. Sister slices were randomly 
assigned to the different groups.  
 
Assessment of viability 
The viability of the neurons in primary culture and 
the slices in organotypic culture was assessed in two 
ways. First, the fluorescein diacetate (FDA) 
hydrolysis assay was used to measure enzyme 
activity in cells. Living cells actively convert the 
non-fluorescent FDA into the green fluorescent 
compound "fluorescin", an indication of cell 
viability. Slices have been incubated with 10 μg/ml 
FDA (Sigma) for 30 min, then images were 
captured using an optical microscope (DMRA2, 
Leica, Germany) and the fluorescence intensity was 
quantified using the software Image-Pro Plus 6.0 
(Media Cybernetics, USA). Second, the lactate 
dehydrogenase (LDH) release assay was used to 
measure cell death in vitro. LDH is a stable 
cytoplasmic enzyme present in all cells, that is 
rapidly released into the culture medium upon 
damage of the plasma membrane; thus, LDH 
leakage to the medium is a marker for cell damage. 
The culture medium was all collected and LDH 
leakage was quantified by using a LDH Cytotoxic 
Test kit (Clontech) according to the manufacturer’s 
instructions.  
 
Immunohistochemistry  
Cultured slices were fixed with 4% paraformaldehyde 
(PFA) in phosphate buffer solution (PBS) for 1 h at 
room temperature. After a 48 h incubation with 30% 
sucrose at 4°C, slices were sectioned to a thickness of 
30 μm in a cryostat (CM1510, Leica, Germany). They 
were then washed in PBS (pH 7.4) and incubated with 
0.3% Triton in PBS for 1 h. PBS with 5% BSA and 
5% normal goat serum was used to block the slices for 
30 min, and then they were incubated overnight with 
the primary antibodies mouse anti 
microtubule-associated protein (MAP2abc; 1:50; 
Immunological Sciences). Finally, they were rinsed 
with PBS and incubated with the secondary antibody 
Alexa 488 goat anti mouse IgG (1:100). The slices 
were mounted onto slides after staining with DAPI 
(1:1000). 
 
Western blot 
To identify the density of the survival neurons within 
a slice, we performed immunoblot analysis of the 
neuron-specific marker neurofilament 68. After 14 
days in culture, slices were rinsed with ice-cold PBS 
and then lysed in sample buffer (ECL western blotting 
kit, Amersham). Aliquots from each sample (15 μg 
protein/lane) were subjected to 10% 
SDS-polyacrylamide gel electrophoresis and 
transferred onto polyvinylidine fluoride membranes 
(Millipore). The blots were blocked in blocking buffer 
(20 mM Tris-HCl, 137 mM NaCl, and 5% skim milk) 
for 1 h at room temperature and then treated with 
anti-neurofilament 68 antibody (diluted 1:500; Sigma) 
overnight at 4°C. Membranes were washed repeatedly 
in Tris-buffered saline containing 0.05% Tween 20, 
and then the HRP-conjugated secondary antibody 
(diluted 1:20000) was added for 1 h. Immunoreactive 
bands were detected using enhanced luminol-based 
chemiluminescence (ECL). The membranes were 
stripped and then immunoblotting for beta-actin 
(1:1000, Sigma) performed, as a loading control. 
Bands were scanned into digital images and analyzed 
with the software of Image-Pro Plus (Media 
Cybernetics, USA). 
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Fig. 1. Recombinant BDNF enhances cell survival in 
primary hippocampal neuronal cultures (PC, panels A and 
B) and in organotypic adult hippocampus slice cultures (OC, 
panels C and D) in a concentration-dependant manner. 
Neurons were cultured with the indicated concentration of 
BDNF for 7 days, slices for 14 days. Panels A and C 
indicate viable cells, as quantified using cell counting for 
PCs and fluorescence intensity of the marker FDA for OCs. 
Panels B and D represent cell death, as estimated measuring 
the levels of released LDH. Data are expressed as the 
mean±SEM (n=6). * P<0.05, ** P<0.01 vs. control (0 
ng/ml); ANOVA and post-hoc Newman-Keuls test. 
Field potential recording 
After 7 days in culture, slices were transferred to a 
holding chamber for 1 hour at room temperature in 
aCSF, while continuously aerated with 95% O2 and 
5% CO2. Slices were then placed in a submerged in 
vitro recording chamber and perfused with 
oxygenated aCSF. The temperature in the recording 
chamber was kept at 36±1°C. Bipolar wire 
electrodes (tungsten with a tip diameter of 90 μm; 
WPI Inc.) were used for stimulation of the Schaffer 
collateral pathway in the CA3 region (70 μs 
duration rectangular pulses at 0.05 Hz for 120 s). 
Glass microelectrodes filled with 0.9% NaCl were 
placed on the CA1 stratum radiatum to record field 
excitatory postsynaptic potential (fEPSP). A 
conventional electrophysiological technique of 
extracellular recordings was employed to identify 
the maximal response and to adjust the stimulus 
strength. The stimulus intensity that could 
repeatedly evoke the maximal synaptically evoked 
response/excitatory postsynaptic current (up to 900 
μA) was used in each slice. Signals were acquired 
under constant conditions, and off-line processed 
using the Patchmaster software (HEKA Instruments 
Inc., Germany).  
 
Statistical analysis 
All values have been expressed as the 
means±S.E.M. The Student’s t-test was used when 
two groups were compared. When three or more 
groups were compared, analysis of variance 
(ANOVA) and post hoc Fisher's least significant 
difference (LSD) test or Newman-Keuls test were 
employed.  
 
RESULTS 
 
Recombinant BDNF exhibits 
concentration-dependent protective effects on 
cell survival in primary hippocampal neuronal 
cultures and in organotypic cultures from adult 
hippocampal slices 
First, we tested if continuous application of 
recombinant BDNF (rBDNF) in the medium 
exerted trophic effects on cell survival in 
low-density primary cultures of hippocampal 
neurons (PCs) and in organotypic cultures of adult 
hippocampus slices (OCs). Thus, culture media 
were supplemented with increasing concentrations 
of rBDNF, ranging from 0.03 ng/ml to 300 ng/ml.  
In PCs, neurons seeded at low density can 
hardly survive without the support of rBDNF. 
Quantification of survival, based on cell counting 
and on LDH release, showed that BDNF produces a 
significant beneficial effect in a 
concentration-dependent manner (Fig. 1A and 1B). 
The maximal effect was reached at a concentration 
of approximately 10-5 M (slightly more than 100 
ng/ml) and the EC50 was approximately 10-7 M 
(slightly more than 100 ng/ml). These data are in 
keeping with previous findings (Cheng and Mattson, 
1994; Lindholm et al., 1996).  
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We also examined the neurotrophic activities 
of rBDNF in OCs. In the absence of rBDNF 
supplementation, OCs displayed degeneration 
aspects (like white spotted cell debris and uneven 
surface) after 6-8 DIV, that were clearly visible 
under phase contrast microscopy. Similar to PCs, 
rBDNF concentration-dependently reduced these 
signs of degeneration. Viability was quantified 
using two assays: FDA fluorescence intensity, to 
identify viable cells; LDH release, to identify the 
degree of cell death. As shown in Fig. 1C and 1D, 
BDNF concentration-dependently increased FDA 
fluorescence, in line with previous observations 
reporting that BDNF (50-100 ng/ml) enhances the 
cell tolerance to serum-deprivation of organotypic 
culture from postnatal slices (Nakagami et al., 
1997), and reduced LDH release. These effects were 
obtained in the same range of concentrations that 
proved effective for PCs. 
 
Soluble mediators from MABs engineered to 
produce BDNF highly improve cell survival in 
 
Fig. 2. MABs-BDNF deliver BDNF and enhance cell survival in primary hippocampal neuronal cultures (PC) and in organotypic 
adult hippocampus slice cultures (OC). (A) and (B): genetically modified MABs-BDNF proliferate and constantly express GFP. 
(C) MABs-BDNF secrete BDNF. Concentration of BDNF in the medium of MABs and MABs-BDNF at various days in vitro 
(DIV), as measured using ELISA. MABs-BDNF were cultured in 2 different types of medium (Medium-1 and Medium-2, see text 
for details) as indicated. (D) Effect of different treatment procedures on the viability of hippocampal PCs, as estimated using the 
LDH release assay. Data are the mean±SEM of 6 replicates in separate experiments. ** P<0.01 vs. Control-1; ? P<0.05 vs. MABs; 
ANOVA and post-hoc LSD test. (E) Effect of different treatment procedures on the viability of adult hippocampus OCs, as 
estimated using the LDH release assay. Data are the mean±SEM of 6 replicates in separate experiments. * P<0.05 and ** P<0.01 
vs. Control-1; ? P<0.05 vs. MABs; ? P<0.05 vs. MABs-BDNF; ANOVA and post-hoc Newman-Keuls test. Control-1 are slices 
treated with the typical medium for MABs culture (Medium-1). Control-2 are slices treated with the typical medium for postnatal 
slice culture (Medium-2). 
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primary hippocampal neuronal cultures and in 
organotypic cultures from adult hippocampal 
slices 
We engineered a line of MABs (MABs-BDNF) to 
stably produce and secrete human BDNF and the 
green florescence protein (GFP) as a tracer. These 
cells can be cultured long-term in vitro and 
constantly express BDNF and GFP (Fig. 2A and 
2B). The amount of BDNF secreted into the 
medium (Medium-1) from MABs-BDNF after 2 
days in culture was approximately 2 ng/ml, as 
measured using an ELISA assay (Fig. 2C). If 
MABs-BDNF were cultured with the medium 
usually employed to culture OCs (Medium-2), the 
amount of secreted BDNF was approximately 
halved (Fig. 2C). Therefore, although controls were 
also performed using Medium-2, the conditioned 
media that we used in all experiments was based on 
Medium-1: 50% culture supernatant from 
2-day-cultured MABs-BDNF and 50% fresh 
Medium-1. Thus, according to the ELISA measures, 
this conditioned medium contained approximately 1 
ng/ml BDNF, whereas no detectable of BDNF was 
present in the medium conditioned with control, 
conventional MABs (Fig. 2C). 
We first screened the trophic effects of the 
MABs-BDNF conditioned medium in the PC 
system. The MABs conditioned media increased the 
number of surviving neurons by about 80%, a level 
similar to the effect of 300 ng/ml rBDNF. The effect 
of the MABs-BDNF conditioned medium was much 
greater (it enhanced neuronal survival by 
approximately 170%). We used the LDH assay to 
measure these effects: as shown in Fig. 2D, both 
300 ng/ml rBDNF and the MABs medium 
significantly (and to a similar extent) reduced cell 
death, but the MABs-BDNF medium had a 
significantly greater effect. Interestingly, 1 ng/ml 
rBDNF (i.e. the concentration of BDNF present in 
the medium) alone did not produce a significant 
effect on neuronal survival. Together with the 
observation of a significant effect of the MABs 
medium, this indicates that other trophic factors are 
secreted by MABs that can synergize with BDNF to 
produce neuroprotection.  
We then extended and deepened this analysis in 
OCs. Adult OCs were cultured with different media 
and, after 14 DIV, cell death was measure using the 
LDH release assay. As shown in Fig. 2E, cell death 
was remarkable in control media (Medium-1 and 
Medium-2, see also Fig. 3A). As with PCs, the 
MABs-conditioned medium significantly decreased 
cell death, to nearly the level of rBDNF 300 ng/ml, 
and the MABs-BDNF-conditioned medium 
produced a significantly more pronounced effect. 
This extra-effect is mediated by the low 
concentrations (1 ng/ml) of BDNF produced by the 
MABs-BDNF, because (1) adding 1 ng/ml rBDNF 
to the MABs medium produced an effect similar to 
the one produced by the MABs-BDNF medium; (2) 
the TrkB inhibitor K252a and the BDNF scavenger 
TrkB-IgG to the medium conditioned by 
MABs-BDNF abolished the extra effect observed in 
the MABs-BDNF group, while these two BDNF 
blockers had no significant influence on the 
medium conditioned by MABs (Fig. 2E). These 
data support the notion that the pro-survival effect 
of the MABs-BDNF medium is mediated by a 
synergy between BDNF and other, yet unidentified, 
soluble substances constitutively produced by 
MABs. Accordingly, 1 ng/ml rBDNF alone did not 
reduce cell death at all, and much higher 
concentrations (300 ng/ml) were needed to almost 
reach the effect of the MABs-BDNF conditioned 
medium.  
 
MABs-BDNF-produced mediators sustain 
neuronal structural integrity and functional 
properties in adult organotypic slices 
The above findings have been confirmed at the light 
microscope and using FDA fluorescence, an 
indicator of viable cells. At the bright field 
observation, as compared with slices cultures in the 
control medium (which, as described, display 
obvious signs of degeneration, Fig. 3A), the slices 
cultured in the medium conditioned on 
MABs-BDNF remained thicker and preserved their 
structural organization for a long period, up to 25 
days (Fig. 3C). Slices cultured in the MABs 
medium appeared healthier that those cultured in 
control medium but less healthy that those cultured 
in the MAB-BDNF medium (Fig. 3B). In line with 
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cultures. Adult slices were cultured for 14 days with the control Medium-1, with medium conditioned in MABs, or with 
medium conditioned in MABs-BDNF. Note that slices cultured in the MABs-BDNF conditioned medium, compared with the 
other two groups, better maintain their integrity based on bright field observation (A-C), remain more viable based on FDA 
(D-E), DAPI staining (G-I) and MAP2 immunohistochemistry (J-L). Nuclei in blue in G-I, neurons in green in J-L. Scale bar: 
200 μm. 
 
these findings and paralleling to the high levels of 
LDH release described above, FDA fluorescence 
was weak and uneven in OCs cultured with control 
medium (Fig. 3D), indicating that most of the cells 
are indeed degenerating. OCs cultured with the 
MABs medium displayed a better labeling quality 
(Fig. 3E), which was further improved in OCs 
cultured with the MABs-BDNF medium (Fig. 3F). 
 Cell counting, performed by using the DAPI 
nuclear stain, confirmed that, even if some cell loss 
was present in slices cultured with MABs-BDNF 
conditioned medium (Fig. 3I), the number of 
surviving cells was much higher than in the control 
group (Fig. 3G). Slices treated with the medium 
conditioned in MABs performed a little better that 
controls, but much worse than those treated with the 
medium conditioned in MABs-BDNF (Fig. 3H). 
We also performed other morphological 
examinations and electrophysiological recordings. 
For morphological analysis, slices were fixed and 
immunostained with microtubule-associated protein 
2 (MAP2). MAP2 is a cytoskeletal protein primarily 
found in neuronal dendrites. As shown in Fig. 3J, 
adult slices cultured in the control media for 14 
days exhibit extensive not only cell loss, but also a 
grossly altered structure, with many lacunae in the 
pyramidal cell layer and just a few remaining, 
exclusively pyknotic neurons. MAP2 staining was 
essentially absent in control slices. While the MABs 
medium only slightly improved this situation (Fig. 
3K), the one conditioned in MABs-BDNF clearly 
attenuated the neuronal loss (Fig. 3L). The dendritic 
network and the cytoarchitectonic characteristics 
were essentially maintained in adult OCs treated 
with the MABs-BDNF conditioned medium, 
although signs of neuronal degeneration could still 
be detected, with loss of neurons, decreased 
dendrites, and many condensed or swelling 
pyramidal cells. These signs of degeneration 
progressively increased in time. Nonetheless, this 
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morphological analysis further confirms that the 
medium conditioned in MABs-BDNF enhances 
neuronal survival and preserves structural 
organization.  
The density of neurons in the slices cultured 
with the different media was also assessed using 
Western blot analysis for the neuron-specific marker 
neurofilament 68. We found that OCs cultured on 
MABs-BDNF conditioned medium contained more 
neurofilament 68, thus more neurons, as compared 
with the slices cultured in the control medium or in 
medium from conventional MABs (Fig. 4). A 
statistically significant difference was also found 
between the MABs and the control group, 
indicating that supplementation of the soluble 
substances produced by MABs can slightly (but 
significantly less efficiently than with BDNF) 
attenuate neuronal loss. 
Finally, we performed electrophysiological 
recordings to demonstrate the viability of the 
surviving neurons and the persistence of synaptic 
connections at a functional level. We measured 
fEPSPs in CA1 pyramidal neurons after stimulation 
of the Schaffer collaterals. We chose 7 DIV as a 
checking time point, because adult slices in culture, 
even those cultured with the MABs-BDNF 
conditioned medium, display a progressive decrease 
in the amplitude and stability of the extracellular 
field potentials in time (data not shown), such that 
currents could not be reliably measured at 14 DIV, 
when neurons are still visible using 
immunofluorescence: this is an indication that, as 
expected, the functional damage precedes the 
morphological one. As shown in Fig. 5A, adult 
slices cultured with the typical medium exhibited 
very small (if any) synaptic response at 7 DIV, 
while relatively stable fEPSPs could be recorded in 
those cultured with the medium conditioned in 
MABs or MABs-BDNF. However, the mean 
amplitude of the evoked fEPSPs in the 
MABs-BDNF group was much higher than in the 
MABs group (Fig. 5B). The presence of evoked 
synaptic currents, albeit lower and less stable than 
in acute slices or in cultured postnatal slices, in 
adult OCs cultured with the 
MABs-BDNF-conditioned medium demonstrates 
that the neuronal activity and the hippocampal 
circuitry remain functional by virtue of the 
beneficial effects of the mediators secreted by 
MABs-BDNF. 
 
Fig. 4. Density of neurons surviving in adult slices after 14 
days in vitro, under the different experimental conditions. 
Neuronal density was quantified performing Western blot 
analysis for a neuron-specific marker, neurofilament 68. (A) 
Representative blot. (B) Data quantification. The data are 
mean±SEM of 4 separate experiments. * P<0.05 and ** 
P<0.01 vs. Control-1; ?? P<0.01 vs. MABs; ANOVA and 
post-hoc LSD test. 
 
DISCUSSION 
Neurodegenerative disease is a condition in 
which cells of the brain and spinal cord are lost. 
NTFs are target-derived molecules that prevent 
neuronal degeneration during development and in 
adulthood (Blesch, 2006). They offer substantial 
promise as therapeutic agents in neurological 
diseases by preventing cell loss and promoting 
axonal regeneration. There are currently several 
experimental approaches for the therapy of 
neurodegenerative diseases, based on modulation of 
the levels of NTFs in lesion areas (Lindsay, 1994): a 
pharmacological approach, based on perfusion of 
NTFs in the brain; a gene therapy approach, based 
on the development of viral vectors capable of 
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efficiently delivering trophic factors; a cell therapy 
approach, aiming at replacing the lost neurons. The 
pharmacological approach confronts the great 
challenge of the difficulties in delivering proteins to 
the CNS (Jones et al., 2001; Boado, 2008). 
Therefore, the development of targeted drug 
delivery strategies becomes necessary. Direct 
localized CNS delivery of NTFs is now achievable 
by cell-based (ex vivo) or direct (in vivo) gene 
delivery. Stem cell-based delivery is of particular 
interest for drug manipulation since stem cells have 
a great therapeutic potential in repopulating 
damaged tissues as well as being genetically 
manipulated and used in cell-based gene therapy 
(Sonntag and Sanchez-Pernaute, 2006). Here we 
described a novel stem cell, the MAB, isolated from 
murine embryonic dorsal aorta, as an attractive 
candidate for localized cell-based gene delivery.  
 
Fig. 5. Maintenance of synaptic connections in adult 
slices after 7 days in culture with the MABs-BDNF 
conditioned medium. Synaptic connections were 
identified by recording evoked fEPSP in CA1 after 
stimulation of the Schaffer collaterals. (A) 
Representative recordings of the evoked fEPSP in the 
different groups. (B) Peak amplitude of the fEPSPs, 
measured and statistically analyzed as described in the 
Materials and Methods. The data are the means±SEM 
of 5 separate experiments. ** P<0.01 vs. Control-1; ?? 
P<0.01 vs. MABs; ANOVA and post-hoc LSD test. 
 
MABs are mesodermal progenitors associated 
with vessels, that are regarded as suitable candidates 
for cell therapy of muscle degenerative diseases 
(Sampaolesi et al., 2003; Sampaolesi et al., 2006), 
as well as myocardial infarction (Galli et al., 2005). 
Owing to their specific homing to the damage areas, 
MABs could be used for targeted delivery of 
therapeutic growth factors, like BDNF, in 
neurodegenerative diseases. Thus, we generated 
MABs engineered to produce BDNF and validated 
the possible effects of the mediators secreted by 
these MABs-BDNF by using primary neuronal 
cultures and organotypic cultures from adult 
hippocampal slices as in vitro models of 
neurodegeneration. 
First, we showed that continuous application of 
the recombinant BDNF provided protective effects 
on primary neuronal cultures and adult organotypic 
hippocampal slice cultures (OHSC) in a 
concentration-dependant manner. The effective dose 
of the rBDNF is similar those previous reported 
using primary cultures (Lowenstein and Arsenault, 
1996) and organotypic hippocampal slice cultures 
from postnatal slices (Nakagami et al., 1997). We 
here used the organotypic hippocampal slice culture 
from adult mice as a model of neurodegeneration. It 
is well known that the age of the animal is crucial 
for the viability of OHSC. OHSC maitained in a 
typical media always result in rapid and continuous 
cell death. This spontaneous cell degeneration may 
be used as a model to screen trophic or 
neuroprotective substances. There are also other 
models based on OHSC from postnatal animal, in 
which cell death is induced by exogenous insults 
such as neurotoxins (Noraberg et al., 1998), 
oxygen-glucose deprivation (Wise-Faberowski et al., 
2009), and trauma (Morrison et al., 2006). As 
opposed to these models based on postnatal slices, 
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the OHSC from adult slices display good regional 
morphology with less cell reorganization, and 
resemble the adult brain in gene expression profile, 
despite the unclear mechanisms of the spontaneous 
cell death. Consistent results in two independent 
assays, FDA hydrolysis and LDH release, suggest 
the feasibility of OHSC as a model of cell 
degeneration. 
Next, we found that MABs-BDNF can be 
grown extensively in culture and stably secrete 
BDNF into the culture medium. Although the 
secreted BDNF is at relatively low concentrations, 
the conditioned media from the supernatant of 
MABs-BDNF still exerted a robust protective effect 
in adult OHSC. According to our 
concentration-response assay with rBDNF, the 
concentration of rBDNF equivalent to that secreted 
by MABs-BDNF (1 ng/ml), and even the highest 
concentration of rBDNF (300 ng/ml) could not 
extend cell survival as much as MABs-BDNF, 
indicating MABs-BDNF produced not only BDNF 
but also some other, yet unknown, survival factor. 
Indeed, the conditioned media from control MABs 
enhanced cell survival in adult OHSC when 
compared with the control medium. The finding that 
the MABs-BDNF beneficial effects could be 
simulated by the combination of MABs and 1 ng/ml 
of BDNF reinforce the conclusion that 
MABs-BDNF can produce two pro-survival 
components: the secreted BDNF, and other 
unknown soluble substances. It also seems that 
there is a synergistic effect between BDNF and 
these unknown factors, because MABs-BDNF 
increased cell survival to a much higher extent than 
the equivalent dose of rBDNF or MABs. 
Synergistic effects between NTFs are common in 
the nervous system. A proper combination of 
different NTFs could enhance the trophic abilities 
and reduce possible side effects. MABs seem to be 
ideal for delivering BDNF since the delivery was 
effective at a low dose, which would reduce the side 
effects in possible, future clinical application. So far, 
the effective components in the culture supernatant 
of MABs have not been identified. A micro-array 
analysis of gene expression revealed that several 
growth factors are expressed at high level in these 
cells, including vascular endothelial growth factor B 
(VEGFB), basic fibroblast growth factor (bFGF), 
FGF7, platelet-derived growth factor AA (PDGF 
AA), hepatomaderived growth factor, and stromal 
derived factor 1 (Galli et al., 2005). Thus, the 
mechanism of the effect of MABs on adult slice 
survival is probably multifactorial, relating with 
various growth factors and chemokines. It is worthy 
to note that MABs express many neural genes 
including receptors and transcription factors in spite 
of their mesodermal origin. Therefore, it is 
reasonable that they express survival factors for 
neurons.  
Several investigations indicate a pivotal role of 
BDNF in neuroprotection in different models of 
neurotoxicity, such as in vivo and in vitro ischaemic 
neuronal damage (Larsson et al., 1999; Kano et al., 
2002), glucose deprivation (Tong and Perez-Polo, 
1998) or glutamate-induced neuronal damage in 
neuronal cultures (Cheng and Mattson, 1994)，
kainate acid-induced excitotoxicity in the striatum 
(Gratacos et al., 2001) and hippocampal kindling 
(Larmet et al., 1995). In this study, we demonstrated 
the beneficial effects of rBDNF or MABs delivered 
BDNF on cell survival in OHSC. These findings 
suggest that BDNF is an essential constituent of the 
microenvironment for neuronal survival in the adult 
hippocampus. It is reported that BDNF 
administration to cultured slices potentiates 
presynaptic release (Li et al., 1998) and promotes 
dendritic and axonal growth (Labelle and Leclerc, 
2000). Independently, other studies have provided 
insights into the effects of BDNF on potentiating 
excitatory transmission in the cultured slices (Huber 
et al., 1998; Jiang et al., 2001). 
The signaling mechanisms underlying the 
pro-survival effects of MABs-BDNF appear to 
involve TrkB activation. The TrkB blocker K252a 
attenuated the protective effects of MABs-BDNF to 
an extent similar to MABs. TrkB receptors have 
long been known to mediate trophic support of adult 
neurons (Ferrer et al., 1999), and a number of 
studies show that decreased expression of this 
receptor is associated with cell loss (Barbacid, 
1994). 
Based on the morphological analysis and the 
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immunoblot assay for neuron-specific marker, the 
evidence supporting the beneficial effects of the 
conditioned medium from MABs-BDNF on adult 
OHSC is solid. Moreover, these OHSC also 
diplayed a better synaptic response with higher peak 
amplitudes of fEPSP compared to the groups of 
MABs and control. The facilitated synaptic 
responses may be ascribed to a better preservation 
of synaptic connections or to a potentiated synaptic 
transmission. It is reported that application of 
BDNF modulates the strength of existing synaptic 
connections (Huber et al., 1998; Jiang et al., 2001) 
and acts in the formation of new synaptic contacts 
within the hippocampal circuit (Lauterborn et al., 
2007). In any event, the MABs-BDNF conditioned 
medium reduced, but did not prevent, cell 
degeneration in adult OHSC, according to our 
morphological analysis and electrophysiological 
recordings. Slices, even those in the MABs-BDNF 
conditioned medium, exhibited continuous signs of 
degeneration during culture. Furthermore, the 
electrophysiological recordings indicate that adult 
OHSC are not as healthy as the postnatal OHSC, 
since the fEPSPs in adult slices were hard to evoke 
and almost disappeared after 10 days in culture 
(data not shown). In the future, an improved culture 
method, together with supplementation of the 
MABs-BDNF conditioned medium might make it 
possible to achieve truly successful adult OHSC, 
which is a technical bottleneck for many studies. 
In this study, we demonstrate that soluble 
mediators secreted by the MABs-BDNF have 
profound survival effects on neurons in adult OHSC. 
We found a potential merit of using MABs to 
deliver BDNF, which were these unknown survival 
factors inherently secreted by MABs. The coaction 
of BDNF and MABs-produced survival factors led 
to a higher tolerance to cell death and a better 
maintenance of the neuronal network, and allowed 
the delivered BDNF to exert a profound protective 
effect at a low dose. Besides, MABs possess the 
other natural advantages for cell-based therapy: they 
can be expanded to virtually unlimited numbers in 
vitro; they are amenable to genetic modification; 
they self-renew and have multipotent capacities; 
they specifically home to the damage area. These 
advantages raise the possibility that the 
MABs-BDNF might be developed into a new 
cell-based strategy for BDNF delivery into the CNS, 
thereby promoting neuronal survival and restoring 
network function in neurological diseases 
associated with brain damages. Transplantation of 
MABs-BDNF might become an alternative and 
possibly more efficacious therapy for brain diseases 
caused by neurodegeneration, including multiple 
sclerosis, stroke, epilepsy and trauma. The 
transplanted MABs-BDNF may protect neurons 
from damage through a “bystander” mechanism, by 
which MABs-BDNF chronically secrete low dose 
BDNF and other survival factors to provide an 
optimal environment for tissue repair and neuronal 
survival.  
Further studies in the animal models of 
neurodegenerative diseases are required to identify 
the therapeutic value of MABs-BDNF 
transplantation. In addition, there might be other 
growth factors more suitable than BDNF in view of 
the different pathophysiological processes in 
neurodegenerative diseases. Using this study as a 
template, advances can be made in the way MABs 
are engineered with other growth factors. Finally, 
this study may have heuristic value for the 
exploitation of stem cell-based therapies in terms of 
cell sources, gene modification, and screening 
methods. 
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